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Major histocompatibility complex class II (MHC II) proteins display peptides to CD4+ T cells. 
Their regulation of expression is important for normal immune function and autoimmunity. 
Two aspects of this were explored here. Expression of HLA-DR, the major human MHCII 
isoform, was manipulated in immortalised antigen-presenting cells (APCs), and characterised 
by qRT-PCR, flow cytometry and Western blot. Mass spectrometry was used to quantify 
expression changes of polymorphic HLA-DR beta chain variants. First, the mechanism of DR 
proteolysis was elucidated. MHCII degradation had been shown to be regulated by 
ubiquitylation and peptide loading. This study showed that cathepsin D (Cat D), a lysosomal 
aspartyl protease, degrades DR molecules not associated with peptide or invariant chain. 
Interestingly, when Cat D activity was ablated, APCs eventually restored wild-type DR levels, 
using feedback mechanisms that remain to be explored. Secondly, the effects of vitamin D and 
retinoic acid (RA) on DR expression were explored. Previous work had shown both indirect 
effects on DR levels and transactivation of some DRB allelic variants by vitamin D. This study 
revealed synergistic actions of RA and vitamin D on DR expression by myeloid model APCs 
but mutual antagonism in lymphoblastoid cells, and suggested that DR beta-chain copy number 
variants may be regulated discordantly. This work suggests that in physiological DR protein 
turnover, Cat D attacks the groove of DR molecules that lost bound peptide, mediating quality 
control of antigen presentation. This could mitigate against autoimmunity by limiting 
unconventional presentation pathways independent of invariant chain or HLA-DM. The small 
size of the vitamin D and RA effects on DR argues against a major role in autoimmunity, with 
the possible exception of the unusual DRB1*15-DRB5*01 MS risk haplotype. Novel tools 
were generated for the quantification of codominant expression of DR allelic and copy number 
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Chapter 1: General Introduction  
 
1.1 Scope of thesis 
 
This thesis investigates the regulation of antigen presentation to helper T cells. This is an 
important process in immune recognition that bridges innate and adaptive immunity, whereby 
antigen presenting cells (APCs) capture antigens and display them in peptide form on the cell 
surface in association with major histocompatibility complex class II (MHC II) molecules 
(Penn and Ilmonen, 2001). The resultant complex can be recognised by helper T cells via 
their T cell antigen receptor (Neefjes et al., 2011). This process provides a mechanism of 
communication between innate and adaptive immune cells about the presence of specific 
pathogens in the context of normal host defence and also seems to be the focus of disease 
mechanisms in auto-immunity. In both contexts it is very important to know how the 
expression of MHC II molecules is regulated by transcriptional and post transcriptional 
mechanisms and by their extensive genetic polymorphism.  
The first part of this thesis characterises the specific enzymes involved in the breakdown 
process of MHC II molecules and its relation to peptide binding.  The second part explores 
the effects of vitamin D and retinoic acid on the expression of HLA-DR allelic and  gene 
variants. Both processes are of potential relevance to the pathogenesis of autoimmune 
diseases. Previous work has postulated links  mechanisms of autoimmunity  with aberrant 
turnover of MHC II molecules (Busch et al., 2005) or to the effects of vitamin D on MHC II 




1.2 Immune System 
 
The human body is continuously challenged by infectious agents, such as bacteria, viruses, 
fungi, parasitic worms, etc., of which some are pathogenic, and their own survival can lead to 
the disease or death of the host. A defence network has evolved in living organisms, 
including humans, ensuring protection against such foreign agents, commonly known as the 
immune system (Barber, 1980, Travis, 2009). It is able to generate an enormous diversity of 
cells and molecules capable of specifically recognizing the large variety of such invading 
pathogens. Generally it is divided into two branches, the innate immune system and the 
adaptive immune system (Warrington et al., 2011), but it consists of several biological 
effector mechanisms. The major agents of both the branches are shown in Figure 1.1. 
  
Figure 1.1 Overview of the Innate and Adaptive Immune Systems. The main elements of both the 
innate and adaptive arms of the human immune system. 
 
Host defence begins with  physical barriers such as the skin and mucous membranes, which 
form the first line of defence and are fundamental to innate immunity (Turvey and Broide, 
2010). Additionally, barrier immunity employs chemical defences, such as antibacterial 
 3 
enzymes in secretions (mucus, saliva, tears) and stomach acid, which produce an 
environment that is difficult for pathogenic organisms to infiltrate. If pathogens do breach the 
body’s physical and chemical barriers, the innate immune system can launch a prompt non-
specific response (Turvey and Broide, 2010). Immune cells such as neutrophils, 
macrophages, and natural killer (NK) cells are recruited to the primary infection site 
(Hoffmann and Akira, 2013). The role of these cells is to capture and destroy invading 
pathogens and to clear damaged or infected host cells. The innate immune system uses 
germline-encoded pattern recognition receptors (PRRs) that survey both the extracellular and 
intracellular space for conserved microbial determinants to detect pathogens (Brubaker et al., 
2015). 
If the innate response cannot clear the pathogen, then cells of the adaptive immune system are 
recruited. A hallmark of the adaptive immune system is the ability to identify specific 
antigens, which are unique structures found within pathogens or their products (Mackay and 
von Andrian, 2001). The adaptive immune cells responsible for this specific recognition are 
lymphocytes (Wherry and Masopust, 2016). Lymphocytes are divided into B and T cells, 
based on their locations during development and maturation, and their antigen recognition. 
Both B and T cells recognize specific antigens (Ag) via clonally variable cell surface 
receptors. The B cell receptor is a cell surface bound antibody and can recognize whole 
antigen. In contrast, the αβ-T cell receptor (TCR) can only recognize processed antigens 
when bound to molecules known as major histocompatibility complex (MHC) molecules 
(Davis and Bjorkman, 1988). An alternative γδ-TCR exists but its main focus does not seem 
to be MHC molecules (Vantourout and Hayday, 2013). Unlike innate immune cells, this 
antigen receptors are not fixed by germ-line encoded sequences; instead, they are somatically 
generated or ‘custom made’ via gene-shuffling events that occur during their development 
(Bonilla and Oettgen, 2010). 
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Immune cells that take up an Ag and process it into a form recognized by, or serve to 
activate, specific helper T cells are known as professional antigen presenting cells (APCs). B 
cells function as APCs by processing whole Ag into antigenic fragments and displaying those 
fragments via MHC molecules to T cells (Chaplin, 2010). Other APCs that play critical roles 
in the immune system are macrophages and dendritic cells (DCs). DCs play a crucial role in 
linking innate and adaptive immunity. Immature DCs migrate from the blood into various 
tissues and specialize in phagocytosis (Alvarez et al., 2008). When they encounter an antigen, 
they rapidly mature and migrate to lymphoid tissues where they carry out antigen 
presentation to T cells (Sallusto and Lanzavecchia, 2002).  
1.3 Major histocompatibility complex (MHC) 
 
MHC glycoproteins are a family of cell surface molecules, which are encoded by MHC genes 
(Penn and Ilmonen, 2001). The major function of MHC glycoproteins is to bind peptides 
derived from pathogens in a groove-shaped peptide-binding site and display them on the cell 
surface for recognition by T cells (Holling et al., 2004). The MHC molecules thus play a 
fundamental role in the immune system (Mak and Saunders, 2006).  The importance of MHC 
genes in the immune response was first determined from studies using inbred mouse strains 
performed by George Snell (Snell, 1948) and inspired by earlier investigations by Peter Gorer 
(Gorer, 1937, Gorer and Schütze, 1938). Jean Dausset subsequently described the human 
MHC (Dausset, 1981).  
The MHC is a 7.6 Mbp multi-locus region of the genome, located on the short arm of 
chromosome 6 in humans (Mungall et al., 2003, Horton et al., 2004). In humans, MHC 
molecules are also known as human leukocyte antigens (HLA). This term was coined due to 
the observation that antibodies identifying MHC molecules targeted polymorphic antigens on 
leukocytes (Thorsby, 2009). There are more than 200 genes in the coding region, which can 
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be categorized into three basic groups: MHC class I (MHC I), MHC class II (MHC II) and 
MHC class III (MHC III) (Erickson, 1987). MHC I molecules are expressed by most 
nucleated cells, where they present mainly endogenous peptide on the cell surface to CD8+ T 
cells (cytotoxic T lymphocytes) (Natarajan et al., 1999a). MHC II molecules are presented on 
specialized APCs like macrophages, dendritic cells and B cells. During infection, they 
present exogenous peptides to CD4+ T cells (Pulendran, 2005). Lastly, the MHC III region 
plays a role in various aspects of innate immunity by encoding complement proteins, 
inflammatory cytokines such as tumour necrosis factor α, and heat shock proteins 
(Hauptmann and Bahram, 2004).  
1.3.1 Structure of MHC II molecules 
 
MHC II molecules contain two different polypeptide chains, a 33 kDa α chain and a 28 kDa β 
chain, which are associated by noncovalent interactions (Cole, 2013). MHC II molecules are 
membrane-bound glycoproteins that contain external domains, a transmembrane segment, 
and a cytoplasmic anchor segment as shown in Figure 1.2. Each chain in a MHC II molecule 
contains two external domains: α1 and α2 domains in one chain and β1 and β2 domains in the 
other chain. The membrane-proximal α2 & β2 domains bear sequence homology to the 
immunoglobulin fold structure (Kaufman et al., 1984). The membrane-distal portion of a 
MHC II molecule is composed of the α1 & β1 domains and forms the antigen binding cleft 
for processed antigen (Ferrante, 2013). MHC II proteins possess a single, open-ended peptide 
binding groove, which accommodates peptides with a 9-amino acid central core and C- and 
N- terminal overhangs of varying lengths (Brown et al., 1993). Most peptides naturally 
binding to MHC II molecules are approximately 13-25 residues in length (Jardetzky et al., 
1991, Chicz et al., 1992). Certain anchor residues are preferentially found within the core 
(typically at relative positions 1, 4, 6, 7 and 9 depending on the allele), where they make 
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complementary contacts with specificity pockets lining the groove. Other residues may vary 
widely, thus allowing MHC II molecules to bind thousands of peptides, so long as they 
satisfy the binding preferences of the anchor residues (Rammensee, 1995). Allelic variants of 
MHC II molecules diversify the peptide binding groove with little impact on the tertiary 
structure, thus giving each variant a unique peptide binding repertoire (albeit with some 
overlap).  
 
Figure 1.2 Basic structure of a MHC II molecule. MHC class II molecules consist of two non-covalently 
associated non-identical polypeptide chains, the α-chain and the β-chain. 
 
MHC class II molecules have a relatively restricted pattern of expression due to the 
regulation by Class II transactivator (CIITA) (Masternak et al., 2000, LeibundGut-Landmann 
et al., 2004) which limits the expression MHC II  to APCs or tissue cells that have been 
induced with pro-inflammatory cytokines. CIITA controls the gene transcription by a 
complex of DNA-binding proteins in the promoter region. Vitamin D can also modify the 
expression of MHC II transcriptionally by binding to the vitamin D response element 
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(VDRE) also present in the promoter region (Ramagopalan et al., 2009). This aspect of 
regulation is discussed further in the introduction towards Chapter 5. 
1.3.2 MHC II Antigen processing and presentation  
 
Classical MHC II molecules bind peptides generated in endocytic compartments of APCs and 
present them at the cell surface, where they engage with clonally variable T cell receptors 
(TCRs) on T cells expressing the co-receptor CD4 (Neefjes et al., 2011). This is critical in the 
generation of an effective adaptive immune response, with CD4+ T helper cells acting to co-
ordinate and activate other immune effectors (Zhu and Paul, 2010); during positive and 
negative selection of thymocytes in the thymus (central tolerance); as well as in peripheral 
tolerance and immune regulation (Morris and Allen, 2012). The generation of peptides from 
native protein antigens is commonly referred to as antigen processing, whereas the display of 
the peptides at the cell surface by the MHC molecule is referred to as antigen presentation 
(Mellman et al., 1998). 
The individual  and  chains of MHC II are synthesised and assembled in the endoplasmic 
reticulum (ER), where they associate with invariant chain (Ii) (Roche and Cresswell, 1990, 
Cosson and Bonifacino, 1992). The peptide binding groove of the MHC II molecule is 
blocked by a disordered region of Ii, thus preventing ER polypeptides from associating with 
the groove (Busch et al., 1996). MHC II/Ii complexes then exit the ER and accumulate 
transiently in  late endosomal compartments under the direction of the cytoplasmic tail of Ii 
(Busch and Mellins, 1996). Earlier work suggested that an Ii trimer associates with three αβ 
heterodimers to form a nonamer, but more recent evidence suggests that once a pentameric 
complex has formed (an Ii trimer and a single αβ heterodimer), binding of additional MHC II 
is inhibited as the complex bends towards the cell membrane (Koch et al., 2011). In any case, 
MHC II/Ii complexes are transported to endocytic compartments, where Ii chain is 
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sequentially degraded, first by aspartic proteases to give the p22 degradation intermediate, 
and then by the cysteine proteases, cathepsin L and S, to yield both the p10 intermediate and, 
finally, class II-associated Ii peptides (CLIP) (Marić et al., 1994, Hsing and Rudensky, 2005). 
However, the initiating role of aspartyl proteases in Ii removal is not universally accepted and 
may differ between cell types (Villadangos et al., 1997, Deussing et al., 1998).The terminal Ii 
degradation fragments, CLIP, continue to block the peptide binding groove and must 
dissociate to allow presentation of antigen.  
Although spontaneous CLIP release may occur (Kropshofer et al., 1995), the non-classical 
MHC II molecule, HLA-DM, which is structurally similar to HLA DR but lacks a peptide 
binding groove, accelerates the process (Sloan et al., 1995, Denzin and Cresswell, 1995). 
Recent crystallographic studies of DM in complex with the MHC II molecule, HLA-DR, 
have elucidated a mechanism for this catalysis (Pos et al., 2012). HLA-DM interacts laterally 
with MHC II-CLIP complexes, causing a tryptophan to flip away from the HLA-DR P1 
pocket, enabling major conformational changes that position hydrophobic HLA-DR residues 
in the P1 pocket. Furthermore, initially incoming peptides have only partial access to the 
peptide-binding groove and must compete with HLA-DR residue for access to the P1 pocket, 
as well as the P2 site. This provides an energetic barrier and creates a stringent selection 
process for the highest affinity peptides (Vogt et al., 1999, Painter and Stern, 2012). Once a 
peptide has bound P1 and P2, the conformational changes are reversed and thus peptide 
selection is terminated through HLA-DM dissociation (Busch et al., 2005). Hence, HLA-DM 
establishes an affinity based hierarchy for peptide binding.  Once stably loaded with peptides, 
MHC II molecules are shuttled to the cell surface, allowing antigen presentation to CD4+ T 




Figure 1.3 Antigen presentation by MHC II molecules. MHC II dimers assemble with the invariant chain 
(li) in the endoplasmic reticulum (ER). This complex is then transported to specialized lysosomal 
compartment known as the MHC class II compartment (MIIC), through the Golgi body. In the MIIC, 
the Iichain is hydrolysed to leave MHC II bound to an Iifragment, called class II-associated invariant 
chain peptide (CLIP).  Simultaneously, the exogenous antigens on internalization are fragmented into 
small peptides for presentation. Peptide exchange is catalysed by the non-classical MHC II molecule, 
HLA DM. The peptide-loaded MHC II can then transported to the cell surface, where antigen 
presentation takes place. Figure adapted from Neefjes et al (2011). 
 
The peptide is an integral part of the MHC molecule, as it stabilizes the structure. In the 
absence of bound peptide or chaperones, MHC II molecules readily aggregate (Kropshofer et 
al., 1997). This ensures that only stable MHC II/peptide complexes are transported to the cell 
surface and MHC II molecules present peptides that were processed within the cell. 
Nevertheless, the peptide binding specificity of MHC II molecule is not the only factor 
affecting antigen presentation.  
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The physiology of antigen presentation is complicated by differential expression of 
endosomal proteases in different APCs. Cathepsins are lysosomal proteases consisting of at 
least 15 members (Stoka et al., 2016). Most of these are ubiquitously expressed, although 
some have more tissue- or cell type-specific expression profiles.  This affects the processing 
of Ii, MHC II and protein antigens. There is some level of redundancy to this system (Reich 
et al., 2011). Lysosomal processing of antigen involves many different exopeptidases, 
endopeptidases and reductases, such as the γ-interferon (IFN)-induced lysosomal thiol 
reductase (GILT), which is required for the degradation of protein antigens containing 
disulphide bonds (Haque et al., 2002, Maric et al., 2001). The presence of different proteases 
can alter the peptide repertoire that binds to MHC II molecules (Hsieh et al., 2002) . 
Moreover, different proteases can play the same role in different cell types; for example, 
cathepsin L and S (Cat L/S) can play the same role in the degradation of Ii, with Cat L being 
abundantly expressed in thymic epithelial cells (TECs), whereas B cells and DCs express Cat 
S (Hsing and Rudensky, 2005, Reich et al., 2011).  This makes it difficult to pinpoint 
particular enzymes responsible for a defined role/s. More details about function of cathepsins 
are  explained in the introduction to Chapter 3. 
Another important criterion for the efficient working of these enzymes is maintenance of a 
low pH in the lysosomes. The pH within lysosomes is acidic (less than 5), whereas the pH in 
the cytoplasm is neutral (around 7.2). This low pH is essential for most proteases found 
within lysosomes to function optimally. This low lysosomal pH is maintained by an 
adenylpyrophosphatase (ATPase) that utilizes the energy liberated by ATP hydrolysis to 




1.3.3 MHC II degradation  
 
Expression levels of MHC II at the cell surface are determined by their rates of synthesis, 
internalization, intracellular retention, recycling and degradation. Several mechanisms that 
control MHC II degradation have been investigated. Cell surface expression of MHC II 
increases during DC maturation. The synthesis of MHC II increases in response to maturation 
signals, but only temporarily, and is virtually absent in fully matured DCs (Granucci et al., 
2001, Wilson et al., 2004). MHC II complexes that are formed from newly synthesized MHC 
II during DC activation become long-lived, generating a pool of stable MHC II complexes 
potentially displaying antigen from the pathogen. On the other hand, MHC II molecules that 
were synthesised prior to DC activation are irreversibly sorted in the lysosomes/endosomes 
(Walseng et al., 2010). MHC II synthesis is shut down after DCs have matured. 
Ubiquitination is a post-translational modification that, amongst others functions in cell 
homeostasis and signalling, mediates sorting of integral membrane proteins to lysosomes for 
their degradation. A highly conserved unique lysine at position 225 in the cytoplasmic tail of 
the MHC II β chain can be ubiquitinated (Ohmura-Hoshino et al., 2006). Lysine at position 
219 in the cytoplasmic tail of DR α can also be ubiquitinated but other features of DR α limit 
the process to a certain extent (Lapaque et al., 2009). This is a variant of the default 
ubiquitination pathway which is responsible for the majority of intracellular protein 
degradation in eukaryotic cells by the proteasome (Finley, 2009). In both of these pathways, 
the specificity is ensured by conjugating substrates to a chain of ubiquitin moieties. This 
polyubiquitination process requires a cascade of three types of enzymes: E1, E2, and E3 
(Iiand Ye, 2008). First, ubiquitin is bound and activated by the E1 ubiquitin-activating 
enzyme. Then the activated ubiquitin moiety is transferred to the E2 ubiquitin conjugating 
enzyme, which finally, via the E3 ubiquitin-protein ligase, transfers ubiquitin to the target 
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protein, which can be rapidly degraded (Pickart, 2001).  The schematic representation of the 
ubiquitination process is shown in Figure 1.4. 
 
 
Figure 1.4 Enzymatic steps in protein ubiquitination. Protein degradation through ubiquitin requires 
sequential action of three enzymes. Free ubiquitin (Ub) is activated by ubiquitin activating enzyme 
(E1) using ATP to form E1-Ub complex. Activated Ub is transferred to a carrier protein (E2), and then 
transferred to a ligase (E3). This will allow the polymerization of one or more ubiquitin molecules on 
target proteins. Figure adapted from Jesenberger and Jentsch (2002) 
 
Ubiquitination of MHC II in APCs is driven by membrane associated ring finger protein I 
(MARCH I), a member of the E3 ligases (De Gassart et al., 2008). More evidence of the 
association of MARCH I with MHC II was found in co-immunoprecipitation studies (Tze et 
al., 2011). The pivotal role of MARCH I in regulating MHC II mediated antigen presentation 
is further illustrated by observations that the anti-inflammatory cytokine IL-10 induces 
MARCH I expression in primary human monocytes (Thibodeau et al., 2008), thereby 
promoting MHC II degradation under immunosuppressive conditions. Down-regulation of 
MARCH I transcription was demonstrated in maturing DCs (De Gassart et al., 2008, Young 
et al., 2008). The half-life of MARCH I is claimed to be shorter than 30 minutes (Jabbour et 
al., 2009), thus explaining the loss of ubiquitination in maturing DCs. Thus, ubiquitination of 
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MHC II regulates its cell surface expression by providing a signal for efficient sorting 
towards degradation in the lysosome (Shin et al., 2006, van Niel et al., 2006). In DCs where 
lysine at 225 position of HLA-DR β was mutated to prevent ubiquitination, there  was a 
reduction of endocytosis by 20-fold when compared to wild type MHC II (De Gassart et al., 
2008). However, ubiquitination of MHC II might involve, in addition to MARCH I, also 
other E3 ligases. In MARCH I knockout mice, ubiquitination of MHC II was absent in B 
cells but remained intact in DCs (Matsuki et al., 2007) indicating overlapping specificities of 
the E3 ligases. 
In summary, MHC II molecules are extraordinarily stable but still display cell type-specific 
half-lives. Factors affecting the degradation of MHC II molecules following internalisation 
are not well understood. It is most likely that MHC II molecules are degraded in a similar 
way to any other lysosomal proteins, but the specific protease(s) involved remain unidentified 
and are investigated in this thesis.  
1.3.4 MHC II polymorphism and inheritance   
 
The entire MHC region is one of the most highly polymorphic gene complexes known and is 
not only multi-allelic, but also multigenic (Trowsdale and Knight, 2013). The genetic 
diversity of MHC II molecules arises from the presence of numerous genes encoding the - 
and -chains and extensive allelic polymorphism. There are three classical isotypes of MHC 
II molecules, called HLA-DP, HLA-DQ, and HLA-DR, which have different specificity of 
peptide binding (Penn and Ilmonen, 2001). Secondly, the genes constituting the HLA region 
are highly polymorphic; i.e., many alternative forms of the gene called alleles exist at each 
locus (Klein and Sato, 2000). The polymorphism and co-dominant expression of MHC 
molecules results in great genetic diversity among humans with regard to their HLA type. 
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Of the MHC II molecules, HLA-DR is the most widely studied isotype (van Lith et al., 2010). 
It is subject to the largest extent of allelic polymorphism and is characterized by having a 
monomorphic -chain and a highly polymorphic -chain, which determines the diversity of 
HLA-DR antigens (van Lith et al., 2010). Only one gene exists for the -chain (HLA-DRA) 
whereas four different loci encode functional HLA-DR -chains (HLA-DRB). These are 
HLA-DRB1, HLA-DRB3, HLADR-B4, and HLA-DRB5 (Figure 1.5). Five additional 
pseudogenes exist, encoding non-expressed -chains; HLA-DRB2, HLA-DRB6, HLA-
DRB7, HLA-DRB8, and HLA-DRB9 (Handunnetthi et al., 2010b). All humans carry HLA-
DRB1, while the presence of any of the three remaining functional genes varies from 
individual to individual, which is referred  gene varaition (Schaschl et al., 2009, Gamazon 
and Stranger, 2015).  
 
Figure 1.5 Schematic representation of the five human HLA-DRB haplotypes. Adapted from Anderson 
(1998). Genes and pseudogenes are shown in dark and light colour. 
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Furthermore, the HLA-DRB1 locus has the most identified alleles of all HLA class II loci. 
Any of the functional HLA-DR -chains can pair up with an HLA-DR -chain to form a 
heterodimeric HLA-DR molecule. Despite the diversity of HLA-DRB, it is possible to divide 
individuals into five different HLA-DR haplotypes, which denote a particular combination of 
HLA-DRB1 alleles and their linked gene variant (Figure 1.5) (Handunnetthi et al., 2010b). 
These groups are characterized by their sole expression of HLA-DRB1 or HLA-DRB1 in 
combination with HLA-DRB3, HLADR-B4, or HLA-DRB5. Since inheritance of HLA 
antigens is codominant (Choo, 2007), an individual may produce up to four different DR 
protein variants: two from the maternally and paternally derived DRB1 alleles, and up to two 
more from the alternate DRB gene loci.  
Henceforth, in the thesis, I will be using the nomenclature of the XVth Histocompatibility 
Workshop (Marsh et al., 2010). Briefly, allelic variation will be represented by two-digit 
numbers following the gene name (e.g. HLA-DRB1*15). The first two digits correspond to 
the type of serological antigen presented by the HLA-DRB1.  Each allele can be further 
resolved in to subgroups that differ due to nonsynonymous nucleotide substitutions 
represented, by the addition of further digits (e.g. HLA-DRB1*15:01). This are used to list 
the subtypes, numbers being assigned in the order in which DNA sequences have been 
determined. Alleles whose numbers differ in the first four digits must differ in one or more 
nucleotide substitutions that change the amino acid sequence of the encoded protein. Lastly, 
differences in the nucleotide sequence of the HLA-DRB1 DNA that do not actually result in 
amino acid differences within the gene product, i.e. synonymous substitutions,  are 
represented by an additional two digits (e.g. HLA-DRB1*15:01:01) (Marsh et al., 2010). 
Further digits can be added to indicate the promoter polymorphism.  
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1.3.5 Role of MHC II in self-tolerance and auto immunity  
 
As implied Section 1.1, the purpose of the immune system is to destroy, isolate, and/or 
remove any pathogens and the toxic substances they produce, which may harm the 
homeostasis of the host. It is therefore crucial that the adaptive immune response is directed 
specifically against the pathogens and not against the host. Occasionally, the immune system 
fails in making this distinction and reacts destructively against particular host-antigens, 
resulting in autoimmunity (Smith and Germolec, 1999). Antigen presentation is not only 
crucial for the regulation of protective immune responses against invading pathogens, but is 
also necessary for the maintenance of self-tolerance.  
MHC II expression directs positive selection (selection of T cells which can recognise MHC 
molecules) and negative selection (deletion of self-reactive T cells (Klein et al., 2014));which 
shape the specificity of the T-cell-receptor repertoire of the CD4+ T-cell population during its 
development in the thymus (Kyewski and Klein, 2006). Nevertheless, T cells with an 
autoreactive repertoire still escape from the thymus, since not all self-antigens are expressed 
in the thymus. To prevent this auto-reactive leakage, a peripheral T cell tolerance process 
exists, whereby self-reactive T cells are physically kept away from self-antigens, are deleted 
e.g. by apoptotic stimuli, suppressed or inhibited, or  simply ignore the antigens due to their 
low concentration (Kamradt and Mitchison, 2001). Despite all the existing tolerance 
mechanisms, auto-reactive cells can still break tolerance and cause autoimmunity. There can 
be several reasons for this, including incomplete expression of self-antigens during T cell 
education, structural similarity between microbial and self-antigens (known as molecular 
mimicry) (Albert and Inman, 1999), the presence of co-stimulatory signals during 
inflammation (Kamradt et al., 1991), infectious agents (Christen et al., 2012), post 
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translational modifications which can generate neo-epitopes from self-proteins, and thus 
result in the breaking of self-tolerance (Anderton, 2004).  
It is therefore perhaps not surprising to find that the human MHC II gene region holds the 
largest number, and some of the longest recognised associations with autoimmune diseases of 
any similar-sized region across the genome. The involvement of the MHC II in many 
complex diseases is confirmed further by Genome-wide association studies (GWAS) 
(WTCCC, 2007), and some examples are listed in Table 1.1.  
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Table 1.1 Genes in the MHC II in which variation has a relationship to disease.  
 






alleles confer high 
risk and the rest 
exhibit a more 
moderate risk 
(Fernando et al., 
2008, Raychaudhuri, 
2010) 







the greatest risk for 
Type 1 Diabetes 
WTCCC, (2007), 
(Howson et al., 2009) 







(Fernando et al., 
2008, Silverberg et 
al., 2009) 






(Stokkers et al., 1999, 
Barrett et al., 2008) 








(Modin et al., 2004, 
Ramagopalan et al., 







 (Sestak et al., 2011) 
Table modified from Handunnetthi et al (2010b) 
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It is not just the MHC molecule but environmental factors also have an impact on the 
development of auto immune disease (Dankers et al., 2016).  Pathogens like viruses and 
bacteria have been implicated in autoimmunity (Ercolini and Miller, 2009). Recently there is 
also growing evidence that the gut microbiota influence the development of autoimmunity 
(Rosser and Mauri, 2016). Dietary components are also linked with the development of auto 
immune disease conditions (Vojdani et al., 2014). Of these, vitamin D, because of its 
immunomodulating effects, also has an impact on the development of autoimmune diseases, 
has been discussed in detail. 
1.4 Vitamin D  
 
Vitamin D is an essential nutrient compound, best known for its role in calcium homeostasis 
and bone mineralization (Veldurthy et al., 2016). The discovery that the vitamin D receptor 
(VDR) is expressed in many human cells, including immune cells, has directed the attention 
to the extra skeletal effects of vitamin D (Morgan et al., 2000). Vitamin D is involved in 
numerous other functions such as modulating immune function, and regulating cellular 
proliferation, differentiation, and apoptosis (Maruotti and Cantatore, 2010) and then in 
development of autoimmune disease (Handel et al., 2013). In addition, vitamin D is neuro-
protective (Wrzosek et al., 2013). 
 
1.4.1 Production and metabolism 
 
In humans, vitamin D is obtained either through synthesis in the skin or through dietary 
ingestion. Ergocalciferol (vitamin D2) can only be obtained via oral consumption through 
dietary intake of oily fish or UV irradiated mushrooms (Kamweru and Tindibale, 2016).   
Cholecalciferol (vitamin D3) is produced in the skin following exposure of 7-
dehydrocholesterol to UVB radiation (sunlight) (Holick, 1981). However, the majority of 
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vitamin D in humans is obtained through synthesis in the skin (Calvo et al., 2005). Vitamin D 
metabolism is a sequential process as shown in Figure 1.6. The first step is the hydroxylation 
of vitamin D3 or vitamin D2 in the liver, performed by the cytochrome P450 mixed-function 
oxidases (CYPs), of which CYP2R1 is the most important one (Zhu et al., 2013). This yields 
25-hydroxy-vitamin D (25-OH-D), the metabolite measured in the blood to evaluate vitamin 
D status. A second hydroxylation step then takes place in the kidney, resulting in 1,25-
dihydroxyvitamin D (1,25-OH2-D).  This is the active form of vitamin D and is also referred 
as calcitriol. The enzyme responsible for this is 1 α-hydroxylase (CYP27B1) (Prosser and 
Jones, 2004). Calcitriol is then transported in the blood by the vitamin D binding protein and, 
on reaching the target cell, it dissociates, binds to vitamin D receptor (VDR) within the 
cytoplasm, and mediates its biological actions (Haussler et al., 1997). This complex enters the 
nucleus and forms a heterodimer with a nuclear receptor, the retinoid X receptor (RXR) 
(Thompson et al., 1998, Thompson et al., 1999). The heterotrimer calcitriol–VDR–RXR 
lastly binds to vitamin D-responsive elements (VDREs) (White, 2004), which are made up of 
a sequence of DNA within the promoter region of the target genes. The complete system thus 
regulates (by activation or suppression) gene transcription and thereby protein synthesis 
(Niino et al., 2008). Thus, calcitriol, secreted into the bloodstream by the kidney and exerting 




Figure 1.6 A schematic representation showing the pathway of vitamin D metabolism and action. 
During exposure to sunlight 7-dehydrocholesterol in the skin is converted to Cholecalciferol D3. 
Vitamin D in the circulation is bound to the vitamin D binding protein which transports it to the liver 
where vitamin D is converted to 25-OH-D. It is biologically inactive and must be converted in the 
kidneys to its biologically active form 1, 25-OH-2D.  Active vitamin D can then enter cells and 
stimulate the vitamin D receptor protein to bind to DNA in the nucleus via  RXR nuclear receptor, 
acting as a regulator for hundreds of genes. At the gene level, the heterodimer comprising calcitriol 
may stimulate or repress protein synthesis, depending on the cell. Abbreviations: C, calcitriol; 
CYP2R1, vitamin D-25-hydroxylase; CYP27B1, 1α-hydroxylase; RXR, retinoid X receptor; UVB, 
ultraviolet B radiation; VDR, vitamin D receptor; VDRE, vitamin D-responsive element; VBP vitamin D 
binding protein. Figure adapted from Charles Pierrot-Deseilligny (2013) 
 
Moreover, various immune cells, including monocytes, dendritic cells, macrophages, B cells, 
and T cells, also have the capability to convert 25-OH-D into 1,25-OH2-D (Heine et al., 2008, 
Jeffery et al., 2012, Bakdash et al., 2014). This allows for local regulation of the 
concentration of 1,25-OH2-D. 
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RXR is a shared nuclear hormone receptor as, it can also bind as a homodimer or as a 
heterodimer with retinoic A receptor (RAR) (Blomhoff and Blomhoff, 2006). Both vitamin D 
and RA exert their cellular effects via nuclear receptors, which bind to the promoters of their 
response genes to facilitate transcription. Once vitamin D is converted to its active 
metabolite, 1, 25 dihydroxyvitamin D (1, 25(OH) D3), it will form a complex with VDR. 
Binding of 1, 25(OH) D3 leads to a conformational change in  VDR and enables binding to 
the retinoic X receptor (RXR) (Mora et al., 2008, Pike and Meyer, 2010).  
 
 After heterodimer formation, VDR/RXR OR RAR/RXR is translocated to the nucleus, where 
it can exert three different effects: it can bind to a vitamin D3 response element (VDRE) in 
the promoter region of target genes and turn on genes; it can bind to what is termed a 
'negative' VDRE and prevent gene transcription; or it can bind to transcription factors present 
in the nucleus and prevent them from binding to target genes (Nagpal et al., 2005). RXR is a 
shared nuclear hormone receptor as it can also bind as a homodimer or as a heterodimer with 
retinoic A receptor (RAR) (Blomhoff and Blomhoff, 2006). The binding of the RAR/ RXR 
heterodimer to the retinoic acid response element (RARE) sequence in the promoter region of 
the target genes results in the transcription of target genes (McGrane, 2007). 
 
1.4.2.1 Role of vitamin D in the immune system 
 
Vitamin D is a pleiotropic regulator of immune functions (as well as calcium homeostasis and 
bone metabolism), with many possible modes of action in auto-immunity (Pludowski et al., 
2013).  Vitamin D plays an important role in both innate and adaptive immune response.   
 
Calcitriol plays an important role in innate immunity, in particular in inducing antimicrobial 
peptides, such as Cathelicidin, an essential innate component for combating Mycobacterium 
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tuberculosis (Liu et al., 2006). Bioactive vitamin D has also been shown to upregulate the 
pattern recognition receptor Nucleotide-binding oligomerization domain containing 2 
(NOD2) which, when activated in the presence of bacteria, leads to release of the 
antimicrobial peptide defensin β2 (Wang et al., 2010). Calcitriol may act on the innate 
immune system in several other ways, with the general result of enhancing innate immunity. 
 
The effects of vitamin D on the adaptive immune system are also numerous. Calcitriol 
inhibits T cell proliferation (Rigby et al., 1990). Calcitriol has also been reported to promote 
tolerance and regulation by inhibiting the maturation of DCs and promoting T regulatory cell 
(Treg) populations (Penna et al., 2005). Thus, calcitriol renders the DCs more immature and 
hence more tolerogenic, and also upregulates molecules on the cell surface of DC resulting in 
the inhibition of effector T cells whilst promoting induction and recruitment of Tregs. In B 
cells, calcitriol has been found invitro to decrease cell proliferation, antibody production and 
plasma cell proliferation (Chen et al., 2007). However, it is still not clear whether this also 
occurs in vivo (Rolf et al., 2014). Calcitriol has also been found to affect DCs; it influences 
their cytokine production (Barragan et al., 2015). Calcitriol has been reported to prevent the 
maturation of DCs, resulting in reduced expression of the costimulatory molecules CD80, 
CD86, and HLA-DR and the maturation marker CD83 (Canning et al., 2001, Sochorova et 
al., 2009). However in Epstein-Barr virus (EBV) transformed B cells, where there is vitamin 
D response element (VDRE), calcitriol is able to increase the expression of HLA-DR 
(explained further in section 1.4.6) (Ramagopalan et al., 2009). There may be different effects 
of calcitriol on APCs depending on the presence of the VDRE. The effects of bioactive 
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vitamin D on the immune system have been summarized in Figure 1.7. 
 
 
Figure 1.7 Roles of vitamin D in the immune system.  Vitamin D has wide ranging immunomodulatory 
properties. Vitamin D effects on the innate immune system include induction of antimicrobial peptides, 
such as cathelicidn and defensin β2 and induction of autophagy. Vitamin D controls the effector CD4+ 
T cell response through decreasing expression of TLR molecules and costimulatory molecules on the 
antigen presenting cells. Additionally Vitamin D enhances regulatory T cell populations by enhancing 
IL-10 production and inhibitory molecule expression on antigen presenting cells.  Figure adapted from 
Chambers and Hawrylowicz (2011). 
 
 
1.4.2.1 Role of RA in the immune system 
 
RA, a derivative of vitamin A (Harrison, 2005),  is important for the immune system (Pino-
Lagos et al., 2008, Hall et al., 2011, Erkelens and Mebius, 2017). The general effects of RA 
on immune system  are summarised in Figure 1.8. RA is also central for the differentiation of 
myeloid cells and affects the maturation and survival of macrophages (Kim, 2011).  RA can 
inhibit B cell proliferation (Blomhoff et al., 1992, Ballow et al., 1996), although it has also 
been found to enhance B-cell activation under some conditions (Saurer et al., 2007). RA can 
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also modulate antigen presentation by exerting direct effects on DC function (Darmanin et 
al., 2007). In addition, in the presence of inflammatory stimuli, RA enhances DC maturation 
and antigen-presenting capacity (Geissmann et al., 2003).   
 
Figure 1.8 Roles of RA in the immune system. RA exerts its effects on several immune cell types, 
including macrophages, DCs, T and B cells. Figure adapted from  Mora et al., (2008) 
 
 
Thus, considering the wide range of immunomodulatory effects of vitamin D, it is not 
surprising to find a lack of vitamin D being associated with several diseases. Multiple 
sclerosis (MS) is the perfect example of an autoimmune disease known for its association 
with both MHC II polymorphism and vitamin D deficiency in the development of disease.  
 
1.5 Multiple Sclerosis  
 
MS is a chronic complex autoimmune disorder of the central nervous system (CNS). MS 
patients develop multiple lesions in their CNS, where the axons of neurons have been 
demyelinated (Lucchinetti et al., 2000, Kornek and Lassmann, 2003). These lesions may 
develop in virtually any region of the CNS and may lead to a wide range of motor, sensory 
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and/or cognitive deficits. Clinically, MS presents in a variety of ways; some of the most 
common initial symptoms are optic neuritis, sensory disturbances and diplopia (Soderstrom et 
al., 1998). During the course of the disease, fatigue, cognitive dysfunction, bladder 
disturbances, weakness, and a wide variety of other neurological dysfunctions commonly 
occur (DasGupta and Fowler, 2003, Opara et al., 2010). The usual clinical definition of the 
disease is “dissemination in time and space” of lesions of inflammatory demyelinating origin, 
i.e. recurrence of symptoms from different locations (multiple) of the nervous system (and 
where other causes have been ruled out).This definition is the basis for the diagnostic criteria, 
the McDonald criteria (McDonald et al., 2001), that have been used clinically and in research 
for the last two decades  with some modifications (Polman et al., 2005, Polman et al., 2011, 
Thompson et al., 2018). Moreover, MS is also classified into four different types based on the 
progression  of the disease. This classification are relapsing remitting MS, primary 
progressive MS, secondary progressive MS, and progressive relapsing MS (Rovaris et al., 
2009). This classification along with common characteristics can be found in Table 1.2. 
There is no cure for MS and the disease can lead to disability and sometimes death 
(Roxburgh et al., 2005, Pachner and Steiner, 2009). Although the age of onset for MS varies 
greatly, most patients receive their diagnosis of definite MS between 20 and 45 years of age 
(Hammond et al., 2000), but recent advances in  magnetic resonance imaging (MRI) 






Table 1.2 Various types of MS.  
Types of MS Characteristics 
Relapsing-Remitting Multiple Sclerosis 
(RRMS) 
Symptom flare-ups followed by recovery; 
stable between attacks 
Secondary Progressive Multiple 
Sclerosis (SPMS) 
progressive worsening of symptoms with or 
without superimposed relapses 
Primary-Progressive Multiple Sclerosis 
(PPMS) 
Gradual but steady accumulation of 
neurological problems from onset 
Progressive-Relapsing Multiple 
Sclerosis (PRMS) 
Progressive course from the onset, 
sometimes combined with occasional acute 
symptom flare-ups 
Benign MS Few attacks and little or no disability after 
15 or more  years 
Table adapted from Miller et al.(2005) 
 
1.5.1 Pathophysiology of MS 
 
The most widely accepted view of the pathophysiology underlying MS is that it is an 
autoimmune disease of the CNS (Holmøy, 2007). Several lines of evidence support the view 
of MS as an autoimmune disease: animal models of MS, the characteristics of MS lesions, 
and the efficacy of immunotherapy in MS. Here, a short overview of the immunological 
dysfunction that may be important for the development of MS is given. 
Virtually all our mechanistic concepts of adult MS are derived from an animal model, 
experimental autoimmune encephalomyelitis (EAE) (Ben-Nun et al., 2014, Baker and Amor, 
2014). EAE is induced by immunizing animals with myelin-derived proteins or peptides such 
as myelin basic protein (MBP), hydrophobic proteolipid proteins (PLPs), and myelin 
oligodendrocyte glycoprotein (MOG) or by transfer of immune T-helper cells that have been 
sensitized to such myelin peptides (Emerson et al., 2009, Ben-Nun et al., 2014). Overall, the 
lesions and clinical signs induced in EAE by these myelin-associated antigens bear 
resemblance to the inflammatory demyelinating processes observed in MS. 
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The prevailing view of MS immunopathogenesis is that autoreactive immune cells are 
activated peripherally and gain access to the CNS (Dendrou et al., 2015). T cells are activated 
against a CNS autoantigen and are transported to the CNS, where they pass across the blood 
brain barrier (BBB), which has become permeable, and then initiate an inflammatory process 
by recognizing the antigen presented by APCs (Broux et al., 2013, Hemmer et al., 2015). The 
macrophages and or microglia have the capacity to secrete cytokines, may thus modulate 
immune responses, and may attract specific activated immune cells (Imitola et al., 2005). 
Recently, the role of the B cell, the other cell type of the adaptive immune system, in MS has 
attracted attention (Hauser et al., 2008, Disanto et al., 2012). The functions of B cells range 
from antibody production to antigen presentation and immune system regulation through 
cytokine production (Hoffman et al., 2016). In MS, it has been postulated that B cells 
produce antibodies which attack the neurons causing demyelination (Dendrou et al., 2015, 
Dolati et al., 2017). The immune-pathogenesis in MS is depicted schematically in Figure 1.9. 
Furthermore, higher circulating levels of immune cells and immunoglobulins specific to the 




Figure 1.9 Postulated immune cascades in multiple sclerosis. Myeloid cells and B cells are competent 
antigen-presenting cells that are thought to present a molecular mimic of a myelin peptide to generate 
myelin-reactive TH cells, which can further activate the myeloid cells into the central nervous system 
(CNS). Activated immune cells produces pro-inflammatory cytokines, which direct phagocytic attacks 
on the myelin sheath. After clonal expansion, B cells mature to plasma and release large amounts of 
antibodies, which can cause damage to the myelin sheaths. Figure adapted from Dolati (2017). 
 
In addition to the inflammation described above, there is also a neurodegenerative component 
to MS that results in axonal damage and neuronal loss (Trapp and Nave, 2008). While the 
increase of new demyelinating lesions can be associated with acute clinical relapse, it is the 
progressive increase of both clinical and subclinical pathological disease (focal areas of 
inflammation as well as widespread neuronal cell loss and axonal) that is thought to trigger 
progression to irreversible disability. The risk of irreversible disability depends on the 
phenotype of MS and increases with disease duration; however, pathological features of 
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tissue injury are also detectable from clinical disease onset (Trapp and Nave, 2008). Effective 
strategies for neuroprotection against MS have not yet been established. 
1.5.2 MS risk determinants  
 
Our understanding of the factors involved in the etiology and progression of MS remains 
incomplete. Epidemiological studies have shed light on ethnic, seasonal and geographical 
variations in MS incidence, leading to the various hypotheses regarding the genetic, hormonal 
and environmental risk factors, and their potential interactions (Ascherio, 2013). While the 
present thesis is largely concerned with the role of vitamin D and genetics in MS, other 
candidate risk factors for MS, such as sex hormones, viral infection (particularly EBV) and 
cigarette smoke exposure are also important (Ascherio et al., 2001, Compston and Coles, 
2002). 
 
1.5.3 Geographical pattern  
 
It became clear during the first half of the 20th century that there are geographical differences 
in MS prevalence. The prevalence of MS is higher in areas with temperate rather than tropical 
climates.  It generally increases with distance from the equator, and is inversely associated with 
average sunlight exposure (McMichael and Hall, 1997). There are several comprehensive 
reviews on this topic discussing the relationship between sunlight exposure and the prevalence 
of MS (Holmøy, 2007, Giovannoni and Ebers, 2007, Pugliatti et al., 2008, Handel et al., 2009, 
Correale and Farez, 2013).  One thing to consider here is that the healthcare system in equatorial 
countries and polar countries are very different and there is a north-south gradient in the quality 
of healthcare surveillance at least historically. But within the same country, when work-related 
sun exposure was evaluated in the USA, based on death certificates, increasing sun exposure 
was negatively associated with death due to MS (Freedman et al., 2000). Also, in Sweden, 
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using register data, a decreased risk of MS with increasing occupational sun exposure was  
found (Westberg et al., 2009). The striking correlation between MS prevalence and latitude has 
suggested sunlight and resultant vitamin D status as a determinant of MS risk (Kampman and 
Brustad, 2008, Pierrot-Deseilligny, 2009). 
1.5.4 Serum 25-OH-D concentration among MS patients 
 
A number of studies have reported  lower serum levels of 25-OH-D, the precursor of active 
vitamin D, in MS patients than in healthy controls (Munger et al., 2006, van der Mei et al., 
2007, Kampman and Brustad, 2008, Kragt et al., 2009, Simpson et al., 2010, Salzer et al., 
2012, Runia et al., 2012, Duan et al., 2014). In most of these studies, there was a control 
group in addition to the patient group, but there was not always a significant difference in the 
serum levels of 25-OH-D between the two groups and therefore clinical significance remains 
unclear.  Lacking to date are studies of vitamin D status in regions where MS is rare. Lastly, 
serum 25-OH-D levels are rarely evaluated in apparently healthy individuals prior to the 
onset of disease; one study did demonstrate that vitamin D status in early adulthood was 
inversely related to subsequent MS risk (Munger et al., 2006), but more such studies are 
needed. 
 
There are several other factors which can affect the serum 25-OH-D serum concentration in 
the blood. Clothing and time in the sun also determine the serum level of 25-OH-D. Even in 
areas of high sunlight, vitamin D synthesis can vary markedly between individuals (Holick, 
2014). Application of sunscreen can impair endogenous vitamin D synthesis. There is also 
evidence that the amount of 7-dehydrocholesterol in the skin decreases with age such that the 
elderly may have reduced capacity to synthesize vitamin D (MacLaughlin and Holick, 1985). 
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In addition, people who have more melanin pigment in their skin also typically require longer 
sun exposure to achieve adequate vitamin D synthesis (Clemens et al., 1982).  
An important unanswered question here is: does vitamin D affect MS or does MS affect 
vitamin D metabolism? While the contribution of vitamin D deficiency to the development of 
MS and other immune-mediated diseases has been suggested for decades, it has not been 
discussed whether the disease process itself and  physiological  effects of the disease could 
modify vitamin D metabolism.  
It also has to be considered that vitamin D insufficiency is common in temperate climates, yet 
most individuals with low serum 25-OH-D concentrations do not develop MS. However, the 
absence of MS in these individuals does not negate the potential importance of vitamin D 
insufficiency as a risk factor for MS. Rather this does suggest that other factors potentially can 
lead to MS progression apart from vitamin D deficiency. One such factor is the genetics. 
1.5.5 MS and Genetics 
 
MS risk increases with increasing degree of relatedness or similarity of DNA. The 
concordance rate of MS among monozygotic twins, who share virtually 100% of their DNA, 
is generally between 25-31% (Dyment et al., 2004). In contrast, the prevalence rate for MS in 
dizygotic twins and full siblings, who share approximately 50% of their DNA, is only 4-5% 
(Willer et al., 2003, Fagnani et al., 2015).  The risk of MS is increased in close relatives of 
MS patients, varying proportionally to the fraction of shared genes. Thus, genetic factors add 
to the disease predisposition. 
The genes with the strongest and most consistent association with MS risk are found on 
chromosome 6 and cluster within regions of DNA that encode the HLA system (Lincoln et 
al., 2005, Ramagopalan and Ebers, 2009). In almost all the studied MS populations in Europe 
there is an association to the HLA DRB1*1501 allele (Masterman et al., 2000, Weatherby et 
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al., 2001, Hensiek et al., 2002, Ballerini et al., 2004, Schmidt et al., 2007, Ramagopalan et al., 
2008, Alcina et al., 2012). This allele is in strong linkage disequilibrium with DRB5*0101 
and DQB1*0602 and therefore no primary susceptibility allele has been resolved (Fogdell et 
al., 1995, Lincoln et al., 2009). This haplotype increases the risk of MS about 2-4 fold in both 
sporadic and familial MS. However the DRB1*1501 allele is not linked with the Asian type 
of MS, which is also characterised by a different pathology than the Western type of MS 
(Asians have fewer brain lesions and more spinal-cord lesions when compared to Western) 
(Kira et al., 1996, Yoshimura et al., 2012). In addition, Sardinians who have a relatively low 
frequency of the MS associated DRB1*1501 haplotypes in both patients and the normal 
population, have the DRB1*13∶03-DQB1*03∶01 haplotype as a susceptibility factor in MS 
(Marrosu et al., 2001).  These observations suggest that MS may be immunogenetically 
different in different populations. Why the risk of MS varies between certain alleles remains 
to be determined, but is likely related to the physiological function of HLA molecules in 
antigen presentation. The effect of vitamin D on the most common alleles is examined in 
Chapter 5. 
 
1.5.6 Biological Plausibility of Vitamin D and HLA-DR interactions  
 
 
Investigation of the major candidate genes, HLA-DRB1, HLA-DQA1 and HLA-DQB1, led 
to discovery of a conserved, functional vitamin D response element (VDRE) in the promoter 
region of the HLA-DRB1*1501 allele (Ramagopalan et al., 2009). Furthermore, the authors 
demonstrated that addition of calcitriol to DRB1*15 homozygous B-cells in vitro resulted in 
increased expression of HLA-DR (Ramagopalan et al., 2009). Therefore, it is plausible that 
the association between the HLA-DRB1 allele and risk of MS may be modified by vitamin D 
status, which determines the availability of the activated metabolite of vitamin D. This 
observation suggests that vitamin D might protect from MS in part by differentially 
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influencing the expression and function of HLA-DR protein variants associated with MS risk. 
It could be that vitamin D deficiency or impaired vitamin D metabolism may lead to lower 
expression of the MHC II molecule (Handunnetthi et al., 2010a). Reduced expression of 
MHC II molecules could impair presentation of self-antigens during negative selection, 
resulting in a lack of tolerance being established against those self-antigens. If the immune 
system fails to establish and maintain immune tolerance to molecules derived from the BBB 
or CNS myelin, this could result in the type of demyelinating immune attacks observed in 
MS. This does form a conceptual basis for a nutrient-gene interaction, thus connecting the 
genetic and environmental evidence implicating sunlight and vitamin D in the determination 
of MS risk or other autoimmune diseases in which MHC and vitamin D plays a pivotal role in 
the pathogenesis.  
 
Since vitamin D is pleiotropic, and other factors do complicate the above explanation. 
Vitamin D responsiveness is shared by a subset of DRB1 alleles, not all of which are 
associated with MS (Cocco et al., 2012), and why the risk of MS varies between certain 
alleles remains to be determined. One possibility is that vitamin D could modulate the 
relative expression levels of DR allelic variants encoded by maternal vs. paternal haplotypes, 
if the co-expressed alleles differ in their vitamin D responsiveness. Moreover, vitamin D 
could influence the relative levels of DR molecules containing DRB1 vs. alternate DRB gene 
products, including DRB5 in the MS-associated DRB1*15 haplotype. These changes could 
help vitamin D to maintain immune tolerance to myelin autoantigens. Therefore, the 
regulation by vitamin D of HLA-DR expression and fate, and the effects of structural and 
promoter polymorphisms need to be investigated at the protein level, before implications for 
MS can be evaluated. The method development for measuring changes in the allelic 
composition, in the presence of vitamin D in heterozygous APCs, constitutes Chapter 6 of 
this thesis.  
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Antibody-based approaches for quantifying allelic composition are potentially biased by the 
antibodies conformational preferences (Woolley et al., 2015), hence mass spectrometry based 
approach will be used to quantify DRB allelic composition in heterozygous APCs. Mass 
spectrometry is an analytical technique that measures the mass/charge ratio of charged 
particles in vacuum. Mass spectrometry can determine masse/charge ratio with high 
accuracy. Molecules in a test sample are converted to gaseous ions that are subsequently 
separated according to mass/charge ratio (Eliuk and Makarov, 2015). A mass spectrometry 
experiment typically consists of five steps: sample introduction, analyte ionization, mass 
analysis, ion detection, and data processing and interpretation of the results (Yates et al., 
2009). A simplified scheme on how mass spectrometry works is shown in Figure 2.0 
 
 
Figure 2.0 A simplify scheme of Mass spectrometry. 
 
Mass spectrometry is a powerful tool in qualitative and quantitative analysis of compounds 
with biological relevance. Owing to its high-resolution mass spectrometry, based approach 
will be used to detect the effect of vitamin D and or RA on the allelic variants of the HLA-
DR in Chapter 6   
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Aims and Objectives  
 
This thesis pursues two objectives as discussed in the general introduction. The first objective 
is to elucidate the regulation of the MHC II molecules particularly its degradation. There has 
been speculation that faster turnover of MHC II molecules is not good for maintaining  
immune tolerance. The first broad aim is to characterise the role of specific lysosomal 
proteases in the turnover of HLA-DR glycoproteins in model APCs. Work described in 
Chapter 3 identified a specific lysosomal protease playing a role in the degradation of MHC 
II (HLA-DR) molecules.  The particular form of DR degraded by the lysosomal protease was 
evaluated in studies described in Chapter 4 of the thesis.  
The second objective of this dissertation is to study the interaction of micronutrients like 
vitamin D and RA on the expression of the MHC II by developing new tool to study the allele 
specific effects on the cell lines that are heterozygous for MHC II allele. The second aim is to 
understand how the expression of MHC II alleles and gene variantgene variants is 
regulated by vitamin D and retinoic acid. Chapter 5 describes the combined effects of 
bioactive vitamin D and retinoic acid on common DRB1 alleles in homozygous typing cell 
lines and in a myeloid APC. Chapter 6 describes the development of new methods using 
stable isotope labelling for quantifying the allelic composition of the HLA-DR β chains in 
heterozygous APCs. This chapter also describes the effects of vitamin D and retinoic acid on 
the allelic composition of HLA-DR β chain. The conclusions are discussed in Chapter 7 of 
the thesis.  
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Chapter 2 Materials and methods 
 
This chapter describes the methods and instruments used in the different experiments 
performed in this thesis. 
2.1 Materials 
2.1.1 Cell lines  
 
The cell lines used in the thesis are listed in Table 2.1. MANN, BOLETH, COX, HOM-2, 
PGF and WDV are homozygous typing cells (HTCs) covering the six most prevalent HLA-
DRB1 alleles found in one or both haplotypes of 90% of the White British/ White Irish/ 
Caucasian individuals. KG-1 cells are an acute myeloid leukaemia cell line. The L243 
hybridoma produces monoclonal antibody L243, which is capable of binding the  domain of 
HLA-DR molecules (Lampson and Levy, 1980). EK and JBUSH are HTCs matched for the 
DRB1 alleles found in KG-1 cells. 
Table 2.1 List of cell lines 
Cell line Type DR  Reference 
KG-1 
Human acute myeloid leukaemia 





Golde, 1978, Ning 
et al., 2011) 
Priess Homozygous typing cell line DRB1*04:01 




Hybridoma cells capable of producing 
L243 antibodies  
- 
(Nagy et al., 2002) 





BOLETH Homozygous typing cell line   
DRB1*04:01 
DRB4*01:03 









COX Homozygous typing cell line  
DRB1*03:01 
DRB3*01:01 
HOM-2 Homozygous typing cell line  DRB1*01:01 
PGF Homozygous typing cell line  
DRB1*15:01 
DRB5*01:01 
WDV Homozygous typing cell line  
DRB1*13:01 
DRB3*01:01 
EK Homozygous typing cell line DRB1*11:01 
JBUSH Homozygous typing cell line DRB1*14:01 
 
2.1.2 Kits and reagents 
 
The reagents used in the study were of the highest grade commercially available. Kits and 
chemicals used in the study are listed in Table 2.2 along with their catalogue number and 
supplier. 
Table 2.2 List of kits and reagents 
Items Supplier 
Kits 
Fixation/Permeabilization Solution Kit BD life sciences (554714) 
SYBR Green Cells-to-Ct Kit  Life technologies (4402954) 
GenElute DNA Miniprep Kit  Sigma-Aldrich, G1N 70 
8 peak and 6 peak validation beads BD life sciences (653145) 
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Bicinchoninic acid assay (BCA) kit Thermofisher (23225) 
Chemicals 
rH Cathepsin D R&D Systems (1014-AS) 
rH cathepsin E R&D Systems (1294-AS) 
Complete protease inhibitor Roche (11697498001) 
Gentamycin Sigma-Aldrich (G1272) 
RT-PCR grade water Ambion (AM 9935) 
Fixation solution  BD life sciences (554655) 
Protein A sepharose GE life science (193256) 
Instablue Expedeon (SKU: ISB1L) 
40% Acrylamide  Bio-Rad (161044) 
Western ECL reagent  Clarity western ECL substrate (Biorad 1705060) 
Pepstatin A Sigma-Aldrich (P5318) 
RA Sigma-Aldrich (R2625) 
Vitamin D3 Sigma-Aldrich  (D1530) 
IMDM  Gibco (12440053) 
RPMI 1640 Gibco (11875093) 
IMDM GlutaMAX Gibco (31980030) 
SILAC labelled RPMI (R6K6) DC Biosciences (LM018) 
L-glutamine Sigma (G7513) 
Fetal bovine serum  Sigma (F3145) 
Penicillin/streptomycin Sigma (P4333) 
Dialysed serum (MWCO 10 kDa) DC Biosciences (DS 1002) 





2.1.3 Culture media 
 
Cell lines were grown in either complete RPMI media or complete IMDM media with L-
glutamine or Glutamax as described in Table 2.3. 
Table 2.3 List of cell culture media 
Media Cells  Description 
Complete IMDM KG-1  IMDM , 20% (v/v) heat-inactivated foetal 
bovine serum (HIFBS), 2mM L-glutamine and 
1% (v/v) penicillin/streptomycin 
Complete IMDM 
Glutamax 
KG-1  IMDM, 20% (v/v) HIFBS and 1% (v/v) 
penicillin/streptomycin 





RPMI, 10% (v/v) HIFBS, 2mM L-glutamine  
and 1% (v/v) penicillin/streptomycin 
Hybridoma media L243 Hybridoma RPMI , 10% (v/v) HIFBS, 2mM L-glutamine 
and  1% (v/v) penicillin/streptomycin  
SILAC  media KG-1, MANN, 
BOLETH, COX, 
HOM-2, WDV, PGF 
RPMI  , 10% dialysed FBS and  1% (v/v) 
penicillin/streptomycin 
Freezing media various 90% HIFBS and 10% DMSO (sigma D2650) 
 
2.1.4 Buffers and Solutions 
 
All dilutions were made volume/ volume (v/v) for liquids and weight/volume (w/v) for solids 





Table 2.4 List of buffers and solutions 
Buffer/ Solutions Recipe/ Manufacturer 
Cell culture 
5 mM Pepstatin A stock  3.5 mg of Pepstatin A in 1 ml of DMSO 
10 mM RA  3mg of RA in 1 ml of DMSO 
10 µM Vitamin D3 4.16 mg of Vitamin D3 in 1 ml DMSO  
1 mM CuSO4 160 mg of CuSO4 in 1 litre ddH2O 
Western Blot 
Phosphate buffer saline 
(PBS) 
10x PBS tablets dissolved in ddH2O 
PBS-T PBS + 5% Tween 20  
RIPA buffer  50 mM Tris-Base, 150 mM NaCl, 1% Triton-X-100 and 
0.1% SDS + Protease inhibitor cocktail (1 in 10ml) 
SDS resolving buffer 1.5 M Tris-HCl pH 8.8; 0.4% SDS 
SDS stacking buffer 0.5 M Tris-HCl pH 6.8, 0.4% SDS 
SDS PAGE running buffer 25 mM Tris, 192 mM glycine, 0.1 % SDS 
LaemmIisample buffer  0.5 M Tris-HCl pH 6.8, 10% glycerol, 2% SDS and bromo-
phenol blue + – β-mercaptoethanol 
Western Transfer buffer  25 mM Tris, 192 mM glycine and 20% v/v methanol 
Western Blocking buffer PBS-T + 5% skimmed milk powder 
Stripping Buffer 0.1 M glycine, 20 mM magnesium acetate, 50 mM HCl, pH 
2.2 
Flow cytometry 
FACS buffer  PBS + 5% Bovine Serum Albumin +0.01% Sodium Azide 
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Perm-Wash buffer  Diluted from 10x stock of wash buffer BD  
Antibody diluent  5% BSA in PBS 
Immunoprecipitation 
Lysis buffer I 150 mM NaCl, 5 mM EDTA (pH 8), 50 mM Tris-HCl (pH 
7.4), 1% CHAPS + complete protease inhibitor 
Lysis buffer II  150 mM NaCl, 5 mM EDTA (pH 8), 50 mM Tris-HCl (pH 
7.4), 0.1% CHAPS 
Protein purification  (L243 antibody) 
Wash buffer 200 mM sodium phosphate buffer, pH 7.0 
Elution buffer  1 M glycine-HCl, pH 2.7 
Neutralizing buffer  1 M Tris ,pH 9.0 
Protein purification (sDR0401) 
Elution buffer  1 M Tris base pH 11.0 
Neutralizing buffer  1 M glycine, pH 2.0 
Molecular biology 
Loading buffer  0.25% bromophenol blue, 30% glycerol  
Tris acetate EDTA (TEA) 
buffer 
40 mM Tris, 20 mM acetic acid ,1 mM EDTA  
Primer dilution (TE buffer) 10 mM Tris, 0.1mM EDTA, pH 8.0 
 
2.1.5 Antibodies  
 
A list of all the antibodies used in this study is provided in Table 2.5, together with their use 
and working dilution. For flow cytometry, antibody dilutions are commonly described as μl 
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of antibody added per test of 50 l cell suspension. Cell numbers can range from 105 to 106 
cells/test.  
Table 2.5 List of Antibodies 





Binds to the DR α of the mature αβ 





(DA2) mouse IgG 
Binds to the DR β of the mature αβ 




CD74 (PIN.1)  
mouse IgG 







Epitope corresponding to class II invariant 






Mouse myeloma cell line NS0-derived 
recombinant human Cathepsin D 
R&D Systems 1µg/ml 
Human Cathepsin 
E (212211) 
Mouse myeloma cell line NS0-derived 
recombinant human Cathepsin E 
R&D Systems 1µg/ml 
Human Cathepsin 
E (polyclonal) 
 Goat IgG  
Mouse myeloma cell line NS0-derived 
recombinant human Cathepsin E 
R&D Systems 0.1µg/ml 
Vitamin D receptor 
(D-6) mouse IgG 
Monoclonal antibody raised against amino 






Monoclonal antibody raised against 






Monoclonal antibody raised against 





anti mouse IgG 
Polyclonal antibody which detects heavy 
and light chains of mouse IgG, raised in 
goat. 
Dako  1:1000 
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HRP conjugate anti 
Goat IgG 
Polyclonal antibody which detects heavy 
and light chains of goat IgG, raised in 
donkey.  
R&D Systems 1:1000 
Flow cytometry and Fluorescence microscopy  
Human HLA-DR –
FITC (L243) 
Murine IgG2a monoclonal antibody 
specific for the α-chain of correctly 
assembled HLA-DRαβ complex.   
Biolegend or 
eBiosciences 
5 µl/ test 
CD 74 (BU45)  
FITC  
Monoclonal antibody raised against 
various isoforms of CD 74 
Novus biotech 5 µl/ test 
CD74 (PIN.1)  
FITC  
Monoclonal antibody raised against amino 
acids 12-28 of CD74. 
Santa Cruz 
Biotechnologies 
5 µl/ test 
Mouse IgG2a k 
isotype control-
FITC  
NA Biolegend 5 µl/ test 
Anti HLA-DR   
Rabbit monoclonal 
Monoclonal antibody corresponding to 
Human HLA-DR amino acids 150-250. 
Abcam  1:50 
Cathepsin D 
Rabbit polyclonal  
Synthetic peptide corresponding to 
residues with the heavy chain subunit of 
human Cathepsin D 
Invitrogen  1:200 
Goat anti-Rabbit 
IgG- APC  
Polyclonal antibody which detects heavy 
and light chains of rabbit IgG, raised in 
goat. 
Invitrogen  1:500 
DAPI A probe which selectively binds to the 
minor groove of the double stranded DNA 
in the nucleus   












2.1.6. Lab instruments 
 
A list of all the instruments used for this work is provided in Table 2.6 
 
Table 2.5 List of general laboratory instruments 
Instrument  Manufacturer 
Agarose gel electrophoresis system Bio-Rad 
Bench-top centrifuge  Eppendorf  
Biochemical fridge  Loviband 
Bio-safety class II cabinet Envair 
End over-end rotor Stuart rotator 
Flow cytometer Accuri C6 B.D 
Fluorescent microscope  Nikon  
Fridge and freezer Various  
Gel imager Bio-Rad 
Gel imager Licor  
Humidified incubator  Hera cell 240 
Light microscope Olympus 
Pipettes Sartorius 
Mass spectrometer  Thermofisher (outsourced to CCP) 
Nanodrop  G.E 
Plate centrifuge Eppendorf 
Plate reader Thermoscientific 
Plate Shaker  VWR 
Power pack  Bio-Rad 
Real time PCR Applied Bio-systems  
SDS gel system Bio-Rad 
Thermocycler Bio-Rad 







2.2.1 Cell culture  
 
All cell culture work was performed in a laminar flow hood under appropriate aseptic 
conditions and as described in Freshney (1987).  
2.2.1.1 Maintenance of cell lines 
 
Cells were maintained in suspension culture in a humidified CO2 incubator at 37 ˚C.  They 
were diluted thrice a week to maintain approximately 105-106 cells/ml. Cell dilution was 
performed after counting by haemocytometer. The average of two counts was used to 
calculate cell numbers in the culture flask. Media used for the cell dilution were incubated at 
37 ˚C for at-least 20 minutes before usage. 
2.2.1.2 Cell freezing  
 
Cells were centrifuged at 300 x g for 5 minutes and the supernatant discarded. The cell pellet 
was re-suspended in ice-cold freezing media at a concentration of 1 x 107 cells/ ml in a 
cryovial. The DMSO in the freezing media acts as a cryoprotective agent (Lovelock and 
Bishop, 1959).  The cryovial was then placed into a “Mr Frosty” (Thermo Scientific 5100-
0001) container for slow freezing and stored at -80°C for 24 hours. The cryovials were 
transferred to liquid nitrogen (-196°C) for long term storage. 
2.2.1.3 Cell thawing  
 
A vial containing a frozen aliquot of the cells was taken from liquid nitrogen and thawed 
rapidly by gently agitating the vial in a water bath set to 37°C. Using a plastic Pasteur pipette, 
the contents of the vial were quickly transferred to a centrifuge tube. To this, 9 mL of pre-
warmed complete medium was added gradually and centrifuged at 300 x g for 10 minutes. 
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The cell pellet was then re-suspended in 10 mL of pre-warmed complete medium and added 
to a tissue culture flask. Cells were monitored for recovery and growth, and split after 2-3 
days.  
2.2.1.4 Cell treatment with protease inhibitor or vitamin D or Retinoic acid  
 
KG-1 cells were incubated in medium supplemented with 20μM Pep A or 10μM Pepstatin A 
–penetratin (Pep A-P) for up to 72 hours, along with untreated cells as a control. 0.4% DMSO 
and PBS were used as vehicle controls for Pep A and Pep A-P, respectively. Cells were 
harvested after 24, 48 or 72 hours and were analysed by flow cytometry and Western blot.  
In order to assess the effect of vitamin D and retinoic acid (RA), cells were grown in 
complete medium supplemented with 10nM active vitamin D (calcitriol) and or 1μM all-
trans RA for up to 96 hours. As vehicle control KG-1 cells were treated with 0.5% DMSO. 
Cells were harvested after 24, 48 or 72 hours and were analysed by flow cytometry. 
2.2.1.5 Protein production 
 
L243 hybridoma cells were cultured as described in section 2.1.2 and expanded to large 
cultures (in T-125 flasks). At a cell density around 106 cells/ ml, cells were left for protein 
recovery (Iiet al., 2010). After 5 days, media were collected and centrifuged at 300 x g for 10 
minutes at 4°C to remove the cells and debris. The supernatant was then transferred to fresh 
tubes. For long term storage 0.1% sodium azide was added to supernatants which were stored 
at -20°C. 
2.2.1.6 Stable Isotope labelling 
 
Stable Isotope labelling of Amino acids in Culture (SILAC) was performed using the 
protocol described by Ong and Mann  (2007a). The cells were diluted in complete SILAC 
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media containing labelled Lysine and Arginine. Cell growth was monitored by regular 
haemocytometer count. Cells were labelled to completion by culturing the cells in SILAC 
media for at least 5 doublings.   
 
2.2.2 Biochemical Techniques   
 
2.2.2.1 Cell lysis 
 
To extract proteins from cultured cells, samples containing at least 1 x 106 cells were taken, 
and the cells were pelleted by centrifugation at 400 x g for 5 minutes. The supernatant was 
discarded, and the cells were washed twice with cold PBS and centrifuged again at 400 x g 
for 5 minutes. Ice-cold RIPA buffer containing protease inhibitor cocktail was added to the 
cell pellet, using 0.5 ml of buffer per 1 x106 cells, as described by Harlow and Lane (2006). 
The samples were placed on an end-over-end rotator for at least 1 hour at 4 °C and were then 
centrifuged at 10000 x g for 30 minutes at 4 °C to pellet the cell debris. The supernatants 
were transferred to a new tube for analysis or kept at -20°C for longer term storage.  
2.2.2.2 Bicinchoninic acid assay (BCA) protein quantification assay  
 
Protein concentration of RIPA extract was estimated using the Pierce BCA Protein Assay Kit 
(Smith et al., 1985). The BCA assay was performed in a 96-well microplate and the 
procedure was conducted as per the manufacturer’s instructions. Bovine Serum Albumin 
(BSA) was used as a standard. Briefly, 200 µL of working reagent was used. To this 10 µL of 
RIPA extract was added per well. Samples were run in triplicate and compared to a standard 
curve (20µg/ml to 2mg/ml BSA in water). The plate was then placed in an incubator at 37°C 
for 30 minutes before the sample concentrations were determined using a microplate reader, 
reading at 570 nm. 
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2.2.2.3 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
As described (Laemmli, 1970), proteins can be separated on the basis of their mass by 
electrophoresis in a SDS polyacrylamide gel under denaturing conditions. To prepare the 
SDS polyacrylamide gel, vertical gels were set between two glass plates within a casting 
chamber and two spacers, giving an internal thickness of 1.0 mm between the two plates. The 
gels were composed of two layers: a 12% acrylamide/bisacrylamide separating gel that 
separates the proteins according to size and a lower percentage (4%) stacking gel that ensures 
simultaneous entry of the proteins into the separating gel. The gel compositions are listed in 
Table 2.7. Protein samples were mixed in SDS LaemmIisample buffer with or without 
reducing agent, 2-mercaptoethanol (5%v/v), and denatured by heating at 95°C for 5 minutes. 
Electrophoresis was carried out using BioRad mini-Protean II electrophoresis equipment in 
SDS PAGE running buffer for 20 minutes at 80 V, followed by approximately 45 minutes at 
120 V or until the dye front reached the bottom of the gel. 
Table 2.7 Solutions for SDS PAGE gels 
Component 12% Resolving gel 4% Stacking gel 
ddH2O 11.15 ml 6.4 ml  
Acrylamide (40%)   7.5 ml 1.0 ml 
1.5M Tris HCl buffer pH 8.8   6.25 ml  - 
0.5M Tris HCl buffer pH 6.8   - 2.5 ml 
10% Ammonium Per-Sulphate  
(APS)(fresh)  
125 l 50 l 
Tetramethylethylenediamine (TEMED)   13 l 10 l 
The above recipes are for four gels. 
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2.2.2.4 Western Blot   
 
Protein samples resolved by SDS PAGE were transferred onto PVDF membrane (Bio-Rad). 
The PVDF transfer membrane was soaked in 100% methanol for one minute, then with 
water, and equilibrated in western blot transfer buffer for a few minutes. The gel was placed 
on top of the PVDF membrane. Care was taken to avoid trapping of air bubbles (Mahmood 
and Yang, 2012). The transfer was performed for 90 minutes at 90 V. A pre-stained 
molecular weight protein ladder (Bio-Rad 1610394) served as an indication of successful 
transfer. Membranes were briefly washed in PBS-T before being blocked in blocking buffer 
overnight. Primary antibody was diluted into blocking buffer at dilution listed in Table 2.4 
and incubated with the membrane for 3 hours at room temperature, unless specified, with 
gentle agitation. The membrane was washed five times for 5 minutes each with 10 mL of 
PBS-T wash buffer. The membrane was then incubated with the species-appropriate 
horseradish peroxidase (HRP) -conjugated secondary antibody at the dilutions given in Table 
2.4 in 10 mL of blocking buffer for 1 hour at room temperature. Again, the membrane was 
washed five times for 5 minutes each with 10 mL of PBS-T. 
In order to visualise the blot using chemiluminescent detection, the membrane was incubated 
in 10 mL of ECL Clarity Western blotting substrate. To prepare the HRP substrate, equal 
volumes of Luminol Reagent and Peroxide Solution were mixed to give a final volume of 10 
mL. The membrane was placed protein side up in a clean container and the HRP substrate 
was carefully applied to the membrane and left to incubate for 5 minutes at room 
temperature. After 5 minutes, excess substrate was drained off and the membrane was imaged 
either by exposure to film or by using the Li-COR Odyssey gel imager Fc. Li-COR’s 
proprietary imaging software, Image studio (version 5.2), was used to quantify bands of 
interest. 
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If necessary, the blot was stripped again and re-probed with another antibody. This was 
mainly done for loading controls (GAPDH or -actin).  The blots were incubated with 
stripping buffer for 30 minutes and later washed with PBS for 10 minutes. The blot was then 
re-blocked for 1 hour and re-probed with primary antibody of the loading controls. 
2.2.2.5 Immunoprecipitation  
 
A 50% slurry (i.e., 50% settled beads by volume) of protein A sepharose beads was prepared 
as per the manufacturer’s instructions. Briefly, lyophilized powder of protein A-sepharose 
beads was allowed to rehydrate by incubating 100 mg of beads in 1 ml PBS at 4°C for 1 hour 
for swelling. The rehydrated beads were then washed three times with 10 volumes of PBS by 
centrifuging at 400 x g for 10 minutes each in a refrigerated benchtop centrifuge, and 
carefully aspirating the supernatant. Lastly the final volume was adjusted with PBS to obtain 
the 50% slurry. In order to preserve the slurr,y sodium azide was added at final concentration 
of 0.2% (Bonifacino and Dell'Angelica, 2001).  
A total of 5 x 106 cells were harvested and lysed at 4°C in 500µl of lysis buffer I, which was 
freshly supplemented with complete protease inhibitor mixture. Nuclei were removed by 
centrifuging at 10,000 x g for 30 minutes. Soluble cell lysates were precleared for 1 hour 
using 40 µl of 50% protein A sepharose beads.  After removing the sepharose beads by 
centrifugation (5 minutes at full speed in an Eppendorf microcentrifuge), the lysate were 
incubated overnight with 10 μg L243 and 40 µl of 50% sepharose beads at 4°C. Unbound 
material was removed by washing four times with lysis buffer II. Immunoprecipitated 
material was eluted in non-reducing SDS sample buffer for 5 min at 100°C and separated by 
SDS-PAGE. Gels were then either fixed and stained using InstantBlueTM, with relevant bands 
excised after scanning them using Licor or Bio-Rad gel Doc system and stored at -20˚C or 
below for later LC-MS/MS analysis. 
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2.2.2.6 Protein purification 
 
Unless specified, the entire process of protein purification was performed at 4°C. L243 was 
purified from the hybridoma supernatant by protein A- sepharose affinity chromatography. 
Debris was removed by centrifuging the supernatant at 3500 x g and filtered through a 0.45 
µm filter. The supernatant was adjusted to pH 8.0 using 1M NaOH and passed over a protein 
A sepharose column.  The column was washed with binding buffer until a baseline 
(monitored by absorption at 280 nm using a Nano-drop) was re-established, and eluted with 
elution buffer. Fractions were immediately neutralized with neutralizing buffer. Eluate 
fractions absorbing at 280 nm were pooled and concentration was established using Nano-
drop. The specificity of the antibody was checked by flow cytometry and 
immunoprecipitation.   
The activity of the purified L243 monoclonal antibody was detected by competitive inhibition 
of HLA-DR using flow cytometry in KG-1 cells. The method and results are described in 
Appendix 2.1. 
2.2.3 Fluorescence staining   
 
2.2.3.1 Preparation of samples for flow cytometry   
 
In order to quantify surface expression of mature HLA-DR molecules, live cells were 
suspended in FACS buffer.  FcR and other free IgG binding sites were blocked by incubation 
with 10% (v/v) normal mouse serum (NMS) for 15 min at 4˚C prior to addition of anti-HLA-
DR (L243) FITC conjugated antibody (5µl) or isotype control (IgG2a-FITC), which was 
incubated for 1 hour at 4 ˚C. Cells were washed twice and re-suspended in FACS buffer or 
post-fixed with BD cytofix buffer and analysed using an Accuri C6 flow cytometer. 
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To detect combined surface and intracellular MHC class II molecules, cells were fixed and 
permeabilised using Cytofix/Cytoperm™ solution as per manufacturer’s instructions. Cells 
were suspended in Cytofix/Cytoperm™ solution (45l per test) for 20 minutes and washed 
with Perm/Wash buffer. FcR and any other free IgG binding sites were blocked by incubation 
with 10% (v/v) NMS for at least 15 min at 4˚C prior to addition of anti-HLA-DR (L243) 
FITC- conjugated antibody, as described above. Cells were washed twice, re-suspended in 
Perm/Wash buffer, and analysed using Accuri C6 after fixing with BD cytofix buffer.  
For the detection of Cathepsin D, KG-1 cells were fixed, permeabilized and blocked as 
described above. Then cells were incubated with 50 µl (1:200) rabbit polyclonal 
unconjugated anti-cathepsin D at 4˚C for 60 minutes. Cells were then washed with wash 
buffer and incubated with 50µl (1:500) goat anti-Rabbit IgG-APC conjugate 4˚C for 30 
minutes. Cells were washed twice, re-suspended in Perm/Wash buffer, and analysed using 
Accuri C6 after fixing with fixation buffer. 
2.2.3.2 Flow cytometry setup and analysis 
 
Flow cytometry analysis was performed on BD Accuri C6. Fluorescence excitation was 
generated using a 488 nm or 640 nm laser while the fluorescence emission was detected by 
either FL1 for FITC conjugates or FL4 for APC conjugates. All samples were run for 20,000 
events in medium flow and all samples were at least run in duplicate. Results were analysed 
using the BD Accuri C6 software (BD Biosciences) and visualized in histogram plot (counts 
versus fluorescence). The median (mean in some experiments) fluorescence intensity (MFI) 
value for each sample run was used for the measurement after gating for single intact cells 
based on light scatter. 
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2.2.3.3 Fluorescence microscope sample preparation  
 
Cells were stained as explained in section 2.2.3.1. In addition, nuclei was visualised by 
counter staining using DAPI. Cells were then washed with wash buffer and fixed with 
fixation solution for 20 min on ice. After washing cells were allowed to adhere on polylysine 
coated slides. Slides were allowed to dry overnight in the dark and once dried, slides were 
mounted with Vectashield and analysed on the microscope (Nikon). 
2.2.4 Molecular Biology Techniques 
 
2.2.4.1 Total RNA preparation  
 
RNA was isolated from cells using the power SYBR® Green Cells-to-CtTM   Kit (Life 
Technologies, 4402954) as per manufacturer’s instructions. Briefly, 1.0 x105 KG-1 or Priess 
cells were incubated with 50 µl lysis solution containing DNase I (1:100 dilutions) for 5 
minutes. After incubation, stop solution was added to the lysis reaction and incubated at room 
temperature for 2 minutes.  The lysate containing RNA were generally used immediately for 
cDNA synthesis. If required, overnight storage was at -20 °C. 
2.2.4.2 c-DNA synthesis  
 
Complementary (c) DNA must be synthesised from mRNA to provide a template for PCR 
amplification. Complementary DNA was synthesised from mRNA by reverse transcriptase 
(RT), transcribing single- stranded DNA from an RNA template. Buffers containing dNTPs 
(25 µl), NF (nuclease free) H2O (12.5 µl), 20x RT enzyme mix (2.5 µl) and RNA (10 µl) 
were mixed. The total volume for each reaction was 50 µl. Using a thermocycler samples 
were incubated at 37°C for 1 h followed by 95°C for 5 min to inactivate the enzyme. The 




PCR (polymerase chain reaction) was carried out using the power SYBR® Green Cells-to-
CtTM   Kit as per manufacturer’s instructions. SYBR Green is a reporter cyanine dye that 
intercalates with double strand (ds) DNA emitting green fluorescence (Ponchel et al., 2003). 
During the denaturing step of the PCR reaction, ds DNA becomes single stranded DNA and 
the fluorescence is lost. When the primers anneal to their target and extension occurs, SYBR 
Green binds the newly synthesised ds DNA strand, and the amount of fluorescence emitted is 
proportional to the quantity of product present in that cycle. The amount of transcript is 
determined by the cycle threshold (Ct) value. The Ct is the cycle at which the fluorescence 
reaches a certain threshold, above that of background fluorescence, during the exponential 
phase of the reaction. To confirm the presence of a specific amplification product, a 
dissociation (melting) curve (Tm) was included (Bustin, 2002). The PCR was set up for 
qualitative analysis, and hence the results were reported as an amplification curve and the 
melting temperature. 
RT-PCR was performed in a 96 well plate format (Applied Biosystems). A 20µl final volume 
was prepared containing 10µl Power SYBR Green Master Mix, 2µl primer pairs (0.5µM), 
4µl NF H2O and 4µl cDNA generated from the  above step. The plates were briefly spun to 
remove liquid from the side of the well, and the plate loaded into the Step one plus qPCR 
instrument (Applied Biosystems). The qRT-PCR cycling programme is detailed in Table 2.8. 
Each set of samples was run for the gene of interest in parallel with GAPDH as an internal 















Primer annealing  55-60* 01:00 
Primer extension  72 00:15 
Dissociation  95 1°C per 
minute 
* The annealing temperature was optimized. 
 
Table 2.9 List of primers used in the study. All primers are shown from 5'to 3' 
















(Puizdar et al., 
2012) 







       *Molecular weight of the amplified PCR product 
 
2.2.4.4 Agarose gel Electrophoresis (AGE) 
 
The PCR product was run on an agarose gel. Agarose (350 mg) was dissolved in Tris EDTA 
buffer (50 ml; TBE) by heating in a microwave until boiling this solution was allowed to cool 
and DNA Sybr safe dye (Invitrogen) was added (5 μl/ 50 ml). Gels were then cast in a 10 x 
20 cm gel tank, which was set in a mould containing a toothed comb. The 10µl PCR product 
was pipetted into wells alongside a well containing 5µl 100 kb ladder combined with 1µl 6X 
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loading dye (Promega UK Ltd.). Electrophoresis was performed at 70V for 90 min. Gels 
were imaged using the LI-COR Odyssey Fc.  
2.2.4.5 DNA extraction  
 
DNA was extracted from the cell lysates using the GenElute DNA Miniprep Kit (Sigma-
Aldrich, G1N 70) according to the protocol provided by the manufacturer. Briefly, cells were 
incubated with lysis solution containing RNase for 2 minutes, followed by incubating with 
Proteinase K solution (20mg/ml) at 70 C for 10 minutes.  After several centrifugation steps 
using DNA- columns, the trapped DNA was eluted in a Tris–EDTA buffer (pH 8–8.5). The 
quality and concentration of the DNA was determined using Nano-drop.  
2.2.4.6 HLA Genotyping  
 
HLA genotyping was performed at the Anthony Nolan Research Institute, Royal Free 
Hospital, Pond Street, Hampstead, NW3 2QG in collaboration with Professor Steven Marsh 
and Dr. Neema Mayor. This was done by using Sequence Specific Primers (PCR-SSP) and 
PCR Sequence Based Typing (PCR-SBT) methods as described by Dunckley (2012). HLA-
DRB1 and any additional DRB3/4/5 genotypes were reported. 
 2.2.4.7 Knockdown  
 
2.2.4.7.1 Lentiviral vector and mechanism of transduction  
Lentiviruses are a subset of retroviruses, which are naturally occurring single stranded RNA 
containing viruses (Baltimore, 1970). Upon entry into the cell cytoplasm, the viral RNA is 
reverse-transcribed into double stranded DNA by the viral enzyme reverse transcriptase, 
encoded by the pol gene. The viral DNA is then translocated into the cell nucleus, where it is 
incorporated permanently and indiscriminately into the host cell genome due to the presence 
of long terminal repeats (LTRs) (Joyner and Bernstein, 1983). As a result, all cells descended 
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from an infected cell carry the viral genome (Walsh and Cepko, 1988). During cellular 
transcription and translation, the viral genomic RNA and viral structural proteins such as gag 
and env, coding for viral capsid and envelope proteins respectively, are produced and 
assembled to generate viral progeny (Kaye et al., 1995). This unique feature of the 
lentiviruses albeit with some modifications is exploited for research purposes (Zhao and 
Lever, 2007, Singer and Verma, 2008, Manjunath et al., 2009). 
The modifications are performed to convert natural viruses into useful tools for genetic 
modification for research and for biosafety. Alterations include the removal of viral genes 
responsible for virulence and pathogenesis (Delenda, 2004). The entire lentiviral vector 
system is usually separated in three or four plasmids in the interest of improving biosafety: 
the packaging plasmid (may be split into 2 plasmids), the gene transfer plasmid and an 
envelope (env) plasmid. Hence, viral packaging can be achieved by using triple (2nd 
generation) or quadruple (3rd generation) co-transfection (Lever et al., 2004) to generate 
lentiviruses that express the desired foreign genetic element. Further modifications include 
the removal of the env gene from the lentiviral genome and replacement with a heterologous 
glycoprotein, vesicular stomatitis virus glycoprotein (VSVG). The presence of this protein 
confers the virus particle with the ability to transduce a wide range of cell types including 
primary cells, stem cells and early embryos (Naldini et al., 1996, Lois et al., 2002, Pfeifer et 
al., 2002).  
In this study, lentiviral cloned into pLKO.1-puro vector were used (Sigma MISSION® 
shRNA Human Gene Family Set, Lentiviral Particles).  In order to obtain sustained 
knockdown of the cathepsin D gene, short hairpin RNA (shRNA) was cloned in the pLKO.1-
puro vector. The vector also carried puroR i.e. the puromycin resistance gene for the selection 
of successfully transduced cells. In order to assess any off-target phenotypical or biochemical 
effects of transduction and/ or selection, an empty vector containing only puroR was used as a 
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control in the experiment. The lentiviral construct is shown in Figure 2.1.  The resulting 
recombinant viral genome thus converts the infection process to an efficient transduction one, 
allowing for non-replicative entrance of a virus into the host cell, followed by expression of 
the desired genetic information it carries in its genome. In the interest of biosafety, the 
resultant viruses produced are replication-incompetent, hence unable to produce viral 
progeny. 
2.2.4.7.2 Method of infection. 
 
KG-1 cells (0.5x105 ) were re-suspended in 200 µl of fresh media in 96 well plate and treated 
with a final concentration of 8µg/ml polybrene, in order to facilitate the fusion of the virus 
particle to the cell membrane, hence increasing the infection efficiency. This was done 15-16 
hours prior to the commencement of the transfection. On the day of infection, the lentiviral 
supernatants were added to the cells at the desired multiplicity of infection (MOI) and the 
plates were centrifuged for 30 minutes at 500 x g at RT.  
Figure 2.1 Lentiviral construct of the PLKO.1 vector. The above diagram is the schematic 
representation of the lentiviral construct used for the knockdown of the cathepsin D gene in the KG-1 
cells.   
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Note: MOI is the number of transducing lentiviral particles per cell. It was calculated as per 
manufacturers’ instruction.  To calculate: (total number of cells per well) x (desired MOI) = 
Total transducing units needed (TU)  
Total ml of lentiviral particles to add to each well = (Total TU needed) / (TU/ml reported on 
certificate of analysis provided). 
 
Cells were monitored for 48 hours and then expanded to 24 well plates with a total volume of 
500 µl in each well. Cells were monitored regularly, and selection was initiated by adding 1 
µg/ml of puromycin into the media. Puromycin resistant cells were identified and expanded 
further into 6-well plates and later to T-25 culture flasks by adding fresh media supplemented 
with puromycin. 
 
2.2.5 Mass spectrometry   
 
This section describes the general approach for generating isotopically labelled standards and 
mass spectrometry. 
2.2.5.1 LC-MS sample preparation  
 
Excised DR α/β bands from SDS gels (section 2.2.2.5) were analysed by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) following tryptic digestion at the 
Cambridge Centre for Proteomics (De Riva et al., 2010, Prevosto et al., 2016). SDS–PAGE 
gel pieces were thawed and transferred into 96-well PCR plates for automated sample 
preparation in a Mass Prep Station (Waters). Briefly, the gel bands were destained, reduced 
(dithiothreitol [DTT]), alkylated (iodoacetamide), and digested with trypsin overnight at 
37 °C. Thereafter, 20 μl of supernatant was pipetted into a sample vial and loaded onto an 
autosampler for LC-MS/MS analysis. 
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2.2.5.2 Liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
 
Tandem mass spectrometry analysis was carried out on an Orbitrap Q-Exactive mass 
spectrometer (ThermoFisher). The Q Exactive instrument includes an atmospheric pressure 
ion source (API), a stacked-ring ion guide (S-lens) in the source region, a quadrupole mass 
filter, a C-trap, an HCD cell, and an Orbitrap mass analyzer. Ions are formed at atmospheric 
pressure, pass through a transfer tube to an S-lens and then via an injection multipole into a 
bent flatapole (Michalski et al., 2011). The data acquisition was carried out at lower 
resolution (17,000) and higher resolution (70,000).  The mass spectrometric raw data were 
analysed further with Proteome Discover (PD) and Maxquant (MQ) (Cox and Mann, 2008) 
software packages. Parameters set for quantitative analysis included up to two missed 
cleavages and variability of mass i.e. due to phosphorylation (S, T, and Y), ubiquitination, 
oxidation (Met, in vitro processing) and carbamido-methylation (iodoacetamide alkylation 
prior to trypsin digestion).  The parameters defined are important, as they can increase the 
stringency of the search, increase confidence in protein identification, and simplify analysis. 
2.2.5.3 Peptide identification and assignment to MHC II alleles 
 
The data generated from the software packages gives the list of all identifiable peptides from 
the proteins in the mass spectrometry analysis with the corresponding normalised 
Heavy/Light SILAC ratios.  The list also included some of the common contaminants like 
human keratin (comes from handling) and bovine serum proteins, which were omitted from 
further analysis.  In addition, neither software programmes are not sufficient for the task of 
peptide assignment for the alleles. It can generate false positive matches to MHC II alleles 
which are not present in the HLA genotype of the cells being analysed. This was due to 
matches of the identified peptides, in novel combinations, to irrelevant MHC II alleles in the 
sequence databases.  
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In order to assign the peptides to the MHC II alleles, the cDNA sequences of the alleles 
(obtained from HLA genotyping section 2.2.4.6) were obtained from IMGT/HLA database 
(http://www.ebi.ac.uk/ipd/imgt/hla/).  These sequences were then subjected to in-silico tryptic 
digestion with Peptide Mass on the Expasy server (http://web.expasy.org/peptidemass/). 
Incomplete cleavages were allowed in order to keep the parameters similar for both the 
tryptic digestion. Virtual digests were used to identify the subset of peptides that are specific 
for a particular MHC II allele, or shared between the alleles. Such peptides were then selected 
from the amongst the MHC II peptides in LC-MS/MS and analysed further for SILAC 
labelling by calculating % light or % heavy values. 
 
2.2.6 Statistical analysis  
 
Statistical analysis was performed either using R software (Knezevic et al., 2007) or SPSS 
statistics 24 software (IBM Corp, 2012). For all tests, a p value ≤ 0.05 was taken as 
statistically significant. For all bar graphs, the mean ± SD was plotted in MS Excel. Mean 
and median fluorescence values were extracted using the native C6 softwar. 
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Chapter 3: Non-redundant role of Cathepsin D in the degradation of 




The expression of major histocompatibility complex class II (MHC II) molecules is post-
translationally regulated by endocytic protein turnover, but the mechanisms remain poorly 
understood. In this study, cathepsin D was implicated in the degradation of HLA-DR. Using 
flow cytometry, pepstatin A (Pep A), an inhibitor of the lysosomal aspartyl proteases, 
cathepsin D and E (Cat D/E), was shown to rescue human leukocyte antigen (HLA)-DR 
molecules from degradation. This was observed in the myeloid cell line, KG-1 but not in the 
B-lymphoblastoid cell line, Priess, correlating with expression of Cat D in these cells, which 
was assessed by Western Blot and qRT-PCR. Fluorescence microscopy of KG-1 cells also 
showed the co-localisation of HLA-DR and Cat D in the vesicular compartment. Lastly, 
lentiviral knockdown of Cat D protein expression in KG-1 cells caused elimination of the Pep 
A effect on HLA-DR expression.  Thus, Cat D has a vital role in the degradation of HLA-DR 
molecules in KG-1 cells. In addition, in cell lines in which Cat D activity was inhibited for 
prolonged periods there was evidence of adaptation, based on steady- state levels of HLA-





As explained in section 1.3, MHC II molecules are expressed mainly on professional APCs 
and display antigenic peptides to CD4+ T cells. (Rigby et al., 1990, Chaplin, 2006, Zhu and 
Paul, 2010). MHC II maturation is a complex process involving the assembly of MHC II αβ 
dimer with invariant chain (Ii)  (Busch et al., 1996), transport of the MHC II/Ii complexes 
and their sorting to endocytic compartments (Busch and Mellins, 1996, Brachet et al., 1997), 
degradation of peptides and their HLA-DM catalysed binding to MHC II (Blum et al., 2013), 
and transport of MHC II/peptide complexes to the plasma membrane (Mak and Saunders, 
2006). After presentation of antigen, MHC II are  degraded in lysosomes (ten Broeke et al., 
2013).  
The cellular factors that regulate MHC II maturation have been studied extensively, but their 
degradation, to date, has not been understood completely. Most cell surface proteins undergo 
ubiquitination and sorting into late endosomal compartments (Wright et al., 2011), and MHC 
II molecules follow this pathway  (Hor et al., 2009). Lapaque et al. have shown that α and β 
chains of MHC II can be ubiquitylated by membrane associated RING-CH 1 (MARCH 1) 
protein, which is a RING- family ubiquitin E3 ligase (Lapaque et al., 2009). Internalisation 
and turnover of MHC II molecules are regulated by ubiquitination of the β-chain (Shin et al., 
2006, van Niel et al., 2006). Moreover, the fact that MARCH 1 knockout mice display 
increased levels of MHC II at the plasma membrane also highlights the importance of 
internalization of MHC II for its degradation. Thus, ubiquitination promotes MHC II 
endocytosis and lysosomal sorting, which results in degradation of MHC II (Furuta et al., 
2013), as shown in Figure 3.1.  
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Figure 3.1 Degradation of MHC II molecules. MHC-II is ubiquitinated at a conserved lysine in the 
cytoplasmic tail of the  chain, which promotes its internalisation into lysosomes, where it may be 




Lysosomes are single membrane-bound intracellular organelles containing various acid 
hydrolyases in their acidic lumen (Mindell, 2012, Luzio et al., 2007). They serve as the final 
destination of molecules targeted for destruction by numerous peptidases, called cathepsins. 
The term “cathepsin” stands for “lysosomal proteolytic enzyme”, regardless of the enzyme 
class. Cathepsins include cysteine proteases, aspartic proteases and serine proteases (Turk et 
al., 2012). They are so named because because the active sites of cathepsins utilises, 
respectively a cysteine thiol, an aspartic acid, or a serine residue to attack the peptide bond at 
the catalytic site (Turk et al., 2000, Turk et al., 2001). They are involved in a number of 
important biological processes, such as intracellular protein turnover, antigen processing, 
hormone activation, remodelling of the extracellular matrix, and apoptosis (Im and 
Kazlauskas, 2007, Nomura and Katunuma, 2005, Friedrichs et al., 2003).   
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3.2.2 Role of cathepsins in antigen presentation. 
 
Lysosomal proteases have several different roles in antigen processing, presentation and 
MHC II maturation. They process antigen and process Iichain. There is certainly a level of 
redundancy to this system (Reich et al., 2011). Even the otherwise non-redundant cysteine 
proteases, cathepsins L and S (Cat L/S), can play the same role in the degradation of Ii, with 
Cat L being copiously expressed in thymic epithelial cells, whereas B cells and DCs express 
Cat S (Hsing and Rudensky, 2005, Reich et al., 2011).  In addition, Cat G, a serine protease, 
plays a vital role in the degradation of some antigens for presentation (Stoeckle et al., 2009). 
Various lysosmal proteases involved in MHC II maturation along with their broad spectrum 





Table 3.1 Proteases found in the Lysosomes along with their Inhibitors. 
 
Catalytic type Protease Role in Antigen presentation Reference Inhibitor  
Cysteine 
Proteases 
Cathepsin B Intracellular proteolysis  (Gondi and Rao, 2013) E-64, E-64d, leupeptin. 
Cathepsin C Antigen processing (Kummer et al., 1996) 
Cathepsin F Degradation of antigenic peptides (Wang et al., 1998) 
Cathepsin L Processing of Iiin Thymic 
epithelial cells  
(Hsieh et al., 2002) 
Cathepsin S Processing of Iiin B cells and DCs (Riese et al., 1996) 




Degradation of antigenic peptides (Manoury et al., 1998) 





Cathepsin G Destruction of auto-antigen myelin 
basic protein 
Destruction and generation of 
specific T cell epitopes 
(Stoeckle et al., 2009). 
 





Cathepsin D Thought to play a role in 
Iidegradation but some studies do 
contradict it. 
Antigen processing 
(Marić et al., 1994) 
(Deussing et al., 1998) 
Pepstatin A, Pepstatin A-
penetratin 
Cathepsin E Antigen processing in APCs like  
Langerhans 
(Hewitt et al., 1997, Chain 
et al., 2005) 
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3.2.3 Lysosomal degradation of MHC II 
 
Early biochemical studies showed that MHC II molecules are resistant to many proteases in 
vitro, but can be cleaved off the plasma membrane by papain (Gorga et al., 1991). The 
proteases that degrade MHC II molecules in vivo remain unknown.  One study showed that 
MHC II molecules accumulate in immature DCs treated with E64, an inhibitor of cysteine 
proteases (Herrmann et al., 2007), but that effect was small, and a number of these enzymes 
failed to cleave purified DR molecules in vitro (Burster et al., 2010). Conversely, the serine 
protease, cathepsin G (Cat G), was able to cleave many HLA-DR alleles in vitro but did not 
cause degradation of membrane bound HLA-DR in vivo, nor did its inhibition cause 
accumulation of HLA-DR, suggesting that in vivo, the Cat G site is sterically inaccessible or 
masked by other associated molecules (Burster et al., 2010).  
The degradation of MHC II is an important un-elucidated process. MHC II molecules are 
extraordinarily stable but still display cell type-specific half-lives (Busch and De Riva, 2013).  
It is most likely that MHC-II molecules are degraded in similar a way to other lysosomal 
proteins. The mechanism/s involved are interesting because MHC II molecules resist 
proteolysis during normal peptide loading in lysosome-like compartment (MIIC) and yet are 
degraded there ultimately. APCs regulate the process actively; therefore, it seems to have 
some functional significance. 
It is surprising that the enzymes involved in the degradation of MHC II have not been 
previously identified. Paul et al. (2011) carried out a genome wide screen to identify various 
factors affecting the MHC II pathway.  They looked for mutant cells that had abnormally low 
or high MHC II expression and looked for genes that were altered in the mutant cells. Some 
interesting interacting proteins were identified, which play important roles in the MHC II 
pathway, but the study did not identify any enzymes involved in the degradation of MHC II. 
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In mice, many cathepsin genes have been knocked out (Potts et al., 2004, Reinheckel et al., 
2012) but no effects on MHC II levels were noted. 
Previously work from Dr Busch’s group implicated lysosomal aspartyl proteases in the 
degradation of MHC II proteins in physiological APCs. Treatment of immature MoDCs and 
acute myeloid cells (AML) like KG-1 with lysosomal aspartyl protease inhibitor, pepstatin A, 
rescued intracellular HLA-DR protein degradation, suggesting that Cat D, Cat E or both 
mediated HLA-DR degradation. Moreover, recombinant Cat D cleaved purified recombinant 
HLA-DR proteins in vitro (Busch 2016, personal communication, 10 October). Building on 
those observations, the aim of this chapter was to identify and characterise specific proteases 
involved in HLA-DR degradation in KG-1 cells. KG-1 cells were selected because they 
express HLA-DR protein constitutively and exhibit a phenotype similar to that of immature 
DC (Ackerman and Cresswell, 2003, Berges et al., 2005)  making this cell line a useful model 
system to study. The experiments here point to a role of cathepsin D and the possible 
additional process that regulate the MHC II levels.  
  
   
 71 
3.3 Results 
3.3.1 Pepstatin A (Pep A) mediated rescue of HLA-DR from degradation 
 
Pepstatin A is an inhibitor of the lysosomal aspartyl proteases, cathepsin D and cathepsin E 
(Cat D/E) (Umezawa, 1976). Previous work by Dr. Busch’s group had indicated that Pep A 
causes accumulation of HLA-DR in intracellular compartments of monocyte-derived 
dendritic cells (MoDCs) and in the myeloid tumour line, KG-1 (Busch 2016, personal 
communication, 10 October). To confirm this, KG-1 cells were cultured for up to 72 hours 
with Pep A (20μM) or DMSO (vehicle control). To quantify total (surface plus intracellular) 
DR, cells from each culture were fixed and permeabilized before blocking of FcR, 
immunofluorescent staining, and flow cytometric analysis. In order to assess the DR level 
only on intact single cells, doublets were gated out, and intact KG-1 cells were distinguished 
based on forward and side scatter as shown in Figure 3.2 (A and B). 
 
Figure 3.2 Gating strategy for immunofluorescence analysis for fixed and permeabilized KG-1 cells. The 
figures show the gating strategy for exclusion of doublets and scatter gating for fixed and permed KG-
1 cells. Doublets were excluded using forward side scatter height vs. area (FSC-A vs. FSC-H). Intact 
single cells were selected using forward side scatter area (FSC-A) versus side scatter (SSC-A). In the 
figure, gate P1 represents the doublet exclusion gate (A), whereas P2 identifies the intact KG-1 cells 
(B). The staining of fixed and permeabilized KG1 cells is represented through histograms (C). The 
staining for IGG2 shown above is the worst-case scenario. In a majority of the studies, less  
background staining was seen. 
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In order to quantify the levels of DR, immunofluorescence staining was quantified by flow 
cytometry. Figure 3.1 (C) shows examples of staining of fixed and permeabilized KG-1 cells 
with L243-FITC (anti-HLA-DR) or IgG2a-FITC along with unstained cells. The IgG2a-FITC 
is an isotype- matched negative control antibody to assess background fluorescence. The 
histograms in this figure show that there was only a small shift in mean fluorescence intensity 
when stained with IgG2-FITC when compared to the unstained cells. By comparison, there 
was a larger shift in the population of cells stained with L243-FITC.  
As shown in Figure 3.3, cell treatment with the aspartyl protease inhibitor, Pep A showed 
higher staining for DR when compared with vehicle controls. Moreover, there was no effect 
of Pep A on autofluorescence or nonspecific staining with isotype control. The maximum 
accumulation of DR was around 50% and observed at 48 hours post treatment. Thus, this 
result indicated that inhibition of aspartyl proteases causes accumulation of HLA-DR in KG-
1 cells. Since the accumulation did not continue past 48 hours, it also raises the possibility 
that cells later adapt to this inhibition of aspartyl proteases. 
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Figure: 3.3 Effect of pepstatin A on HLA-DR in fixed and permeabilized KG-1 cells. KG-1 cells were 
cultured for the indicated periods of time in the presence or absence of 20 M pepstatin A in DMSO. 
Cells were harvested, fixed and permeabilized, stained with FITC-conjugated anti-DR antibody to 
reveal total HLA-DR molecules and analyzed by flow cytometry. Each bar represents the median 
fluorescence intensities.  (MFI; mean +- S.D. of triplicate analysis).(A) Y axis in normal scale (B) Y 
axis is in log scale. 
 
Two-way ANOVA indicated a significant effect of the treatment on HLA-DR levels, F (2, 
18) = 150.306, p<0.001 (Appendix 3.1). Post-hoc Tukey's HSD tests showed that KG-1cells 
treated with pepstatin A had significantly higher HLA-DR expression than the other groups 
(Appendix 3.1, Post-hoc test). It also indicated that the increase in the DR level was 
dependent on time, F (2, 18) =27.527, p<0.001 (Appendix 3.1). The effect of time was 
statistically significant, but this was not necessarily biologically meaningful because of 
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confounding technical variables, as the cells were stained separately on each day of analysis. 
On each occasion, the incubation conditions are not quite the same, and therefore staining 
intensities vary.  
The effect shown in Figure 3.3 was reproducible in nine independent repeats performed on 
KG-1 cells (shown in Figure 3.4). A single sample t-test was conducted to determine if a 
statistically significant difference existed in DR accumulation in KG-1 cells treated with and 
without Pep A. There was significant accumulation of DR in KG-1 cells treated with Pep A, t 
(8) = 5, P<0.01 (Appendix 3.2). This result confirms that Pep A reproducibly prevents DR 
degradation in KG-1 cells.  
 
Figure 3.4 Summary of nine independent experiments of pepstatin A treated KG-1 cells at 48 hours. The 
increase in HLA-DR staining on pepstatin A treatment was reproducible in KG-1 cells at 48 hours. 
 
The ~50% mean increase in total HLA-DR observed after 48 hours in Pep A-treated KG-1 
cells may not be the maximal effect. Previous unpublished work in Dr Busch’s group has 
shown that the effects of Pep A was dose-dependent up to 20 M and at higher concentration 
toxic effects of the treatment were observed. Therefore, in order to increase the 
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bioavailability of the enzyme without increasing toxicity, Pepstatin-A-Penetratin (Pep A-pen) 
was used. 
A number of natural and synthetic peptides, soluble in water, are able to translocate across 
cell membranes non-endocytically. One such peptide, Penetratin, has a sequence 
corresponding to the 16 residues of the third α-helix (residues 43 to 58: 
RQIKIWFQNRRMKWKK) of the Antennapedia homeodomain of Drosophila (Derossi et 
al., 1994, Prochiantz, 1999). This helix is able to translocate the entire homeodomain across 
cell membranes (Derossi et al., 1996) and therefore has been used as an intercellular delivery 
vector. Accordingly, Pepstatin-A-Penetratin (Pep A-pen), which is Pep A conjugated with the 
cell penetrating peptide, enhancing its cell permeability (Zaidi et al., 2007), was used to 
rescue DR. 
Pep A-pen, used at 10 M, was able to cause the accumulation of DR in KG-1 cells (Figure 
3.5).  The effect size was similar to that observed with 20 M of Pep A (around 50%). 
Perhaps, therefore, the 50% accumulation is the maximum DR accumulation possible using 
this inhibitor. Two-way ANOVA indicated that the increase in the DR level on the treatment 
with Pep A-pen was statically significant, F (2, 18) =133.6, p<0.001 (Appendix 3.3). Post-
hoc Tukey's HSD tests showed that KG-1cells treated with Pep A-pen had significantly 
higher HLA-DR expression than the other groups (Appendix 3.3, post-hoc test) 
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Figure 3.5 Accumulation of HLA-DR in fixed and permeabilized KG-1 cells with Pepstatin-A-penetratin. 
There was accumulation of DR molecules in Pep A-pen treated KG1 cells as compared to the 
controls. L243-FITC antibody was used to stain the DR molecules. Cells were analysed after fixation 
and permeabilization. Staining was quantified by flow cytometry. Each bar represents the median 
fluorescence intensities (MFI; mean +- S.D. of triplicate analysis). This experiment was performed 
once. (A) Y axis in normal scale (B) Y axis is in log scale.In the EBV-transformed B-cell line, 
Priess, previous work had shown that DR molecules exhibit very slow turnover rates 
(unpublished work from RB). Priess cells were treated with Pep A or vehicle for 72 hours, 
and DR was quantified by flow cytometry after fixation and permeabilization. The 
accumulation of the DR was not as evident as in KG-1 cells but there was a small effect 
(between 5-7%) observed as shown in Figure 3.6. This increase  in the HLA-DR level on 
treatment with Pep A was statistically significant F (2, 18) =30.817, p<0.001 as analysed by 
two-way ANOVA (Appendix 3.4), consistent with slow turnover observed in this cell line. It 
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may take longer to accumulate DR molecules, resulting in the smaller effect of Pep A 
observed in Priess cells than in KG-1 cells. 
 
 
Figure 3.6 Small effect of Pepstatin-A on fixed and permeabilized Priess cells. There was little 
accumulation of DR molecules in Pep A treated Priess cells. L243-FITC antibody was used to stain 
the DR molecules. Cells were analysed after fixation and permeabilization. Staining was quantified by 
flow cytometry. Each bar represents the median fluorescence intensities (MFI; mean +- S.D. of 
triplicate analysis). This experiment was performed three times with similar results. (A) Y axis is in 
normal scale  (B) Y axis is in log scale. 
 
3.3.2 Effect of Glutamine hydrolysis 
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Glutamine in the culture media is capable of raising the endocytic pH due to its 
decomposition into pyrrolidone-carboxylic acid and the weak base ammonia (NH3) (Ozturk 
and Palsson, 1990, Slivac et al., 2010). Ammonia can be protonated to NH4
+ and can 
neutralize the endocytic pH, which may affect the activity of the lysosomal enzymes. In order 
to examine whether this altered the effect of Pep A on HLA-DR accumulation cells were 
cultured in media containing GlutaMAX.  
As shown in Figure 3.7 (A), Pep A treated KG-1 cells cultured in GlutaMAX media had an 
effect of similar magnitude as Pep A treatment of KG-1 cells cultured with glutamine. Two-
way ANOVA indicated a noteworthy increase in the DR level on treatment was significant, F 
(1, 20) = 71.449, p<0.001 (Appendix 3.5). Since there were only two groups post-hoc test 
was not performed. The maximum rescue of HLA-DR by Pep A was of 50%, similar 
magnitude, as observed in the cells cultured with glutamine (Figure 3.3). The maximal effect 
was observed earlier, however, which is consistent with the idea that in GlutaMAX media 
there is faster lysosomal turnover. Lastly, despite the continuous presence of inhibitor, the 
effect waved over time. 
 
Figure 3.7 The peak effect of pepstatin A treatment in KG-1 cells seems to be independent of glutamine 
hydrolysis. KG-1 cells were cultured for the indicated periods of time in the presence or absence of 20 
M pepstatin A in DMSO. Cells were harvested, fixed and permeabilized and stained with ant-DR 
FITC conjugated to reveal total HLA-DR molecules and were analyzed by flow cytometry. (A) Each 
bar represents the median fluorescence intensities (MFI; mean +- S.D. of triplicate analysis). (B) 
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shows the comparative fold change (Pep A treatment/ control) in KG-1 cells cultured in glutamine and 
GlutaMAX media at different time points.  
 
Taken together, the results showed that Pep A and Pep A-pen are able to rescue HLA-DR 
molecules in KG-1 and to a lesser extent in Priess cells, correlating with their known 
difference in DR turnover. The effect of pepstatin A on accumulation of DR was also seen in 
immature monocyte-derived dendritic cells (MoDCs) (Appendix 7.1).  
 
3.3.3 Differential expression of aspartyl proteases in Priess and KG-1 cells 
 
Cat D and Cat E are the only aspartyl proteases present in the lysosomes of human APCs 
(Tang and Wong, 1987, Szecsi, 1992, Eder et al., 2007). In order to examine the expression 
of aspartyl proteases, Priess and KG1 cell extracts were separated by SDS-PAGE under non-
reducing conditions (in order to preserve Cat E as a disulphide-bonded homodimer (Finley 
and Kornfeld, 1994)), and Western Blots were probed with antibodies to Cat D and Cat E. 
Cat D was clearly detected in KG-1 but not Priess cells, as shown in Figure 3.8. Two Cat D 
bands were observed at molecular weights around 48 kDa and 33 kDa, corresponding to the 
previously-reported molecular weights of pro Cat D (48 kDa) and mature Cat D (33 kDa) 
(Horikoshi et al., 1998). On longer exposure, faint bands were observed in Priess cells and an 
additional band at 25kDa (Figure 3.8). Thus, a small amount of Cat D was present in Priess 
cells. Recombinant human Cat D was used as a quantitative standard, and recombinant 
human Cat E was used as a control for any cross-reactivity of the antibody. As visible from 
the figure, no cross-reactivity with recombinant Cat E was observed.  
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Figure 3.8: KG-1 and Priess cells express Cat D. Protein extracts from equal cell equivalents of KG-1 and 
Priess were resolved by 12% non-reducing SDSPAGE and immunoblotted for Cat D. Recombinant 
human Cat D (rh Cat D) was used as a standard while, rh Cat E served as a control for any 
crossreactivity. The amounts of rh Cat D used was 250 ng, 50 ng, 10 ng and 2 ng while the amount of 
rh Cat E used was 50 ng and 250 ng. This is image is representative of 4 independent informative 
repeats. 
 
Similarly, Western blots were probed with a goat polyclonal anti-Cat E antibody to detect the 
presence of any Cat E in the extracts. Cat E is a homodimer consisting of two monomers 
linked by an inter molecular di-sulphide bond (Fowler et al., 1995). As shown in Figure 3.8, 
rh Cat E resolved at molecular weight 80 kDa (homo-dimer) and 44 kDa (monomer), whereas 
no bands were detected in  KG1 or Priess extracts. Hence, there was no detectable Cat E 
present in these cells. Recombinant human Cat E and Cat D were used as standards and also 
as a control to detect any cross-reactivity of the antibody. As visible from the figure, there 
was no cross-reactivity observed with recombinant Cat D. 
The product literature for the commercial monoclonal anti-cat D and polyclonal anti-cat E 
antibodies left open the possibility that the antibodies were crossreactive. In the blots shown, 
this was not observed. Cross reactivity was observed, however, when a monoclonal anti-cat E 
antibody was used (Appendix 3.6). In that case, immuno-reactivity with recombinant Cat D 
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and with the KG-1 cell extract were observed. However, there was no dimer observed in the 
KG-1 cell extract, and hence it was concluded that there was no evidence of Cat E being 
present. The polyclonal anti-Cat E antibody showed no crossreactivity (Figure 3.9), so this 
experiment was more definitive. 
 
 
Figure 3.9 No detectable cathepsin E present in KG-1 and Priess cells. Protein extracts from equal cell 
equivalents of KG-1 and Priess cells were resolved by 12% non-reducing SDS PAGE and 
immunoblotted for Cat E. rh Cat E migrated partly as a homo-dimer, which is observed at 80 kDa 
(homo-dimer) and as a 44 kDa (monomer). The quantities of rh Cat E used ranged from 2 ng to 250 
ng while for rh Cat D they were 50 ng and 250 ng. This is image is representative of two independent 
informative repeats. 
 
The blots were quantified, using Image Studio 5.2 software. The band intensity was 
quantified after subtracting the local background. In five different attempts, the amount of 
pro-Cat D ranged from 17 femtogram (fg) to 26 fg per KG-1 cell. But in no experiment it was 
possible to detect Cat E, even though 2ng of r-Cat E per lane was readily detected. Based on 
this it was estimated that the amount of Cat E could not be more than 7 fg per cell. These 
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calculations are based on the assumption that the antibody binds equally to native and 
recombinant forms of the enzyme.   
The Western blot results showed the presence of Cat D in KG-1 cells as well as low level 
expression in Priess cells. Absence of evidence for Cat E expression does not rule out low 
level expression, below the sensitivity of these Western Blots. Enzymes are able to act 
catalytically on their substrates even in minute quantities. Thus, the levels of Cat D encoded 
by CTSD and Cat E encoded by CTSE mRNA were assessed by real time PCR using SYBR 
green chemistry. The RNA from both KG-1 and Priess was extracted, reverse transcribed for 
c-DNA synthesis, and amplified using primers specific for CTSD and CTSE. As explained in 
section 2.2.4.3, SYBR green dye binds to all double stranded products including nonspecific 
PCR product or primer dimer. Thus, the proper amplicons or the PCR products were 
identified using melt curve analysis after qRT-PCR and confirmed by agarose gel 
electrophoresis (AGE). 
The RNA from both KG-1 and Priess was amplified with primers for Cat D or Cat E 
encoding transcripts. As expected from the Western blots, KG-1 cells showed the presence of 
CTSD mRNA but not CTSE mRNA, shown in Figure 3.10 (A).  Melt curve analysis of Cat D 
showed the presence of a single peak, which assured the amplification of genuine PCR 
product.  On the other hand, melt curve analysis of Cat E revealed that the slight 
amplification observed towards the end of the PCR cycle was a primer dimer (Figure 3.10 B). 
For the Priess cells, as shown in Figure 3.11, CTSD was amplified and also through melt 
curve analysis a single peak was observed, suggesting the presence of CTSD mRNA. As 
observed with KG-1 there was no detectable amount of CTSE present in the Priess cells 
(Figure 3.11). GAPDH was used as a housekeeping control gene in all sets of PCR. 
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Figure 3.10 Expression of CTSD mRNA in KG1 cells. CTSD and CTSE mRNA expression in KG1 was 
detected by real time RT-PCR using SYBR green chemistry. The presence of CTSD mRNA appeared 
on the amplification plot (A), which was also confirmed through melt curve analysis (B).  There was no 
detectable level of CTSE mRNA in KG-1 cells.  GAPDH was used as a positive control. This image is 
representative of three independent repeats. 
 
Figure 3.11 Expression of CTSD mRNA in Priess cells: CTSD and CTSE mRNA expression in Priess was 
detected by real time RT-PCR using SYBR green chemistry. The presence of CTSD mRNA was 
detected through amplification plot (A), which was also confirmed through melt curve analysis (B).  
There was no detectable level of CTSE in Priess cells. GAPDH gene was used as a house keeping 
gene. This image is representative of three independent repeats. 
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The PCR products were also analysed by agarose gel electrophoresis to detect the presence of 
the gene. The results as shown in Figure 3.12 confirm the presence of CTSD and not CTSE 
mRNA in both KG-1 and Priess. The band intensities of GAPDH and CTSD in case of Priess 
cells were very low when compared to KG-1 cells, even though equal numbers of cells were 
used.  The reason for this can either be low RNA yield per cell in Priess cells, or there may 




Figure 3.12 Presence of CTSD and not CTSE in KG-1 (A) and Priess cells (B). The RNA from both KG-1 
and Priess were extracted, reverse transcribed for c-DNA synthesis and later were amplified. After 
amplification they were run through 0.7% agarose gel. There is band visible corresponding to 
amplification product of CSTD in both KG-1 and Priess. GAPDH was used as positive control. The 
band intensities of CSTD and GAPDH in Priess cells were faint. 
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Cat D was also detected when fixed and permeabilized KG-1 cells were stained with 
unconjugated anti-cathepsin D polyclonal rabbit antibody. Anti-rabbit IgG conjugated with 
allophycocyanin (APC) [2(Ab)-APC] was used as a secondary antibody to detect anti-
cathepsin D. Appropriate controls were used to quantify auto-fluorescence and any non-
specific background from the APC conjugated secondary antibody. This staining of the Cat-D 
is shown in Figure 3.13. 
 
 
Figure 3.13 Staining of  Cat D in KG-1 cells by flow cytometry. The figure shows the presence of Cat-D 
in the KG-1 cells. Fixed and permeabilized KG-1 cells were stained with L243-FITC and unconjugated 
anti-Cat D rabbit polyclonal.   Anti-rabbit IgG conjugated with APC [2(Ab)-APC] was used as a 
secondary antibody control. Unlabelled sample (US, unstained) was used as another control. The 
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3.3.4 Co-localisation of Cat-D and HLA-DR. 
 
In order to investigate whether Cat-D and HLA-DR are co-localized, KG-1 cells were fixed, 
permeabilized, and stained for HLA-DR (green) and Cat-D (red), and then were attached to 
polylysine coated slides at 4 C to visualise by fluorescence microscopy. Individual cells were 
identified by their fluorescent blue nucleus through DAPI staining. HLA-DR staining was 
observed in green on the cell surface and also in intracellular vesicular compartments, 
whereas Cat D staining was observed in red in the vesicular compartment, shown in Figure 
3.14. The intracellular compartments that can be stained by L243-FITC are the MHC II 
compartment (MIIC) and related compartments. Cat D is a known lysosomal marker. So from 
this, it can be inferred that some DR molecules end up in cathepsin D positive lysosomes, 
where degradation of HLA-DR is hypothesised to be taking place. 
 
Figure 3.14 Co-localization of HLA-DR and Cat D with fluorescence microscopy in KG-1 cells.  Co-
localization of DR molecules and Cat D in KG-1 cells. KG-1 cells were fixed and permeabilized and 
blocked with normal mouse serum. DR molecules are stained green with L243-FITC antibody and Cat 
D in Red. Cat-D was stained with anti-Cat D rabbit polyclonal IgG and Alexa-Fluor 568 conjugated 
anti-rabbit IgG second-step reagent. Cells were counterstained with DAPI to highlight the nuclei. 
Arrows indicate protein localization.  
 
In summary, Cat D was the only aspartyl protease that was detected in KG-1 by Western Blot 
and qRT-PCR. In Priess cells, it was possible to detect the presence of CTSD mRNA by 
qRT-PCR, and Cat D bands were observed on overexposing Western blots, albeit with a 
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different band pattern. There might be some differences in the transcriptional activity of the 
CTSD and post-translational fate of enzyme in both cell lines. Co-staining of KG-1 cells for 
Cat-D and HLA-DR and their co-localization by fluorescence microscopy were consistent 
with expectations. 
3.3.5 Lentiviral knockdown of Cat D.  
 
In order to provide formal proof that degradation by Cat D is responsible for the Pep A effect 
on HLA-DR levels in KG-1 cell lines, the CTSD gene was knocked down using a 
commercially available lentiviral vector at a multiplicity of infection (MOI) of 5 and above. 
Cat D sh-RNA transduced cells were selected by culturing cells in complete IMDM media 
containing 1μg/ml puromycin (the viral constructs had a puromycin resistance gene for 
selection).  Non-targeting sh RNA vector was used as a negative control in order to observe 
cellular effects, if any, of the transfection process. This control vector will activate RISC and 
the RNAi pathway, but does not target any human genes, thus offering a useful reference for 
interpretation of the knockdown experiment (Moore et al., 2010)  
To examine knockdown efficiency, cell extracts from Cat D and control knockdown 
transduced  KG-1 cells and non-transduced KG-1 cells were immuno-blotted with Cat D 
antibody after separation by SDS-PAGE under non-reducing conditions.  Recombinant 
human Cat D at 10ng was used as a positive control. Two Cat D bands were observed, as 
seen previously, at molecular weights around 48 kDa (pro Cat D) and 33 kDa (mature Cat D). 
In contrast, there was a 96% decrease when the band intensity of Cat D knockdown KG-1 
cells was compared with the control knockdown and non-transduced KG-1 cells (Figure 3.15 
(A)). The cell extracts from all the samples contained comparable amount of protein extract, 
as judged by re-probing for GAPDH after stripping the blot (Figure 3.15 (B)). The band 
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intensity was quantified with image studio version 5.2 and the quantification results confirms 
the successful knockdown of the Cat D (Figure 3.15 (C)).   
 
Figure 3.15 Knockdown of Cat D protein expression in KG-1 cells. The CTSD gene was knocked down 
(KD) in KG-1 cells to validate its role in DR degradation. Control knockdown and non-transduced KG-1 
cells were used as controls in the experiment. (A) Whole cell lysates, prepared in RIPA buffer, were 
resolved by 12% SDS-PAGE, and Western Blots were probed using anti-Cat D antibody. (B) The blot 
was stripped and re-blotted with anti-GAPDH antibody as a loading control. (C) Bar graph showing ratio 
of intensities of Cat-D and GAPDH. This experiment was performed once.  
 
3.3.6 Loss of DR accumulation in Cat D knockdown KG-1 cells through Pep A. 
 
As shown in Figure 3.3, the maximum accumulation of DR caused by Pep A was seen after 
48 hours of treatment, and thereafter there was no further accumulation.  It took weeks to 
expand the knockdown KG-1 cells for analysis, so it was technically impossible to detect DR 
accumulation within 48-72 hours after successful knockdown. However, if Cat D is indeed 
responsible for DR degradation, then there should be no accumulation of DR when Cat D 
knockdown cells are treated with Pep A.  
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Hence, Cat D knockdown KG-1 cells were treated with 20 μM Pep A or vehicle control for 72 
hours. Control knockdown KG-1 cells were used to control for any effect of transfection on 
DR levels. The total DR was then quantified, as described earlier, by L243-FITC antibody daily 
for up to 72 hours following treatment. As shown in Figure 3.16, the control knockdown in 
KG-1 cells showed accumulation of DR when treated with Pep A.  Two-way ANOVA showed 
that accumulation of HLA-DR at 24 hours in control knocked down KG-1 cells was statistically 
significant, F (1, 6) =81.159, p<0.001 (Appendix 3.7). Similarly, in control knocked down KG-
1 cells, accumulation of HLA-DR was statistically significant at 48 and 72 hours F (1, 6) 
=200.851, p<0.001 (Appendix 3.8) and F (1, 6) =81.03, p<0.001 (Appendix 3.9). Cat D knock 
down cells had no persistent accumulation of DR when analysed several of weeks after 
selection. The statistical analysis showed that the effect of Pep A in Cat D knocked down KG-
1 cells was statistically significant but magnitude was very small (Appendix 3.7, 3.8, and 3.9). 
Their HLA-DR levels seemed to have returned to the wild type. However, in these cells Pep A 
mediated accumulation of HLA-DR molecules was no longer effective, which suggests that the 
Pep A effect is due to Cat D. There may be some adaptation in cells, similar to that seen in KG-
1 cells in which Cat D was inhibited for longer times (72 hours in Figure 3.3 and 3.7).  
 
 




Figure: 3.16 Loss of Pepstatin A-mediated accumulation of HLA-DR in cathepsin D knockdown KG-1 
cells. Staining of DR molecules was quantified by flow cytometry and is reported as median 
fluorescence intensities (MFI; mean +/- S.D. of triplicate analysis). There was a significant 
accumulation of the DR molecules in the pepstatin A treated control knockdown (KD) KG-1 cells but 
not in Cat Dknockdown KG-1 cells, when compared to the controls. Cells were analyzed after fixation 
and permeabilization. L243-FITC antibody was used to stain the HLA-DR molecules 
 
To summarize, Cat D was the only aspartyl protease that was detected in KG-1 by Western 
Blot and qRT-PCR. In Priess cells, it was possible to detect the presence of CTSD mRNA by 
qRT-PCR, and Cat D bands were observed on overexposing Western blots, albeit with a 
different band pattern. There might be some differences in the transcriptional activity of 
CTSD and the post translational fate of the enzyme between both cell lines. Nevertheless, the 
Cat D may well be responsible to initiate the DR degradation. This assumption is also 
supported through the co-localization of Cat D and HLA-DR in KG-1 cells. The loss of the 
Pepstatin effect in Cat D knockdown KG-1 cells demonstrates the involvement of Cat D in 
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3.4 Discussion  
 
The inhibitor, gene expression and knockdown studies reported here support the idea that 
HLA-DR protein turnover in KG-1 cells is critically dependent on Cathepsin D. Cat D is the 
only target enzyme of Pep A that seems to be expressed in KG-1 cells. The Pep A effect is 
ablated in KG-1 cells in which Cat D gene expression is knocked down.  The proposed 
hypothesis for HLA-DR degradation is shown in Figure 3.17. 
 
Figure 3.17 Proposed hypotheses for HLA-DR degradation. Rescue of the HLA-DR molecule by 
Pepstatin A and other evidence (see text) suggests a role of Cathepsin D in HLA-DR degradation.  
 
The Pep A effect occurs in a variety of cell types, including immature MoDCs (Appendix 
7.1). Pep A also rescues HLA-DP molecules in KG-1 cells from degradation, and the effects 
of Pep A on mouse class II molecules vary. Moreover, the result also suggest a correlation 
between the expression of Cat D and the turnover of HLA-DR molecules. This is based on 
the similarity in the effect of Pep A in MoDCs (Appendix 7.1) and KG-1 cells and thus it is 
indirect. However, Priess cells have slow turnover (t1/2 > 60 h), and in this cells Pep A had at 
most a very small effect and the abundance of Cat D was much lower (Figure 3.7), suggesting 
that cells that are low in Cat D have slower turnover of HLA-DR proteins. The different 
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effects of Pep A on different cell lines suggest that different rates of turnover correlate with 
differential expression of aspartyl proteases. Independent of this, differences in ubiquitin-
mediated internalisation into lysosomes could contribute to differences in DR turnover 
between cell types. In any case, the ability of Pep A to rescue DR in KG-1and MoDCs (and 
to a small extent in Priess cells) indicates the involvement of aspartyl proteases in DR 
degradation. The accumulation of DR was observed intracellularly on fixed and 
permeabilized KG-1 cells, but was not observed when only cell surface HLA-DR was stained 
(Appendix 7.1). In conclusion, this data suggest this is more broadly relevant phenomenon.   
When KG-1 cells were cultured in the GlutaMAX media, which favours lysosomal activity 
(Heeneman et al., 1993, Ten Broeke et al., 2010), the Pep A effect was of similar magnitude 
as in regular media but peaked earlier. Thus, the Pep A effect (and therefore the role of Cat D 
in DR degradation) is not an artefact of having worked in culture conditions that inherently 
slow down lysosomal degradation.  
Previous work by Dr Busch’s group has mapped the initial cleavage site of Cat D on HLA-
DR. The observed initial cleavage site after residue Phe 54 in the α-chain maps to an 
extended strand shared between MHC II molecules, which flanks the N terminus of the 
bound peptide. The α-chain is highly conserved in the HLA-DR molecules (Trowsdale, 
1993). Thus, based on the cleavage preference of Cat D, the mechanism of degradation 
observed in KG-1 cells will apply to all variants of HLA-DR, including gene variantgene 
variants. 
Prior attempts to identify MHC II regulatory factors have used genetic manipulation, and that 
may be the reason why Cat D was not identified. The cells seem to adapt, as can be seen in 
KG-1 cells cultured with GlutaMAX media where, after the initial peak effect of Pep A, the 
effect wears off. Even in cells grown in regular media, in which lysosomal activity is lower, 
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further DR accumulation ceased on the third day of treatment. Moreover, when Cat D was 
knocked down in KG-1 cells, the cells were expanded for 2-3 weeks before analysis, by 
which time HLA-DR levels were no longer elevated above baseline.  
Together, these lines of evidences indicate that cells eventually adapt to maintain the levels of 
HLA-DR. There can be two possibilities: either there is feedback down- regulation of HLA-
DR protein synthesis or there is adaptation of the lysosomal compartment to the lack of Cat D 
by up-regulating other enzymes, possibly with similar cleavage specificities, so that overall 
lysosomal function is restored. Further studies on this interesting issue are needed.   
Since various cathepsins play different roles in the MHC II maturation, it is also possible that 
Cat D might be involved in maturation of HLA-DR and thus the Pep A rescue, which is 
observed, is merely an accumulation of immature HLA-DR molecules. The L243 antibody 
used in this chapter does not recognize immature HLA-DR molecules (Roche and Cresswell, 
2011), but there was no control used to detect immature HLA-DR in this study. Therefore, 
Chapter 4 examines the form of HLA-DR rescued by the Cat D. Nevertheless, all the results 
so far indicate that Cat D has a vital role to play in the degradation of HLA-DR molecules.  
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Chapter 4: Characterizing the molecular form of HLA DR molecules 
degraded by cathepsin D  
 
4.1 Abstract  
 
Several key stages of HLA-DR maturation take place in lysosomes. Different molecules may 
be found ssociated with HLA-DR in lysosomes: invariant chain (li), Class II associated 
invariant chain peptide (CLIP), other peptides. Cathepsin D (Cat D) could act on any of these 
forms or it could be more selective in its action.  Work described in this chapter characterised 
the form of the HLA-DR degraded by Cat D. Biochemical and immunological tools were 
used to investigate which of the different forms of HLA-DR accumulate in KG-1 cells when 
Cat D action is blocked with pepstatin A. Resistance to SDS-induced denaturation at room 
temperature was used as a known proxy for  peptide binding to HLA-DR. Results showed no 
rescue of SDS stable HLA-DR molecules. Of the known SDS unstable species, Iiassociated 
molecules seemed not to be rescued, because quantification of Iiby flow cytometry or 
Western Blot did not show any change after pepstatin A treatment. There was no detectable 
accumulation of ubiquitinated DR β chain which would have been seen as multiple higher 
molecular weight bands on a Western blot. Of the different association states of MHC II 
molecules, the results are consistent MHC II molecules which either never acquired a peptide 
or lost peptide following antigen presentation to be degraded by Cat D. This study supports a 
working model for HLA-DR degradation in which peptide loading and the associated 
molecular machinery protect HLA-DR from Cat D attack, whereas MHC II are degraded 
selectively upon loss of bound peptide by Cat D.  




Lysosomal proteases carry out several steps in the maturation and peptide loading pathway of 
MHC II molecules (van Kasteren and Overkleeft, 2014). They generate peptides that are 
loaded into the peptide binding groove (Hsing and Rudensky, 2005). They also participate in 
the way in which Iiregulates access to peptide binding groove by mediating the degradation 
of the Iichain (van Kasteren and Overkleeft, 2014). Results from Chapter 3 provided 
evidence that one lysosomal protease, Cat D, plays a specific role in the disposal of HLA-DR 
molecules.  Cat D might act not just by degrading the HLA-DR molecules themselves but 
also at other points where proteases influence the maturation of HLA-DR molecules. The 
objective of this chapter was to examine which forms of HLA-DR are susceptible to attack by 
Cat D.  
The antibody used in Chapter 3 to quantify DR levels was the well-characterised L243 
antibody (Lampson and Levy, 1980), which reacts well with the DR  chain of mature DR 
 dimers, but reacts poorly with immature, Ii-associated DR during pulse/chase analyses 
(Roche and Cresswell, 2011). PIN.1 is an antibody which binds to the N terminus of Ii(Roche 
et al., 1991) whereas the CerCLIP.1 antibody binds to CLIP (van Luijn et al., 2011). The 
invariant chain degradation and antibody binding specificities are shown in Figure 4.1.  
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Figure 4.1 HLA-DR protein maturation, fate, and antibody binding specificity. Full length invariant chain 
creates steric interference, preventing L243 binding. PIN.1 binds the N-terminus of Ii. Ii and its 
degradation intermediates are indicated. Initiation of Ii degradation (generating p22) may involve 
aspartyl proteases; subsequent steps (generating p10 and CLIP) are mediated by cysteine proteases. 
L243 binds to DR  chain of mature DR  dimers, either loaded with peptide or empty. DR 
molecules loaded with peptide are SDS stable, while empty DR molecules are SDS unstable. 
 
In order to address whether peptide loaded HLA-DR, immature forms of HLA-DR, or both, 
were rescued by Pep A, SDS stability assays were performed. The peptide loaded DR is 
highly stable, and cannot be dissociated by SDS (without boiling) at room temperature. 
However empty DR or DR bound to Iiis generally less stable and dissociated by SDS at room 
temperature (Busch et al., 1998, Natarajan et al., 1999b, Sadegh-Nasseri et al., 2010).  In cells 
that lack HLA-DM catalysed peptide editing and/or where CLIP dissociates spontaneously, 
the resulting MHC II molecules, which are either empty or not loaded with stable peptides, 
exhibit faster turnover (Busch et al., 2012, De Riva et al., 2013). Ubiquitination is a known 
regulator of degradation, in which ubiquitin, a 76 residue protein (Callis, 2014), is covalently 
attached to the  chain of the HLA-DR and initiates its internalization (Shin et al., 2006, van 
Niel et al., 2006).   
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These different forms of HLA-DR can be distinguished in cells according to their 
biochemical phenotype, based on SDS stability, reactivity with different antibodies and 
molecular weight of associated Iichain fragments. 
 
4.2.1 Potential role of cathepsin D in MHC II pathway 
 
Cat D is a major aspartyl protease of the lysosomal compartment, thanks to its localization in 
multi-vesicular endosomes (MIIC) (Benes et al., 2008). Considering the entire life span of 
MHC II molecules, Cat D has the potential to act at several steps in antigen presentation and 
MHC II maturation, with distinct biochemical consequences as set out below. 
4.2.1.1 Potential role of Cat D in the degradation of antigens. 
 
Antigen processing is the process by which antigens are prepared for presentation by MHC 
molecules (Mellman et al., 1998).  The general steps in antigen processing are unfolding of 
native proteins, reduction of disulphide bonds and proteolytic fragmentation (Watts, 2012).  
MHC II binding can occur at any stage after the unfolding step (Santambrogio et al., 1999). 
Some studies have shown Cat D to have a role in antigen degradation (Mizuochi et al., 1994, 
Villadangos et al., 1999). In contrast, DCs derived from Cat D deficient mice were capable of 
antigen processing as well as antigen presentation. Microglia isolated from such mice also 
retained ability for antigen presentation (Nishioku et al., 2002). In knockout mice, cells might 
adapts and even if there is a role of Cat D in antigen processing perhaps a remodelling of 
other lysosomal enzymes could compensate  to some extent. There might be a role of Cat D 
in processing of antigens but it is not one that is quantitatively important. There is no 
evidence that lysosomes that are deficient in Cat D are inefficient at processing antigens in 
general or result in an overall peptide loading defect.  
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If Cat D were primarily important for antigen supply, its inhibition would reduce SDS 
stability and accelerate HLA-DR degradation by other proteases due to the under supply of 
stabilizing peptides (Busch et al., 2012, De Riva et al., 2013). This is not in accordance with 
the rescue of HLA-DR from degradation by Cat D inhibition seen in Chapter 3. 
 
4.2.1.2 Potential role of Cat D in degradation of invariant chain 
 
MHC II αβ heterodimers assemble in the endoplasmic reticulum (ER), where they associate 
with invariant chain (Ii) (Neumann and Koch, 2005). The peptide binding groove of the MHC 
II molecule is blocked by a disordered region of Ii, thus preventing ER polypeptides from 
associating with the groove (Busch et al., 1996). MHC II/Ii complexes accumulate transiently 
in  late endosomal compartments under the direction of the cytoplasmic tail of Ii (Busch and 
Mellins, 1996). MHC II/Ii complexes are then transported to endocytic compartments, where 
Ii chain is sequentially degraded by cysteine proteases to give the p22 or p10 degradation 
intermediates and then finally, CLIP. The process of Iidegradation is depicted in Figure 4.1. 
The terminal Ii degradation fragments (Mak and Saunders, 2006), CLIP, continue to block 
the peptide binding groove and must dissociate to allow presentation of antigen. The enzymes 
involved in the initial steps of degradation have been in debate.  
 
The enzyme that initiates degradation of Iihas been proposed to be an aspartyl protease 
(Marić et al., 1994), but this has not been reproduced by others (Villadangos et al., 1997, 
Deussing et al., 1998). Riese et al (1996) reported that cathepsin S, but not cathepsin B or D, 
is necessary for the digestion of Ii from MHC II molecules. The progressive degradation of 
p22 to p10 and then to CLIP is performed by the cysteine proteases, cathepsin L and S (Hsing 
and Rudensky, 2005). Costantino et al. (2008) reported that there is considerable variation in 
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lysosomal activity between different cell lines. Thus, results reported earlier  may not be 
mutually contradictory and the activity of lysosomal enzymes depends on the cell system 
used.  
If Cat D were important in initiating Iiprocessing in KG-1 cells, as reported by Marić et al., 
(1994), one would predict accumulation of Iiand li/DR complexes. Data in Chapter 3 had 
shown accumulation of HLA-DR molecules using an antibody, L243, which poorly reacts 
with Iiassociated HLA-DR molecules (Lampson and Levy, 1980, Roche and Cresswell, 
2011). However, this did not fully rule out the possibility that Cat D acts to prevent the 
degradation of li/DR complexes. If Cat D has a role in the degradation of  Iithen there would 
be accumulation of PIN.1 reactive DR/Ii complex on Pep A treatment.  
4.2.1.3 Potential role of Cat D in degradation of empty MHC II molecule 
 
Unpublished work by the group of Dr Busch has shown that cathepsin D is able to degrade 
HLA-DR molecules in vitro (Appendix 7.1). This observation suggests the vulnerability of 
HLA-DR towards direct attack by the cathepsin D. Moreover, Cat D fragments of DR chain 
were identified by Orbitrap LC-MS/MS analysis of tryptic digests, and compared with 
cleavage preferences predicted from the MEROPS database to identify the cleavage site. 
Initial Cat D cleavage in vitro was mapped to α54 a site in DR  that interacts with bound 
peptide and changes conformation when peptides bind (Ferrante, 2013). Thus, it is possible 
that peptide binding regulates Cat D attack so that empty molecules are degraded.  
If empty HLA-DR molecules are selectively targeted for Cat D attack in KG-1 cells, then Pep 
A treatment will result in the accumulation of SDS-unstable DR molecules but not of Iior its 
fragments.  
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4.2.1.4 Potential role of Cathepsin D in the activation of other proteases 
 
Many of the proteases, including Cat D, are synthesised as pre-pro or immature forms. The 
activation of such forms is achieved by cleaving the pre-pro form by other proteases. So it is 
possible that cathepsin D might act on the pre-pro form of another enzyme that then attacks 
HLA-DR molecules.  However to our best knowledge, there has been no previous evidence 
of this role of cathepsin D in the literature (Brix, 2005, Colbert Jeff et al., 2009). So this 
function of cathepsin D seems to be less likely. Also there isevidence, as reported in section 
4.2.1.3, that Cat D is capable of attacking HLA-DR molecules directly. 
As the preceding sections have shown the rescue of specific forms of HLA-DR will produce 
distinct phenotypes. The objective of this chapter was to compare the biochemical 
phenotypes of HLA-DR molecules rescued by Pep A with these expectations and thereby 
infer which forms of HLA-DR is being rescued.   
  




The objective of this chapter was to findout which forms of HLA-DR are susceptible to 
attack by Cat D.  
4.3.1 No evidence that Iiis rescued by Pep A 
 
Marić et al. (1994) observed that an inhibitor of aspartyl proteases accounted for 
Iidegradation. If this observation was true then in the KG-1 cells blocking Cat D should 
rescue li.  In order to address this, KG-1 cells were treated with pepstatin A for up to 48 
hours, fixed and permeabilized, and analysed for Iiusing PIN.1-FITC antibody. PIN.1 binds 
to the N terminus of the Iichain (Roche et al., 1991).  
Flow cytometry showed immunoflurorescence staining with anti-Iiantibody (PIN.1) in KG-1 
cells at baseline, over and above unstained control and isotype control IgG2, as shown in 
Figure 4.2 (A).  In Pep A, treated KG-1 cells, there was no effect on the invariant chain, as a 
positive control we reproduced the finding of Pep A mediated rescue of HLA-DR molecules 
as it had done in previous experiments in Chapter 3 (Figure 3.6), as shown in Figure 4.2 (B). 
There was no detectable accumulation of Iiin Pep A treated KG-1 cells compared, to the KG-
1 cells that were left untreated or treated with DMSO as a vehicle control. One-way ANOVA 
indicated no significant effect of Pep A on Iiaccumulation F (2, 15) =1.388, p=0.280 
(Appendix 4.1).  However, the increase in DR level on treatment with pepstatin A in KG-1 
cells was significant, F (2, 15) =18.17, p<0.001, as analysed by one-way ANOVA (Appendix 
4.2). Hence there is no evidence that cathepsin D degrades li.  
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Figure 4.2 No evidence for rescue of invariant chain by Pepstatin A in KG-1 cells. KG-1 cells were 
treated with 20 µM Pepstatin A, DMSO (vehicle) or left untreated (control) for 48 hours. Cells were 
fixed and permeabilized and analysed for Iiand HLA DR with PIN.1-FITC and L243-FITC respectively, 
by flow cytometry. (A) Shows the overlay of histograms in FL-1 when stained with L243-FITC, IgG2-
FITC, PIN.1-FITC or nothing. (B) Shows staining of Iiand DR molecules quantified by flow cytometry 
and reported as median fluorescence intensities (MFI; mean +/- S.D. of triplicate analysis). The 
results show no evidence for the rescue of IiI KG-1 cells when the action of cathepsin D was blocked 
by Pepstatin A. This experiment was repeated three times.  
 
Thus, PIN.1 staining showed no evidence that Iichain is degraded by Cat D. In contrast, 
HLA-DR molecules that are preferentially recognised by L243 were rescued in the same 
experiment (Figure 4.2).  The li-DR complexes are reactive to PIN.1 antibody and poorly 
reactive to L243 antibody. Thus li-DR complexes are unlikely to be the potential targets for 
the DR degradation. 
To confirm Pep A does not rescue Iichain complexes, extracts from Pep A- treated and 
control KG-1 cells were resolved by 12% reducing SDS PAGE, and Western blots were 
probed with PIN.1 antibody. The quantification results from the Western blot, shown in 
Figure 4.3, also showed that there is no accumulation of Ii or its degradation intermediates by 
Pep A in KG-1 cells. Thus, cathepsin D does not detectably act on the degradation of Ii chain 
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in the KG-1 cells. Not only is there no measurable change in the total Ii chain but also there is 




Figure 4.3 No accumulation of invariant chain when KG-1 cells are treated with pepstatin A: KG-1 cells 
were treated with 20 µM Pepstatin A, DMSO (vehicle control) for 48 hours. (A) KG-1 cell extracts were 
resolved by 12% reducing SDS PAGE and immuno-blotted for invariant chain (li) using PIN.1 
antibody. Ii and its degradation intermediates were observed at (molecular weights of) 43kDa, 33 kDa 
and 20 kDa. There was no visible difference between the band intensities of the Iidegradation 
intermediates between pepstatin A treated KG-1 cells and untreated cells. This was confirmed by 
quantification of p-33 and the p-20 bands by Image studio version 5.2 software. (B) Bar graph 
showing to the band intensities of p-33 and p-20 intermediate of li. This confirmed that there is no 
measurable change in Iiprocessing in Pep A treated KG-1 cells. 
 
These experiments were done in regular media supplemented with glutamine. In Chapter 3 it 
had been shown that the peak pep A effect on mature HLA-DR levels occurred earlier 
(section 3.3.2) in media containing GlutaMAX. This is likely to be related to release of 
ammonia on hydrolysis of glutamine. So the KG-1 cells were cultured in media containing 
GlutaMAX. Once adapted to the new media, KG-1 cells were treated with pepstatin A for up 
to 48 hours, fixed and permeabilized, and analysed at various time points for Iiusing PIN.1-
FITC antibody. The staining intensity was indistinguishable between the controls and Pep A- 
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treated cell for the Iias shown in Figure 4.4 (A). Figure 4.4 (B) compares the Pep A effect on 
levels of Ii, as detected with PIN.1-FITC, between KG-1 cells grown with L-glutamine and 
GlutaMAX.  Two-way ANOVA revealed no significant change in the Ii levels on treatment 
with Pep A in KG-1 cells cultured in GlutaMAX media, F (1,20) =0.124, p=0.729 (Appendix 
4.3). As before, cells were stained separately at each time point, so that effect of time in 
culture was statistically significant but not necessarily biologically meaningful, due to 
possible confounding technical variations. 
 
Figure 4.4 No accumulation of Iichain in KG-1 cells treated with Pep-A using GlutaMAX media.. KG-1 
cells were cultured in IMDM media containing GlutaMAX instead of traditional glutamine containing 
medium, and the effect of Pep A was analyzed. (A)There was no accumulation invariant chain (li) 
when stained with PIN.1 antibody in KG-1 cells treated with Pep A in GlutaMAX media. Cells were 
analysed after fixation and permeabilization. Staining was quantified by flow cytometry and is reported 
as median fluorescence intensities (MFI; mean +/- S.D. of triplicate analysis). (B) There was no effect 
of Pep-A on the Ii regardless of whether cells were grown in glutamine or GlutaMAX containing 
media. Each bar represents the fold change, i.e., Pep-A treatment divided by the control. This 
experiment was repeated twice.  
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4.3.2 Rescue of SDS-unstable DR molecules by pepstatin A 
 
In order to examine whether peptide loading influences the susceptibility of the HLA-DR 
molecules to cathepsin D, the SDS stability (as proxy of stable peptide loading) of HLA-DR 
molecules from Pep A-treated and control KG-1 cells was compared. The resistance to SDS-
induced denaturation was investigated by comparing the migration on polyacrylamide gels of 
identical boiled and non-boiled protein samples containing SDS. 
Accordingly, KG-1 cells were treated with 20 M Pep A or vehicle control for 48 hours, and 
the rescue of DR molecules was confirmed by flow cytometry with similar results as shown 
before in Figure 3.3. Proteins were extracted from both sets of samples and quantified using 
BCA assay. Protein quantities were matched between the extracts. The samples were then 
resolved by 12% SDS PAGE in either boiled or non-boiled conditions, and Western blots 
were probed with anti- DR and DR antibodies. On boiling the sample, the native structure 
is denatured and the observed single band (35 kDa for α and 29 kDa for β) would consist of 
total DR (including both SDS stable and unstable DR molecules). In non-boiled samples, the 
SDS-stable form will retain its native structure, whereas SDS unstable molecules will be 
denatured in SDS. Thus, SDS-stable DR will be observed at around 55 kDa (for both α and β 
since structure is intact) whereas the unstable DR should be observed around 35 kDa for α 
and 29 kDa for β.  
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Figure 4.5 Accumulation of SDS unstable DR molecules in Pep A treated KG-1 cells. Whole cell lysates, 
prepared with RIPA buffer, were resolved by 12% SDS-PAGE with or without boiling (lanes labelled B 
and NB respectively); Western Blots were probed using anti-DRα (A) and anti-DRβ antibodies (B). 
The position of monomeric DRα (35 kDa), DRβ (29 kDa) and SDS stable DR α/β dimers (55 kDa) are 
indicated in the figure.(C) The HLA DRβ membrane was stripped and re-probed with anti-GAPDH 
antibody as a loading control. Please note that the order of pepstatin A and control was reversed in 
panel B. This experiment was repeated twice. 
 
The blots shown in Figure 4.5 revealed similar amounts of SDS stable DR (αβ dimer at 55 
kDa) in KG-1 cells treated with and without pepstatin A. On the other hand, the SDS unstable 
DR was rescued by pepstatin A. Both cell extracts contained comparable amounts of protein 
extract, as judged by re-probing for GAPDH. The molecular weight of GAPDH 37 kDa, is 
similar to HLA-DR α (35 kDa), and stripping of anti-DR α from blots was inefficient, so only 
the HLA-DRβ blot was re-probed with the GAPDH antibody. The band intensities were  
quantified with Image studio version 5.2. The quantification results confirm the selective 
rescue of SDS unstable DR molecules (Figure 4.6).  
 




Figure 4.6 Quantification of Western Blots shown in Figure 4.5. (A) Bar graph representing the fold 
change in Pep-A treated KG-1 cell extracts. Bands were quantified by Image Studio version 5.2 
software. The SDS stable DR complexes remained unaffected, while there was an increase in the 
SDS unstable DR molecules after Pep A treatment. (B) Bar graph showing intensities of total DR (C) 
Bar graph comparing intensities between both the extracts of the loading control GAPDH, based on 
the re-plot of the DRβ blot. The graph shows mean +/- SD of the band intensities in experiments such 
as the one showed in Figure 4.5.  The values are from two independent repeats.  
 
Together, these experiments showed that pepstatin A rescues SDS unstable DR molecules 
which are not associated with li. In most allelic variants of DR, CLIP-DR complexes form 
SDS-unstable complexes. To check whether pepstatin A rescues CLIP-DR, KG-1 cells 
treated with pepstatin A were analysed by flow cytometry using the Cer-CLIP.1 antibody, 
which binds to CLIP. As shown in Figure 4.7, there was no detection of the CLIP using the 
Cer-CLIP antibody. This may be due to low levels of CLIP-DR molecules present in the KG-
1 cells. A caveat is the lack of a positive control showing that Cer-CLIP antibody was 
actually working. 
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Figure 4.7 Inability to detect CLIP on KG-1 cells with Cer-CLIP antibody. Fixed and permeabilized KG-1 
cells, treated with pepstatin A, were stained with Cer-CLIP-FITC and PIN1-FITC. Unlabelled and 
IgG2-FITC samples were also used as controls. The figure shows the overlay of gated histograms in 
FL-1 when stained with Cer-CLIP-FITC and PIN.1-FITC. Unlabelled sample and irrelevant antibody 
(IgG2-FITC) were used as a control. There was no shift in the histogram when KG-1 cells treated with 
Pep A were stained with Cer-CLIP- FITC antibody, suggesting a failure to detect CLIP. This 
experiment was repeated twice.   
 
In conclusion, SDS unstable DR molecules that are not associated with the Iiare selectively 
rescued by pepstatin A in KG-1 cells. 
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4.4 Discussion  
 
Cat D, as discussed in Introduction section 4.1, could conceivably target several molecular 
forms of MHC II. The molecular form of DR accumulated in KG-1 cells treated with Pep A 
was characterised here. In KG-1 cells treated with Pep A, there was no evidence for the 
accumulation of Iichain and the rescued DR molecules were SDS unstable, implying that 
cathepsin D targets empty mature HLA-DR molecules. Table 4.1 shows the expected features 
of different forms of HLA-DR and compares them with the form that the data shows being 
rescued. 
















+ + - -  - - 
L243 
reactive 
low high High High High High + 
Cer-CLIP 
reactive 
- - + - - - Not detected 
β chain MW 29kDa 29kDa 29kDa 29kDa > 37 kDa 29kDa 29kDa 
SDS stable - - - + - - - 
 
Flow cytometry and Western blot data showed that PIN.1 immuno-reactive molecules were 
not rescued by Pep A, suggesting that Ii chain, and its degradation intermediates were not 
targets of the cathepsin D degradation. This finding contradicts Marić et al (1994) who had 
found that a proprietary aspartyl protease inhibitor blocked the first step of Iidegradation, but 
consistent with negative findings by other groups in this regards (Deussing et al., 1998, 
Villadangos et al., 1997). Accordingly, in KG-1 cells, cathepsin D does not target the early 
forms of the DR, which are PIN.1 reactive. Similarly, there was no accumulation of Ii when 
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KG-1 cells cultured in GlutaMAX media were treated with pepstatin A. Thus, Ii is not 
targeted by cathepsin D regardless of whether lysosomes are highly active or less active. 
Considering that there is variation in lysosomal activity between different cell lines as 
reported by Costantino et al., (2008). This finding indicates that in KG-1 cells, Cat D is 
dispensable for Ii chain processing, and the interference with early maturation steps does not 
explain the accumulation of HLA-DR molecules follow Pep A treatment.  
Having been unable to detect CLIP in untreated KG-1 cells, we did not pursue the possibility 
that Cat D inhibition could affect the exchange of CLIP for antigenic peptides. This is less 
plausible because it would involve changing a non-covalent interaction, rather than blocking 
a degradation step (Kropshofer et al., 1996).  Thus, there is no reason to expect CLIP 
exchange for antigenic peptide to be affected by Cat D inhibition. CLIP generation involves 
cysteine proteases, which are not affected by Pep A (Riese et al., 1996).  
Ubiquitination takes place at the DR β chain of mature DR αβ dimers (Moffat et al., 2013). 
Ubiquitination is the covalent attachment of ubiquitin to target proteins (here DR). Ubiquitin 
is a small, 76-residue, protein (8.5 kDa) which attaches to the DR β chain (De Gassart et al., 
2013). Hence the ubiquitin associated DR would produce a ladder like pattern above the β 
chain when observed on Western blot. The Western Blot shown in Figure 4.5 does not show 
this. It is not clear whether KG-1 cells use ubiquitin-dependent or alternative internalisation 
pathways to target HLA-DR molecules for degradation. Thus, degradation happens either to 
molecules that were never ubiquitinated or to the DR molecules that have been de-
ubiquitinated before being degraded. 
The biochemical and immunological profile of the rescued molecules fits best, having 
excluded the other possibilities, with that of empty DR molecules. Thus, I propose that Cat D 
in KG-1 cells selectively degrades empty HLA-DR. 
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4.4.1 Working model 
 
The working model that emerges from these observations is that the lysosomal degradation of 
HLA-DR follows a multi-step processes as shown schematically in Figure 4.8. 
 
 
Figure 4.8 Working hypothesis of DR degradation. This study shows that the aspartyl protease 
Cathepsin D is responsible for the selective degradation of empty DR molecules in KG-1 cells. Once 
the peptide is presented by mature DR (black), empty DR (red) is internalized, which may depend on 
ubiquitination (green) based on he studies in other cells. In lysosomes, Cat D initiates the degradation 
by cleavage at the Phe 54 site on the  chain. The DR molecules that are poorly loaded with peptide 
during endosomal maturation (blue). 
 
Even though a role of MARCH 1- dependent ubiquitination has not been documented in KG-
1 cells, studies in other cell systems suggest that in primary APCs, the first step in the 
lysosomal disposal of MHC II molecule is the ubiquitin-mediated internalization (Shin et al., 
2006, Moffat et al., 2013, ten Broeke et al., 2013), followed by the loss of ubiquitin to restore 
the HLA-DR, which is then degraded by Cat D. It is not clear where de-ubiquitination of 
MHC II molecules takes place or which enzymes mediate the process. It is also unclear 
whether empty DR molecules can selectively ubiquitinated and then internalised, or 
selectively attacked by Cat D or both.   
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Mapping of the initial Cat D cleavage site of DR by Dr Busch’s group onto the crystal 
structure of HLA-DR (Appendix 7.1) strongly suggests a model for the initiation of DR 
breakdown. The observed initial cleavage site after residue Phe 54 in the α-chain maps to an 
extended strand, which flanks the N terminus of the bound peptide (Figure 4.9). It is 
potentially accessible to proteolytic attack in the native structure but not when it is hydrogen-
bonded to the peptide. Thus, cleavage after αPhe54 may only be possible following release of 
peptide. Moreover, the known interactions with Ii, DM, and bound peptide may protect 
maturing MHC II molecules from proteolysis throughout the process of peptide loading (Pos 
et al., 2012). This region of the molecule is conformationally flexible in mutant DR 
molecules that undergo rapid peptide exchange without DM (Painter et al., 2011). This model 
explains how stable peptide occupancy would render DR molecules highly resistant to initial 
cleavage at this site. Cathepsin D may serve as an initiator in the degradation of HLA-DR, 
after the loss of peptide. This causes a partial loss of conformation in DR potentially 
revealing otherwise sterically inaccessible cleavage sites for further degradation by Cat D and 
other lysosomal proteases. 
 
 
Figure 4.9 Crystal structure of HLA-DR bound to CLIP. α Phe 54 is the predicted Cat D cleavage sites 
Image from Protein Data Bank (PDB). 
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In conclusion, the results in this study suggest that the accumulation of DR molecules 
induced by Pep A in myeloid APCs is due to inhibition of direct cleavage of empty DR 
molecules by Cat D. Initial cleavage occurs at the peptide bond between Phe54 and Glu55, a 
conserved site on the monomorphic DR α chain. The known interactions of MHC II 
molecules with Ii, DM, and bound peptide may protect maturing MHC II molecules from 
proteolysis throughout peptide loading, but release of bound peptide without participation of 
these molecules may render them susceptible to cleavage by cathepsin D. The working model 
proposed in Figure 4.9 provides a mechanism by which MHC II molecules survive during 
maturation, yet are degraded at the end of their useful lifespan.  Thus, this fills a key gap in 
our understanding of the molecular pathways by which MHC II proteins are degraded in 
APCs. 
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Chapter 5: Interacting effects of vitamin D and retinoic acid on HLA-DR 




Vitamin D plays a major role in immune regulation. Thus, it is associated with protection from 
autoimmune diseases, including multiple sclerosis (MS).  Retinoic Acid (RA) has been ascribed 
crucial roles in immunological fitness. These micronutrients play a vital role in immune homeostasis. 
Moreover, MS risk is influenced by polymorphisms in HLA-DRB1, which encodes the β chain of 
HLA-DR antigen-presenting molecules, and by polymorphisms affecting vitamin D metabolism. 
Vitamin D regulates antigen-presenting cell function, including the transcription and expression of 
some DRB alleles, such as the DRB1*15 MS risk variant. Vitamin D might protect from MS in part 
by differentially influencing the expression of HLA-DR protein variants associated with MS risk. 
Here, the effect of vitamin D (10nM) and or RA (1µM), at pharmacologically active doses, on HLA-
DR expression was investigated in lymphoblastoid cell lines (LCL) homozygous for eight common 
DRB1 alleles and in KG-1 cells. In most LCL, neither vitamin D nor RA consistently altered HLA-
DR expression. However, vitamin D enhanced HLA-DR expression in LCL homozygous for 
DRB1*15 PGF cells, and DRB1*13 WDV cells, whereas RA increased HLA-DR levels in the 
DRB1*07 homozygous LCL, MANN. Vitamin D effects were reversed by RA, and vice-versa 
consistent with  mutual competition for the shared RXR transcription factor. In contrast, the combined 
treatment of KG-1 cells with vitamin D and RA resulted in decreased HLA-DR expression. The result 
confirms previous findings that vitamin D has allele dependent and independent effects of HLA-DR 
protein expression, which are modest in size, involve several different mechanisms and are further 
modulated by RA. The finding highlights the need for studying how these effects are integrated in 
primary APCs. 
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5.2 Introduction  
 
This chapter investigates the interaction between vitamin D and RA signalling in the 
regulation of MHC II protein expression in model APCs.  As discussed in Chapter 1, section 
1.4.2., vitamin D metabolites are involved in the regulation and expression of several hundred 
genes implicated in innate and adaptive immune defence (Hewison et al., 2003, Liu et al., 
2009, Smolders and Damoiseaux, 2011, Tiosano et al., 2013). Similarly, retinoic acid (RA) is  
pleotropic in terms of its effect on the immune system.  
5.2.1 Interaction of vitamin D and retinoic acid 
 
As discussed earlier in the Chapter 1, (1.4.1)RXR is a shared nuclear hormone receptor as it 
can also bind as a homodimer or as a heterodimer with retinoic A receptor (RAR) (Blomhoff 
and Blomhoff, 2006). The binding of the RAR/ RXR heterodimer to the retinoic acid 
response element (RARE) sequence in the promoter region of the target genes results in the 
transcription of target genes (McGrane, 2007). Figure 5.1 shows how vitamin D and RA 
regulate the transcription of target genes.   




Figure 5.2 Regulation of nuclear receptor mediated gene transcription: The figure provides a schematic 
representation of the pathway via which vitamin D and RA mediate the transcriptional effects on target 
genes.  In panel (A) the binding of active vitamin D to VDR results in activation of VDR. Active VDR 
than heterodimerizes with RXR and binds to VDRE within target gene promoters and modulates their 
transcription. Similarly, RA can also mediate gene transcription via RAR/RXR binding to RARE, as 
shown in (B). 
 
This common ability for RXR to bind to both VDR and RAR can lead to the possibility of 
cross-talk within their response elements (Tavera-Mendoza et al., 2006) that may lead to a 
synergistic (Anand et al., 2008) or antagonistic effect (Bastie et al., 2004) depending on the 
response element being evaluated. Previous research has found RA and vitamin D to have a 
synergistic effect in inducing  tumour cell differentiation in the hematopoietic system (Muto 
et al., 1999). Researchers have also reported the synergistic differentiation of myeloid 
leukemia cells by RA and vitamin D, which was probably mediated through their cognate 
nuclear receptors (Defacque et al., 1994, MasciulIiet al., 1995, Nakajima et al., 1996).  
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5.2.2 Vitamin D and HLA-DR protein 
 
As discussed in section 1.5.6 of Chapter 1, VDREs exist in the promoter region of certain 
DRB1 alleles, which can enhance the expression of HLA-DR molecules. A study performed 
by Ramagopalan et al. (2009) showed that bioactive vitamin D enhances the expression of the 
particular HLA-DRB1 allele most strongly associated with increased risk of MS, 
DRB1*15:01.  However, other studies have failed to find similar effects of bioactive vitamin 
D on other DRB1 (DRB1*13:03 and DRB1*04:05) alleles, which are associated with MS in 
a Sardinian population (Cocco et al., 2012). The authors found VDREs in close proximity of 
the examined HLA haplotypes, but they did not find a consistent HLA expression increase 
when adding vitamin D, and some of the VDREs were not functional. Thus, there may be a 
gene environment interaction at the level of regulating expression of one MS risk allele but 
not of other risk alleles that are prevalent in other populations. Cocco et al. (2012) examined 
gene promoter activity in response to bioactive vitamin D in the particular allele. It is also 
possible that some of the effects of vitamin D on HLA-DR protein expression are not 
transcriptional but post-translational. There might be redistribution of HLA-DR taking place 
in the APC that could have different rate of turnover and so potential of an indirect effect of 
vitamin D on the expression of HLA-DR cannot be ruled out.  
The main objective of this chapter was to examine the effect of vitamin D and / or RA on  
HLA-DR expression in model cell lines. The earlier studies (Ramagopalan et al., 2009, 
Cocco et al., 2012) only examined the effect of vitamin D on some HLA-DR alleles in 
homozygous typing cells (HTCs), by either measuring the activity of the DRB1 promoter or 
by measuring surface expression of the protein. The current study investigates the combined 
effect of vitamin D and RA on the total (surface + intracellular) HLA-DR expression in a 
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similar cell system, but expanding the panel of cell lines in a systematic way to include 
alleles most prevalent in  majority of the UK population.  
KG-1 cells were also selected because they have more active turnover of HLA-DR molecules 
as compared to HTCs (Chapter 3) and they are heterozygous in the expression of HLA-DR. 
Considering the aim of looking at the effect on the alleles, HTCs representing the alleles 
found in KG-1 cells were also selected to investigate whether there is any similarity between 
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5.3 Results  
 
In order to examine the responsiveness of HLA-DR expression in HTCs to vitamin D and 
RA, cells were treated with either of these reagents, or both, and the HLA-DR levels were 
quantified by flow cytometry. 
Pharmacological bioactive doses of 10 nM vitamin D and 1 µM RA were selected, based on 
those previously reported for cell cultures (Adamson, 1996, Ryan et al., 2013). These doses 
were deemed to be non-toxic for cell culture and are considered to be comparable with doses 
of vitamin D (25-OH-D) and RA found in the serum of adults (Bischoff-Ferrari et al., 2012, 
Johnson and Redner, 2015).  
The group of Professor Steven G E Marsh at the Anthony Nolan Research Institute identified 
the top six most frequent HLA-DRB1 alleles in the UK cohort (White British / White Irish / 
Caucasian).  The frequencies of these were calculated both as predicted proportions by 
Hardy-Weinberg (Chen et al., 1999) and based on actual counts from a cohort of adult donors 
from the UK. This information was also crosschecked with the allele frequency database 
(http://www.allelefrequencies.net/default.asp). Thus, these six alleles represents a 90% of the 
population in the UK (White/Irish/ Caucasian) cohort having one of the allele and 50% for 
the two allele. The list of the cell lines along with their alleles is provided in Chapter 2 Table 
2.1. 
5.3.1 Effect of vitamin D and RA on total HLA-DR expression in HTCs  
 
HTCs representing the six commonest HLA-DRB1 alleles in the Caucasian British/ Irish 
population and the two DRB1 alleles present in the KG-1 cells were selected for the study. 
The HTCs were treated with calcitriol, RA, or both. The maximum treatment was for 72 
hours, and DMSO matched to the volume used in the combination treatment (0.02% v/v) was 
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used as a vehicle control. Earlier studies examining at the effect of vitamin D on specific 
alleles of HLA-DR have not considered any possible interaction with RA (Ramagopalan et 
al., 2009, Cocco et al., 2012). The cells were cultured with vitamin D and or RA, fixed and 
permeabilized, stained for HLA-DR using L243-FITC antibody, and analysed by flow 
cytometry at 48 hours and 72 hours post treatment. Representative FACS plots are shown in 
Figure 5.3, which show total HLA-DR staining for the HTCs.  
 
Figure 5.3 Representative FACS plots for total HLA-DR staining of HTCs. The figure shows 
representative FACS plots for total HLA-DR staining of HTCs representing eight common DRB1 
alleles. Cells were fixed and permeabilized and stained with anti-DR (L243-FITC) antibody. Unstained 
   
 121 
(US) and isotype control (IgG2-FITC) staining were used as controls in the experiment. The analysis 
was performed by flow cytometry. 
Unstained cells (US) and IgG2a-FITC, an isotype matched negative control, were used as 
controls to assess autofluorescence and background fluorescence. The histograms show that 
there is little if any increase in fluorescence intensity when stained with IgG2-FITC 
compared to the unstained cells. By comparison, there was a substantial increase in 
fluorescence when HTCs were stained with L243-FITC. 
In such flow cytometry experiments, fluorescence intensities vary for technical reasons 
between staining experiments performed on different days. Moreover, different batches of the 
antibody were used between experiments, which can also have impact on the staining 
intensities. So because of the way the experiments were set up, day-to day variations were not 
considered biologically meaningful. Internal comparisons, however, with the control on the 
same day, are more valid. The raw data showing day-to-day fluctuations are shown in the 
Appendices (5.1 and 5.2), and Figure 5.4 shows the effects of vitamin D and/ or RA, 
normalised to vehicle control (DMSO) =100% on the same day. Figure 5.4 summarizes two 
independent experiments for eight HTCs. The cell lines responded differently to individual or 
combination treatment with vitamin D and RA. The effects observed on HLA-DR expression 
was reproducible in most cases. Based on the experience from Chapter 3 in quantifying 
modest changes in HLA-DR levels, effect sizes of more than 20% were considered 
meaningful if they were reproduced in both experiments. Most cell lines showed no or small 
effects of vitamin D or RA, except PGF, WDV and MANN. 
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Legend    
Figure 5.4 Fold changes of HLA-DR in HTCs covering eight common DRB1 alleles on treatment with 
vitamin D and RA. A panel of eight HTCs, covering the six common DRB1 haplotypes present in over 
90% of white British/Irish/Caucasian people and the two alleles present in KG-1 cells, were treated 
with 10 nM Vit D, 1μM RA, or both (Combi) for up to 72 hours. Total HLA-DR expression was 
quantified using flow cytometry on fixed and permeabilized cells using FITC-conjugated anti-DR mAb 
(L243). Each bar represents the fold change, i.e. treatment divided by vehicle control (DMSO). Some 
HTCs responded to individual treatment with vitamin D or RA. The figure shows two independent 
repeats denoted by Exp 1 and Exp 2. 
 
Bioactive vitamin D (calcitriol) alone increased HLA-DR expression levels in PGF and WDV 
cell lines, which are homozygous for the DRB1*15 and DRB1*13 alleles, respectively. The 
increase in HLA-DR expression level was dependent on time. For the other HTCs, the effect 
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of vitamin D was not detectable. There was a modest increase in HLA-DR expression in 
MANN cells, homozygous for DRB1*07. In each of the above-mentioned HTCs, the effect 
were reproduced in both experiments. There were some effects of RA (increase in the HLA-
DR level), in EK and JBUSH cells, in one of the experiment but were not reproduced in the 
other experiment. 
In PGF and WDV cells, the effect of combination treatment of vitamin D and RA is not the 
sum of the individual effects. The effect of vitamin D alone was not reproduced by 
combination treatment in both the cell lines. Conversely, the effect of RA on HLA-DR 
expression in MANN cells was lost when vitamin D was added in the combination treatment. 
So in HTCs the effect of each individual was neutralized in the presence of the other agent. 
5.3.2 Unresponsiveness of KG-1 cells to pharmacological doses of bioactive vitamin D 
 
Myeloid cells may behave differently when compared to the EBV- transformed 
lymphoblastoid cells (HTCs), and hence the effect of vitamin D and RA on HLA-DR 
expression was studied in KG-1 cells. KG-1 cells were treated with 10 nM calcitriol 
(recommended pharmacological dose) or DMSO (vehicle control) for up to 72 hours. DR 
levels were quantified either on live or fixed and permeabilized cells using L243-FITC 
conjugated antibody by flow cytometery. Total DR (i.e. surface HLA-DR and intracellular 
HLA-DR) was detected by staining of fixed and permeabilized cells, whereas only surface 
HLA-DR was detected by staining of with live cells (Figure 5.5 (A)). Vitamin D alone had no 
detectable effect on surface HLA-DR levels in live KG-1 cells. Similarly, there was only a 
very slight increase in the expression of HLA-DR in fixed and permeabilized KG-1 cells 
treated with vitamin D over control. The result is shown in Figure 5.4 (A) for surface DR and 
in Figure 5.5 (B) for total DR. Two-way ANOVA indicated a significant difference between 
treatment for surface HLA-DR, F (2,18) = 3.859, p = 0.040 (Appendix 5.3) and for total 
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HLA-DR F (2, 18) = 17.956, p = 0.010 (Appendix 5.4). However, in both cases the 
magnitude of the effect is very small, less than 5 %, reproduced in both the attempts. 
 
 
Figure 5.5 Minimal effect of vitamin D alone on HLA DR protein expression in KG-1 cells. KG-1 cells 
were treated with 10 nM bio-active vitamin D (1 α, 25-dihydroxyvitamin D3) or DMSO (vehicle control) 
or nothing (control) for up to 72 hours. The HLA DR levels were assessed on either live KG-1 cells (A) 
or fixed and permeabilized KG-1 cells (B). L243-FITC antibody was used to stain the DR molecules 
while IgG2a- FITC was used as an isotype control. Unstained cells (US) were also used as a control 
for auto-fluorescence. Staining of DR molecules and isotype control was quantified by flow cytometry 
and is reported as median fluorescence intensities (MFI; mean +/- S.D. of triplicate cultures). The 
graphs show no biologically meaningful difference on the HLA-DR levels on treatment with 
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5.3.2 Reduction of HLA-DR expression in KG-1 cells treated with vitamin D and RA 
 
KG-1 cells were treated as described earlier in order to assess the effect of vitamin D and RA 
on HLA-DR expression. Total DR was detected on fixed and permeabilized KG-1 cells using 
flow cytometry. The individual treatments had no effect on HLA-DR levels, but the 
combination treatment of RA and vitamin D was able to reduce HLA-DR expression by 
around 20-36%.  As before, there was day-to-day variability in the staining intensities in the 
control on any given day due to technical reasons, and therefore the informative analysis is 




Figure 5.6 Fold changes of HLA-DR observed when KG-1 cells treated with VitD and or RA.  Each bar 
represents the fold change i.e. treatment divided by control.  When treated with either Vit D or RA 
alone, there was very little effect on HLA DR, but on combination treatment there was a decrease in 
total HLA DR over time. This graph is representative of four independent repeats. 
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Two-way ANOVA revealed that neither vitamin D nor RA individually had a statistically 
significant effect on HLA-DR expression (F (1, 8) = 6.22, p = 0.166 and F (1, 8) = 10.531, p 
= 0.084 respectively (Appendix 5.5)), at 24 hours after treatment. However, there was a 
significant interaction between vitamin D and RA, F (1, 8) = 37.885, p <0.001 (Appendix 
5.5) at 24 hours on the expression of HLA-DR. Similarly, there was a statistically significant 
interaction observed at 48 and 72 hours after treatment F (1, 8) = 36.873, p <0.001 (Appendix 
5.6) and F (1, 8) = 32.647, p <0.001 (Appendix 5.7) respectively as determined by two-way 
ANOVA. At 48 and 72 hours post treatment, vitamin D and RA individually showed 
statistically significant effects on the HLA-DR expression (Appendix 5.6 and 5.7 
respectively), but the effect sizes are not impressive relative to the error in the system.  
 
In the overall data set, vitamin D and RA individually have very little effect but there is a 
reduction in HLA-DR expression when combined with each other. Therefore, the effect of 
two reagents (vitamin D and RA) shows up statistically significant (though effect is 
unimpressive) but their interaction shows impressive and statistically significant effects, as 
the effect is not additive. Thus, a synergistic effect leads to the reduction of the HLA-DR 
expression when vitamin D and RA are combined. In the four independent repeats the % 
decrease of the HLA-DR at 2-3 days after treatment varied between 20-36%.   
  




The objective of this Chapter was to investigate how HLA-DR levels in cell lines respond to 
the combined or separate treatment with vitamin D and RA. To our knowledge, this is the 
first examination of this interaction with any cell line. In HTCs, the effects of vitamin D and 
RA on the expression of HLA-DR varied between the cell lines and over time and competed 
with each other. In contrast, in the myeloid cell line, KG-1, combined treatment with vitamin 
D and RA synergistically lowered HLA-DR expression. 
5.4.1 Increase in HLA-DR expression on vitamin D treatment of HTCs is limited to DRB1*15 
and DRB1*13 alleles 
 
Of the six most common HLA-DRB1 alleles in the White British/ White Irish/ Caucasian 
cohort, and the alleles found in KG-1 cells, calcitriol treatment increased total HLA-DR for 
HTCs expressing the DRB1*15 allele (PGF cell, Figure 5.4). There also was an increase in 
the total HLA-DR also observed in case of HTC expressing the DRB1*13 allele (WDV cell, 
Figure 5.4).  Ramagopalan et al. (2009), had reported increased DRB1*15 gene transcription 
in PGF cells after treatment with vitamin D and increased protein expression of the same 
magnitude as observed here. They also reported no such effect on HTCs expressing the 
DRB1*07 allele, which was also reproduced in this work, although the cell lines used were 
different (DBB vs. MANN in this chapter).  It was reassuring to reproduce similar effects as 
reported earlier. In the other HTCs, no effect of biologically active vitamin D was detectable 
(Figure 5.4). 
The magnitude of increase in the HLA-DR expression observed in PGF and WDV cells was 
between 25-50 %, and its biological significance might be questionable. The PGF cells, 
homozygous for HLA-DRB1*15, however, express an alternate β-chain gene, DRB5 
(Andersson et al., Horton et al., 2008) at a higher level, whereas the DRB1*15 gene product 
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is in the minority, at the mRNA and protein level. As reported earlier by Ramagopalan et al. 
(2009), vitamin D interacts on a VDRE in the HLA-DRB1*1501 promoter to enhance its 
transcription. That the total HLA-DR expression increases by upto 50 % (in PGF cells) may 
all be attributed to DRB1,whereas the expression of the DRB5 could remain constant. In this 
case, the increase could be much bigger than 50 % for the DRB1 gene product. The increase 
in the expression of  HLA-DR after vitamin D treatment could be important in the particular 
genetic variant DRB1*15:01. Further examination of gene variant is described in Chapter 6.  
In addition, RA increased total HLA-DR in MANN cells which is homozygous for the 
DRB1*07 allele (Figure 5.4). The increase may be due to transactivation of RARE, as 
observed in the PGF cells, but more work is required before definite conclusions can be 
drawn.  
No effects of either vitamin D or RA on the remaining cell lines were observed in this study. 
This highlighted the need for further controls to test whether these cell lines are vitamin D 
responsive using other criteria, such as CD38 expression (Ramagopalan et al., 2010). 
Preliminary findings (RB et al., unpublished) show an increase in CD38 expression after 48 
hours of vitamin D treatment in HOM-2 and JBUSH HTCs, in which HLA-DR expression 
was unresponsive. PGF cells included as a positive control also showed increased CD38 
expression under these conditions. Although these controls need to be extended to the full 
HTC panel, so far no HTCs have been found to be unresponsive to vitamin D.  
5.4.2 Competition for the binding of RXR receptor 
 
The effect of vitamin D on the expression of HLA-DR depended on the interaction with RA. 
In those HTCs in which vitamin D increased the expression of  HLA-DR (PGF, WDV), that 
effect was abolished by the addition of RA. Conversely, in MANN cells the modest effect of 
RA on HLA-DR expression was lost with the addition of vitamin D.  One reason for this non-
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additive effect may be because VDR and RAR compete for their shared binding partner, 
RXR (Bastie et al., 2004).  The common ability for RXR to bind to both VDR and RAR can 
lead to the possibility of cross-talk within their response elements (Tavera-Mendoza et al., 
2006). This would explain why the combination treatment did not show the effects of 
individual treatment, suggesting that there is mutual interaction between the two pathways, 
such that activation of one pathway stops the other pathway from up-regulating HLA-DR 
expression in some way.  
5.4.3 Protective effect of vitamin D in auto-immunity 
 
The presence of a functional VDRE in the promoter region of HLA-DRB1*15 has been 
reported (Ramagopalan et al., 2009). In addition, the expression of HLA-DRB1*15 increased 
on adding the biologically active vitamin D both in this study and the study by Ramagopalan 
et al. (2009), confirming a functional link between this important genetic risk factor and the 
environmental factor, vitamin D. This suggests that vitamin D deficiency could lead to lower 
HLA-DRB1*15 expression and subsequently lack of deletion of autoreactive T cells, which 
could  increase the risk of autoimmune disease. However, HLA DRB1*15 is not the only 
allele associated with MS. In Sardinia, where the MS prevalence is also high and HLA 
DRB1*15 is a rare allele, the HLA alleles associated with MS are DRB1*04:05 and 
DRB1*16:01 (Lampis et al., 2000, Cocco et al., 2013). VDREs were found in close proximity 
to several examined HLA-DRB1 haplotypes, but there was no consistent HLA-DR 
expression increase when adding biologically active vitamin D (Cocco et al., 2012). So even 
if the sequence motif that defines VDREs is conserved, in a highly polymorphic gene like 
MHC (HLA), there is individual variation such that some alleles may have functional VDREs 
and others have mutant VDREs. Nonetheless, in individuals harbouring the DRB1*15, allele 
the regulation of vitamin D could be an important mechanism that contributes to the balance 
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between tolerance and auto-immunity. Thus, vitamin D might play a protective role against 
autoimmune disease like MS in populations expressing a particular allele.  It is difficult to 
rule it out, even though the effects are not impressive (35-50% increase).  However, it also 
has to be considered that vitamin D can protect from auto-immunity independent from this 
gene environment interactions. 
Interestingly, a study found a functional VDREs in the promoter region of the HLA-
DRB1*03∶01 allele in a population of patients from North India (Israni et al., 2009).  The 
patients were screened for Type 1 diabetes, an autoimmune disease. The authors reported an 
increase in HLA DR levels, around 1.2 fold, on treatment with vitamin D in the homozygous 
B-lymphoblastoid cells. They also speculate that in conditions of low vitamin D levels, the 
expression of HLA DRB1*03∶01 is insufficient to reach the threshold of thymic deletion, 
similarly to that hypothesized in MS. When COX cells containing HLA DRB1*03:01 were 
used in the present study, no such increase was observed when treated with calcitriol. Israni 
et al. (2009) used VAVY and DUCAF B-lymphoblastoid cells, which are different from the 
ones used in the present study. Sometimes promoter polymorphism does not track closely 
with structural polymorphism, and so the choice of cell line does matter. A significant 
difference between both studies was the concentration of calcitriol used. Israni et al. (2009) 
used 100 nM calcitriol, whereas this study was performed using 10 nM calcitriol. The higher 
concentration may be un-physiological and cause off-target effects, including apoptosis. 
Hence, a careful dose response needs to be performed before considering the cells un-
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5.4.4 Suppressive effect of RA and vitamin D co-treatment on HLA DR in KG-1 cells. 
Unlike the EBV transformed B cell lines, KG-1 cells have more active turnover of the HLA-
DR molecules, suggesting post-translational effects of vitamin D and RA might be observed. 
Indeed, there was a reduction in the expression of total HLA-DR on combination treatment of 
vitamin D and RA. On the other hand, the individual agents had no effect on the expression 
of HLA-DR. In EK and JBUSH cells, which are haplotype matched to the DRB1 alleles in 
KG-1, there was no effect of vitamin D and a variable effect of RA on the expression of 
HLA-DR molecules.   
Calcitriol is a ligand  for VDR, which in its active state forms heterodimers with RXRs 
(Haussler et al., 1997). After ligation, VDR and RXRs undergo conformational changes that 
induce binding to specific sequences in the promoter regions of target genes (Aranda and 
Pascual, 2001, Janik et al., 2017). Interaction with the general transcription machinery is 
essential to initiate target gene transcription. In KG-1 cells this plays out differently than in 
HTCs, and one possible reason could be because cell line specific differences in the handling 
of the HLA-DR molecules post transcriptionally or post translationally. There are examples 
of genes, such as interleukin 2 (IL 2), which are repressed by vitamin D via direct 
transcriptional repression (Alroy et al., 1995, Issa et al., 1998) but there is no evidence of 
such thing happening to VDRE genes.  
However, the most probable possibility is that the combination of vitamin D and RA for some 
unknown reason changes the differentiation of KG-1 cells. KG-1 cells may degrade  HLA-
DR molecules faster under the influence of treatment with vitamin D and RA, or co-treatment 
may lowers the gene transcription of HLA-DR proteins in KG-1 cells. Thus, the reduction in 
the expression of HLA-DR in KG-1 cells on treatment with vitamin D and RA could also be 
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either transcriptional or post-translational. These possibilities are not mutually exclusive, and 
hence further studies are required. 
A technical limitation of the study is that a low level of vitamin D may be present at baseline. 
The two media preparations used in the experiments contained no vitamin D. Fetal bovine 
serum (FBS) may contain some vitamin D, but at pharmacological dose it was possible to see 
effects on HLA-DR expression, consistent with previous literature (Ramagopalan et al., 2009, 
Israni et al., 2009). In some cell lines, a small effect of vitamin D might be observed by the 
background stimulation from residual vitamin D. This might be important for the cells where 
no effect has been observed. In future, charcoal-stripped FBS could be used to see any minor 
effects (Dembinski et al., 1985, Dang and Lowik, 2005). 
This study does reproduce the effects of vitamin D on the phenotypic expression of HLA-DR, 
which another group has attributed to transcription (Ramagopalan et al., 2009) and the work 
extends to other HTCs corresponding to the common alleles found across the UK (White 
British/ Irish) population. This is the only study to have looked at the combined effects of 
vitamin D and RA. In the myeloid KG-1 cells, vitamin D alone had no effect on the 
expression of HLA-DR but the combination with RA reduced the expression of HLA-DR. 
There was no consistent increase in the HLA-DR expression in HTCs, other than PGF and 
WDV, on treatment with vitamin D, suggesting that there is allele specificity most probably 
via VDRE.  In contrast, in DRB1*07 HTC, MANN, RA alone increases the expression of 
HLA-DR molecules. Lastly, the effect of vitamin D is abolished on addition of RA and vice 
versa probably because of the competition between activated VDR and RAR for the shared 
RXR subunit.  
 If more than one gene variant is present, then it is not clear whether any effect is specific to 
either variant or shared. Therefore, there is a need to be able to track them separately. This 
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may be especially important for the DRB1*15:01 haplotype (MS risk allele), given that the 
abundance of the DRB5 gene product is known, at least in B lymphoblastoid cells, to be 
higher than DRB1 gene product (Horton et al., 2008). Thus, the DRB3/4/5 gene loci have to 
be considered and evaluated separately, and an approach to this will be provided in the 
Chapter 6. 
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Chapter 6: Quantifying changes in HLA-DR allelic composition using 





Of the MHC II genes, HLA-DRB1, which encodes the β chain of the HLA-DR molecule, is 
the most polymorphic. HLA genes exhibit codominant expression of the maternally and 
paternally inherited alleles and gene variation. The codominant expression of these alleles is 
functionally important, but how it is regulated by external factors is not fully understood 
because of difficulties in its measurement. Here, a stable isotope and mass spectrometry 
approach was used to quantify changes in the relative amounts of co-expressed HLA-DR 
allelic and gene variants in response to vitamin D and RA. As a model system, KG-1 cells 
were treated for up to 72 hours with bio-active vitamin D3 (10 nM), RA (1 µM), both, or 
vehicle control (DMSO). As a quantitative standard, KG-1 cells were labelled with all-[13C]-
Arg/Lys SILAC media, and were mixed 1:1 with cell pellets from each culture condition. 
DRβ was isolated by immunoprecipitation and SDS-PAGE and SILAC ratios determined by 
Orbitrap LC-MS after tryptic digestion. This approach reliably detected subtle effects of 
different culture media and RA on the contribution of the DRB3 gene product to the total DR 
β chain pool. This highlights the sensitivity of the SILAC approach. However, neither 
vitamin D nor RA changed the mix of DRB1 alleles. Alternatively, SILAC standards were 
prepared from HTCs expressing only one of the two DRB1 alleles expressed in KG-1 cells, 
expecting to obtain information about the DRB1 allelic composition from differences in 
SILAC ratios between shared and allele specific peptides. However, these differences were 
too small to allow reliable estimates of allelic composition. Mathematical analysis indicated 
that for optimal quantification of allelic composition, the SILAC standard must be matched to 
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the unknown for total DR content. The results provide proof of principle that this approach 
can quantify changes in DR β allelic composition and informs the design of experimental 
strategies for future studies in primary antigen presenting cells.  
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6.2 Introduction  
 
The overall objective of this chapter is to quantify the effects of vitamin D and RA (alone or 
combined) on the co-dominant expression of HLA-DR proteins, using stable isotopes and 
mass spectrometry. This chapter also aimed to devise strategies for measuring the effect of 
vitamin D and/or RA in primary APCs from healthy donors and patients with DRB1-linked 
autoimmune diseases like MS. 
6.2.1 Variations in HLA-DRB genes 
 
As explained in Chapter 1, section 1.3.4, DRB genes, which encode the HLA-DR β, chain are 
highly polymorphic, existing in hundreds of variants in the human population (Reche and 
Reinherz, 2003). All haplotypes have one major DRB locus, DRB1. In addition, many 
haplotypes have an additional, closely linked locus, which encodes an alternate DR β chain 
polypeptide, DRB3/4/5 (Andersson et al., 1998).  Thus, any one individual human can 
produce between two and four different variant DR molecules, due to the genetic variation. 
These variants are difficult to distinguish in the experiments normally used to quantify the 
amounts of HLA-DR molecules, but this is important because HLA-DR variants may respond 
differently to vitamin D, as seen from the results from Chapter 5. It is still unknown how 
environmental factors such as vitamin D and RA influence the allelic composition of HLA-
DR, as well as the relative expression of gene products of HLA-DRB1 and any gene variants 
(DRB3/4/5). Antibody-based approaches for quantifying allelic composition are potentially 
biased by the antibodies, conformational preferences (Woolley et al., 2015), so there was a 
need to develop unbiased methods for quantifying DRB allelic composition in heterozygous 
APCs and their responsiveness to environmental factors. 
 




The term proteome refers to the complete set of proteins expressed in cells or tissue of an 
organism at a given time (Wilkins et al., 1996, Garrels, 2001). Accordingly, proteomics is 
used to describe the methods used to study proteomes (Clark and Pazdernik, 2013). These 
methods include chromatographic and electrophoretic techniques for protein or peptide 
fractionation, mass spectrometry for their identification, and the use of computational 
methods to assist the complicated data analysis (Godovac-Zimmermann and Brown, 2001).  
In order to interpret the biological phenomena a quantitative analysis is required. In 
proteomics, quantification can be absolute or relative (Bantscheff et al., 2007). Within 
quantitative proteomics, relative quantification is much more commonly used to compare 
protein levels between two or more different biological conditions. Relative quantification 
methods used in proteomics studies can be divided in two main categories, namely gel based 
quantification and mass spectrometry based quantification (Ong and Mann, 2005). Different 
relative quantification approaches are depicted in Figure 6.1. 




Figure 6.1 A flow-chart  of different stages in  quantitative proteomics experiments: A) Metabolic 
labeling, B) DIGE- Difference Gel Electrophoresis, C) SILAC Stable Isotope Labelling of Amino-acid in 
Cultures, D) ICAT Isotope-Coded Affinity Tags and E) iTRAQ Isobaric Tags for Relative and Absolute 
Quantification Methods. A and B present gel-based methods, while C, D and E present mass 
spectrometry based methods. Stable isotopes are incorporated in the mass spectrometry based 
methods metabolically (C), or chemically (D, E). Different symbols and solid lines in the figure indicate 
the stages performed in the method, while the stages marked with dashed lines are not necessary in 
the method. Red circles describe the labelling stage, and hexagons with id and/or q indicate the 
identification and quantification stages, respectively. Figure adapted from Bantscheff et al., (2007). 
 
From the variety of options available, as set out in Figure 6.1, the SILAC approach seemed 
well suited to our problem. Even though LCMS is capable of quantifying peptides of interest 
with accuracy and precision, its dose response to different tryptic peptides from the same 
protein varies, for two main reasons: first, the efficiency of tryptic digestion may vary 
between samples; secondly, different peptides vary in their ionisation efficiency (Mann, 
2006). In the SILAC approach for quantification, the addition of an internal standard to the 
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experimental data ensures any variation that is technical can be corrected for, because it will 
affect both the internal standard and the unknown. SILAC does not require any changes to the 
routine tissue culture method in practice, the heavy amino acids have no influence on cellular 
metabolism and the labelling strategy is universal throughout the protein; therefore, several 
peptides can be used for quantification (Ong and Mann, 2007b, Chokkathukalam et al., 
2014). This takes out the problem of variability and downstream processing that some of the 
other methods suffer. Additionally, the advantage of labelling lysine and arginine is that  all 
tryptic cleavage products are labelled (Gan et al., 2007). Hence metabolic labelling, which 
allows protein labelling at the time of protein synthesis, presents a valuable strategy for 
quantitative proteomics. 
6.2.3 SILAC experiment 
 
SILAC is a relative quantification method used for the proteomic analysis of cell lines to 
compare the expression levels of proteins between two or more samples (Harsha et al., 2008). 
This method was  developed to analyse complex proteomes in cell culture by Mann and Ong 
(Ong et al., 2002, Ong and Mann, 2007b).  In SILAC, cells are cultured either in a normal 
medium (light) or in a medium containing 13C-labelled arginine and lysine (heavy). 
Generally, cells grown in heavy media are supplemented with dialysed foetal bovine serum 
(FBS) instead of  normal FBS to ensure there is no contamination from free amino acids or 
peptides present in normal FBS (Ong and Mann, 2006).  Samples are prepared from cells 
cultured in both light and heavy media and mixed in a 1:1 ratio at a very early stage of the 
experiment, such that both samples are treated identically in subsequent steps, ensuring that 
the abundance ratios are maintained throughout and are not affected by any experimental 
errors. The sample is then prepared for mass spectrometry analysis (Ong and Mann, 2006). 
The light and heavy labelled peptides ions are chemically identical but exhibit distinctively 
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different mass spectra (Hoedt et al., 2014). The basic workflow of a proteomic experiment 
using SILAC is depicted in Figure 6.2.  
 
Figure 6.2 General workflow for SILAC experiment. The workflow illustrates the overview of SILAC for 
relative quantification in cell culture system. 
 
6.2.4 SILAC approach and experimental strategies 
 
KG-1 cells were chosen as a model cell line because  is heterozygous for HLA-DR, having 
the DRB1*11, *14, DRB3*02 alleles (Ning et al., 2011) and has turnover of the HLA-DR 
comparable to physiological APCs ( As discussed in Chapter 3 from the comparable Pep A 
effects on MoDCs). There will be three different strategies used for the quantification of the 
HLA-DR admixture.  
6.2.4.1 SILAC analytics in KG-1 cell 
The first experimental aim was to develop analytics and establish proof of feasibility. A 
SILAC approach was used as depicted in Figure 6.2, where SILAC labelled KG-1 cells were 
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mixed with unlabelled KG-1 cells following protein extraction. Mixed samples were 
immuno-precipitated with the L243 monoclonal antibody, which binds the conserved α chain 
of assembled DR αβ dimers. Following SDS-PAGE separation, the mixed β chains were 
excised, digested with trypsin, and resolved by mass spectrometry. If light and heavy samples 
are cultured identically, all peptides present are expected to exhibit the same L: H ratio. This 
strategy helped in establishing the protocols for the other experiments.  
 
6.2.4.2 Relative quantification with SILAC 
 
The standard SILAC approach, as depicted in Figure 6.2, measures changes with respect to 
controls when quantified by use of SILAC labelled control samples as an internal standard. 
This approach was used to determine the effect of vitamin D, RA, or both on the individual 
alleles present in the KG-1 cells. SILAC labelled KG-1 cells were used as control samples 
whereas un-labelled KG-1 cells were treated either with vitamin D, RA, or both and used as 
unknowns.  The workflow for this experiment is depicted in  Figure 6.3. This experiment 
quantifies changes from baseline in the relative expression of allelic or  gene variants in the 
KG-1 cell line.  This helped to determine whether the reduction of total DR on treatment with 
vitamin D and RA (as observed in Chapter 5, Figure 5.6) is general or  selective for a 
particular allele. 
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Figure 6.3 SILAC workflow for relative quantification from baseline. For relative quantification, SILAC 
labelled KG-1 cells were used as standards, and unlabelled KG-1 cells treated with vitamin D, RA, or 
both were used as unknowns and mixed in 1:1 ratio following protein extraction. Mixed samples were 
immuno-precipitated and following SDS-PAGE separation, the mixed β chains were excised, digested 
with trypsin, and resolved by mass spectrometry. 
 
6.2.4.3 Quantification of HLA-DRB1 alleles using SILAC  
 
In order to quantify the relative admixture of different HLA-DR allelic variants, the general 
SILAC approach was modified.  HLA-DR variants share some tryptic fragments but differ in 
other tryptic fragments as a result of allelic polymorphism. The key way of quantifying the 
allelic mix involves the use of a labelled reference preparation containing only one of the two 
allelic forms present in a heterozygous sample. If this is done, allele-specific and shared 
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peptides will differ in their admixtures of heavy reference peptides, depending on the 
abundance of the second allele in the test sample.Hence homozygous typing cells (HTCs) 
which are monoalleleic for the DR expression were used as a reference cell line. . The SILAC 
strategy is depicted in Figure 6.4 
 
Figure 6.4 Experimental design for quantitative measurements of co-dominant DR protein expression. 
(A) Tryptic digestion of a mixture of two co-expressed allelic variants yields shared as well as allele-
specific peptides. (B) The corresponding peptide mass spectrum does not, in practice, reflect the 
relative amounts of the two alleles, because of variation in the efficiency with which different peptides 
are released by trypsin and ionised in the mass spectrometer. (C) If an isotopically labelled (Heavy) 
variant of ONE of the alleles is added, the relative admixture of the two alleles can be determined by 
the relative amounts of heavy and light species in the mass spectrum (D). In the example, the heavy 
reference allele and the two unlabelled alleles are present in equimolar amounts, so that the 
measured L/H ratio is 1:1 for allele-specific and 2:1 for shared peptides (figure obtained from MS 
society project proposal by Dr Busch). 
 
In order to quantify the DRB1 allelic composition of KG-1 cells, protein extracts from un-
labelled KG-1 cells (treated with vitamin D, RA, or both) were mixed with labelled extracts 
of EK and JBUSH (HTCs for DRB1*14 and 11 respectively). Mixed samples were immuno-
precipitated with anti-DR antibody (L243) and resolved by SDS-PAGE. Following SDS-
PAGE, the mixed β chains were excised, digested with trypsin, and resolved by mass 
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spectrometry. HLA-DR peptide ions were identified by tandem mass spectrometry, and the 
relative proportions of labelled reference and unlabelled test peaks were quantified to 
estimate the mixture of DR alloforms present in the unlabelled test sample, as depicted 
schematically in Figure 6.4. Usually, more than one allele-specific and more than one shared 
peptide were detected, which allowed measurement error to be estimated. This approach, if 
successful, could also be used to study primary APCs without the use for bespoke autologous 
SILAC standards. So in order to inform the design of experiment with primary cells, it was 
necessary to evaluate the different ways of quantifying either changes in allelic composition 








The procedure for generating labelled standards and performing mass spectrometry is 
described in Chapter 2, section 2.2.5. This section focuses on calculations to determine the 
allelic mix within heterozygous cells for the strategy described in section 6.1.4.3. SILAC 
ratios should be an accurate reflection of the molar ratios between heavy and light peptides 
and assuming that the molar amounts need to add up in theory and on that basis the following 
formula has been derived. The objective here was to derive from the experimental data about 
measured SILAC ratios an estimate of the contribution of an allele that is shared with a 
homozygous typing cell line mixed to the total DRB1 pool. 
Consider a SILAC experiment in which the heavy labelled standard expresses one of two 
DRB1 alleles, which we will call A and B. DRB1 alleles will have shared peptides derived 
from their conserved domains and allele specific peptides coming mostly from their peptide 
binding grooves. Let the suffix  𝑠ℎ represent shared peptide and the subscript A, refer to the 
allele that is shared between HTCs and unknown heterozygous (here, KG-1). Allele B is the 
non-shared allele, which is only present in the unknown heterozygote, and for which no direct 
calculations be made from the SILAC ratios. 
    H 𝑠ℎ = HA    
L 𝑠ℎ = LA + LB                   (1) 
Where H stands for the amount in moles of the heavy protein and L stands for light. 
The molarity of A specific peptides is aL 𝑠ℎ while for B specific peptides it is (1-a) L 𝑠ℎ, in 
order to add up to 100%.  So, 
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 LA= a L𝑠ℎ  &   LB= (1-a) L𝑠ℎ 
Where a, is the mole fraction of allele A in the light sample 
Thus replacing those value in equation 1 
  L 𝑠ℎ = a L𝑠ℎ + (1-a) L𝑠ℎ 
The % light value for shared peptides, expressed in terms of the molar abundance of their 





 Or equivalently,   













                            
And then   






                      (2) 
 Similarly % Light for allele-specific peptides (LA) will be   
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And, expressing it in terms of a, the allelic contribution of A in the heterozygote,     































                     (3) 


















                            (4) 
 Thus, based on this equation the allelic contribution for each allele in the heterozygous cells 
can be calculated from the % light values for shared and allele specific peptides obtained 
from mass spectrometry data.  




The overall objective of this chapter was to quantify changes in HLA-DR allelic composition 
in response to external stimuIilike vitamin D and or RA using stable isotope and mass 
spectrometry.   
 6.4.1 Characterisation of KG-1 cells, preparations of SILAC standards and method 
optimization 
 
 KG-1 cells were used as a model cell line since it is heterozygous for HLA-DR (Ning et al., 
2011) and based on Pep A effects, has turnover of the HLA-DR comparable to physiological 
APCs  (Appendix 7.1 and Chapter 3). SILAC labelling was performed in order to generate 
labelled standards. 
6.4.1.1 KG-1 genotyping and qualitative analysis of peptide  
HLA typing of KG-1 cells has previously been reported to only two digits as having 
DRB1*11, *14, DRB3*02 alleles (Ning et al., 2011), hence higher resolution HLA typing 
was done at the Anthony Nolan Research Institute. The higher resolution was helpful in 
picking the most appropriate homozygous typing cell lines (mono-allelic) as reference cells.  
The higher resolution HLA typing gave the following results: HLA-DRB1*11:01, 14:01/54, 
DRB3*02:02/12/28/29N/34/42/46/54. 
Owing to the ambiguous results of genotyping, it was necessary to perform qualitative 
peptide analysis to compare the observed peptides to those expected from the HLA genotype 
of KG-1 cells. To address this, translated protein sequences of all the possible results for 
HLA-DRB1*14 (01/ 54) and DRB3*02 (02/12/28/34/42/46/54) were obtained from the 
IMGT/HLA database. DRB3*02:29N was not considered because it is a null allele. 
IMGT/HLA database (http://www.ebi.ac.uk/ipd/imgt/hla/) is a public database for the storage 
of sequences of the HLA system including the official nomenclature for genes and alleles 
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(Robinson et al., 2016). The predicted protein sequences were then subjected to in-silico 
tryptic digestion with Peptide Mass (http://web.expasy.org/peptidemass/) (Wilkins et al., 
1997). The work flow has been depicted in Figure 6.5.  
 
 
Figure 6.5 Flow chart for in silico tryptic digestion. The peptide sequences of the relevant HLA-DRβ) 
allele were obtained from the IMGT/HLA database (http://www.ebi.ac.uk/cgi-bin/ipd/imgt/hla), and 
were subjected to in silico tryptic digestion with Peptide_Mass (http://web.expasy.org/peptide_mass). 
A virtual digest was obtained. These virtual digests were used to identify the group of peptides that 
are specific for a particular allele or shared between the allele 
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With the help of  the virtual digest, peptide list , representing each of the alleles obtained 
through genotyping, was made. This list was than matched with the peptides obtained after 
tryptic digestion of the KG-1 cells during the actual mass spectrometry to identify HLA 
typing of the KG-1 cells. The peptide list and the virtual digest gave the following: HLA-
DRB1*11:01, HLA-DRB1*14:54 and HLA-DRB3*02:02 as the best matched HLA typing of 
the KG-1 cells. This is depicted schematically in Figure 6.6.  
 
 
Figure 6.6 Mapping of shared and allele specific peptide sequence to the DRB genes in KG-1 cells. This 
is a schematic representation and do not show accurate distances between the loci. N.B one of the 
DRB3 allele could be null. 
 
The virtual digests were also used to identify the subset of peptides that are specific for a 
particular HLA-DRB allele or shared between two or all three alleles. Such peptides were 
then selected from amongst the observed HLA-DR derived peptides and used for analysis.  In 
total, 29 peptides were identified which are shown in Table 6.1. The list is colour-coded 
based on the schematic representation shown in Figure 6.7.  Of the 29 peptides, eight peptides 
were unique to DRB1*11:01 (red), six peptides unique to DRB1*14:01 (purple) and seven 
peptides unique to DRB3*02:02 (green). There were five peptides that were shared between 
the two DRB1 alleles (DRB1*11:01 and DRB1*14:54) depicted in black. One peptide each 
was shared between DRB1*11:01 and DRB3*02:02 (yellow) and between DRB1*14:01 and 
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DRB3*02:02 (blue). There was one peptide which, according to virtual digests was shared 
between all three alleles, shown in maroon, but it was not detected in the actual experiment.   
  
   
 152 





no. Sequence DRB1*11:01:01 DRB1*14:54 DRB3*02:02 
1 WFRNGQEEK x x x 
2 FLEYSTSECHFFNGTER x x  
3 GHSGLQPR x x  
4 SGEVYTCQVEHPSVTSPLTVEWR x x  
5 VHPKVTVYPSK x x  
6 VTVYPSK x x  
7 HNYGVGESFTVQR x  x 
8 AAVDTYCR x   
9 AVTELGRPDEEYWNSQK x   
10 AVTELGRPDEEYWNSQKDFLEDR x   
11 DFLEDRR x   
12 FDSDVGEFR x   
13 FLDRYFYNQEEYVR x   
14 RAAVDTYCR x   
15 YFYNQEEYVR x   
16 FDSDVGEYR  x x 
17 AEVDTYCR  x  
18 AVTELGRPAAEHWNSQK  x  
19 FLDRYFHNQEEFVR  x  
20 HNYGVVESFTVQR  x  
21 RAEVDTYCR  x  
22 YFHNQEEFVR  x  
23 DLLEQKR   x 
24 ELGRPDAEYWNSQK   x 
25 ELGRPDAEYWNSQKDLLEQK   x 
26 GQVDNYCR   x 
27 HFHNQEEYAR   x 
28 RVHPQVTVYPAK   x 
29 VHPQVTVYPAK   x 
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6.4.1.2 Qualitative peptide analysis of HTCs  
The mono-allelic standards, JBUSH (DRB1*11:01) and EK (DRB1*14:54) were selected 
based on the higher resolution genotyping and qualitative analysis of peptides in KG-1 cells.  
HLA-DR preparation for JBUSH and EK cells were also subjected to tryptic digestion, and 
the peptides obtained were matched with the translated cDNA sequences of the particular 
alleles present in the HTCs in order to facilitate the SILAC analysis. In both HTCs, a DRB3 
gene was also present, but it was not considered for the SILAC analysis to quantify the allelic 
composition in the heterozygous KG-1 cells, since only the peptides coming from the shared 
allele are useful for this analysis. The list of informative peptides is shown in Table 6.2. 
Moreover, for of the HTCs, MASCOT search identified some peptides which were 
genetically not plausible. There was one example in JBUSH cells where two peptides (* 
marked, they are length variants) belonging to the DRB1*14 gene were identified, which 
should not be present. The reason for this mismatching is still not clear since analysis of the 
peptide peak did not indicate a false positive result.  In this experiment, not all the peptides 
were found and blanks are shown where applicable. 
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1 WFRNGQEEK    
2 FLEYSTSECHFFNGTER x x x 
3 GHSGLQPR x x 
 
4 SGEVYTCQVEHPSVTSPLTVEWR x x x 
5 VHPKVTVYPSK x   
6 VTVYPSK x x x 
7 HNYGVGESFTVQR x x x 
8 AAVDTYCR x x  
9 AVTELGRPDEEYWNSQK x x  
10 AVTELGRPDEEYWNSQKDFLEDR x   
11 DFLEDRR x   
12 FDSDVGEFR x x  
13 FLDRYFYNQEEYVR x   
14 RAAVDTYCR x   
15 YFYNQEEYVR x x  
16 FDSDVGEYR x x x 
17 AEVDTYCR x * x 
18 AVTELGRPAAEHWNSQK    
19 FLDRYFHNQEEFVR x   
20 HNYGVVESFTVQR x  x 
21 RAEVDTYCR x * x 
22 YFHNQEEFVR x  x 
23 DLLEQKR x x  
24 ELGRPDAEYWNSQK x x x 
25 ELGRPDAEYWNSQKDLLEQK    
26 GQVDNYCR x x x 
27 HFHNQEEYAR x x x 
28 RVHPQVTVYPAK    
29 VHPQVTVYPAK    
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6.4.1.3 SILAC labelling of KG-1 cells 
Since SILAC labelled IMDM media are not commonly used, bulk purchase of custom media 
would have been required, which was expensive. There are some published papers in which 
KG-1 cells have been grown in the RPMI media (Furley et al., 1986, Kojima et al., 1999, 
Gadeock et al., 2012).  Hence, KG-1 cells were adapted to RPMI media before initiating 
SILAC labelling. Adaptation was monitored by regular cell counting and there was no 
obvious difference noticed in the growth rate. HLA-DR levels were compared in KG-1 cells 
grown in both IMDM and RPMI media and there was no substantial difference in HLA-DR 
expression between the cells grown in the two media, as shown in Figure 6.7. 
 
 
Figure 6.7 Effect of RPMI1640 media on HLA-DR expression in KG-1 cells. HLA-DR levels were 
compared between the KG-1 cells cultured in IMDM and adapted to RPMI media. Cells were fixed 
and permeabilized, stained with L243-FITC antibody, and analysed by flow cytometry. (A) 
Fluorescence histograms after staining with L243-FITC. (B) Staining, quantified by flow cytometry, 
was reported as median fluorescence intensities (MFI; mean +- SD of triplicate analysis). The result 
shows no effect on the DR levels when the KG-1 cells were switched from IMDM to RPMI media.    
 
After successful adaptation to RPMI media, SILAC labelling of KG-1 cells was initiated. 
KG-1 cells were cultured in SILAC RPMI media containing all-[13C] - Arginine and Lysine 
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supplemented with 20% dialysed FBS.  Cells were cultured for a minimum of 5 doublings in 
order to allow complete labelling. During the course of the labelling, cell growth was 
monitored. SILAC labelled cells were growing more slowly than cells grown in unlabelled 
IMDM media, as shown in Figure 6.8. The slower growth kinetics can be attributed to the use 
of dialysed serum (MW < 10,000 kDa), which may be devoid of some growth factors.   
 
Figure 6.8 Growth Kinetics of KG-1 cells in SILAC labelled and IMDM unlabelled media.  KG-1 cells were 
grown all-[13C]-Arg/Lys media (SILAC RPMI media) containing dialysed (MW <10KDa) foetal bovine 
serum in order to label them. SILAC labelled cells grew more slowly than cells grown in unlabelled 
IMDM media. The dots in the graph represents count of cells on a particular day as if no cells had 
been discarded. The Y-axis is on a log scale. 
 
The HLA-DR levels of KG-1 cells cultured in SILAC labelled RPMI media and unlabelled 
IMDM media were assessed by flow cytometry on fixed and permeabilised cells using FITC 





















SILAC RPMI Unlabelled IMDM Expon. (SILAC RPMI) Expon. (Unlabelled IMDM)
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reduction in total HLA-DR levels by around 20-25% when compared with KG-1 cells 
cultured in unlabelled IMDM. This plus the slower growth rate may be due to the difference 
in growth factor supply between the two culture media. A t test, confirmed that the reduction 
in HLA-DR expression was statistically significant F (1, 1) = 484.83, p <0.001 (Appendix 
6.1). 
 
Figure 6.9 Reduction in total HLA-DR in SILAC labelled KG-1 cells. HLA-DR levels were compared 
between KG-1 cells grown in SILAC labelled RPMI media and unlabelled IMDM media by flow 
cytometry.  Briefly cells were fixed and permeabilised stained with L243-FITC or isotype control IgG2-
FITC or kept unstained (US) and analysed by flow cytometry.  The graph shows the median 
fluorescence intensity (MFI; mean +- SD of triplicate analysis). Cells grown in SILAC RPMI expressed 
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6.4.1.4 SILAC labelling of HTCs 
Unlike KG-1 cells, HTCs (EK and JBUSH) were normally cultured in RPMI media 
containing 10% FBS for regular cell culture. So their SILAC labelling was straightforward 
and cells maintained healthy growth in the SILAC media containing 10% dialysed FBS with 
no detectable difference in the growth rate. Cells were cultured for a minimum of 5 doublings 
in order to allow nearly-complete labelling.  
6.4.1.5 HLA-DR isolation and mass spectrometry 
SILAC labelled standards (KG-1 cells and HTCs) and unlabelled test samples (KG-1 cells 
treated with vitamin D and/or RA, or left untreated, depending on the experimental strategy) 
were subjected to detergent extraction. Labelled and unlabelled samples were mixed  
mixtures were immuno-precipitated using L243 antibody and resolved by SDS-PAGE.  The 
DR- bands were then excised and sent to the Cambridge Centre for Proteomics for further 
analysis by mass spectrometry. Figure 6.10 (A) is  a representative SDS-PAGE image 
showing DR- and DR- bands while (B) is the same gel following excision of  and  chain 
bands. 
 
Figure 6.10 Isolation of DR α and β molecules from KG-1 cells.  KG-1 cell extracts were immuno-
precipitated with in-house prepared L243 mAb and protein A-sepharose. Samples were resolved on 
12% acrylamide SDS-PAGE gels under non-reducing conditions and stained with Instant Blue. HLA-
DR-α and β chains are indicated (A). The samples S1 and S2 were the fully labelled and unlabelled 
samples, respectively. In contrast, S3 and S4 were 1:1 mixtures of labelled and unlabelled samples. 
(B) Shows the excision of HLA DR α and β, which were stored at -80C until further analysis. 
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At Cambridge Centre for Proteomics, the excised DR β bands were analysed using Q 
Exactive™ Hybrid Quadrupole-Orbitrap (Thermo Fisher). Figure 6.11 shows representative 
mass spectra for the unlabelled, labelled and mixture of peptides specific for the three alleles 
present in the KG-1 cells. 
  





Figure 6.11 Representative mass spectra. The figure shows representative mass spectra for peptides from each of the alleles for labelled, unlabelled and 1:1 
mix.  There was a 6 Dalton mass shift for the peptides derived from the cells cultured in the SILAC media when compared to the unlabelled samples. These 
spectra samples were provided by Mike Deery from Cambridge Centre for Proteomics under collaborative arrangements.   
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6.4.1.6 Method optimization 
For method optimization, the excised DR- bands were analysed at two different m/z 
resolutions, 17K and 70K, using Q Exactive™ Hybrid Quadrupole-Orbitrap at the Cambridge 
Centre for Proteomics. Data analysis was performed using the output from two different 
software packages: MaxQuant (MQ) (Cox and Mann, 2008) and Proteome Discover (PD) 
(Välikangas et al., 2017). Next, I investigated which of the resolution settings and software 
packages provided the most robust quantification of the proportion of labelled peptides in the 
mixed samples. These comparisons are shown in Figure 6.12. 
 
Figure 6.12 Comparison between 17K and 70K resolution and Proteome Discover and MaxQuant 
software.  For method development SILAC, labelled and unlabelled KG-1 cells were mixed 1:1 by cell 
number. Protein extraction was carried out and DR β was isolated by IP with L243. The excised DR β 
band, after tryptic digestion, was analysed at two different m/z resolutions (17K and 70K) using Q 
Exactive™ Hybrid Quadrupole-Orbitrap. Post run, data analysis was performed using two different 
software packages, MaxQuant (MQ) and Proteome Discover (PD). In this figure, the X-axis represents 
the individual peptides obtained through LCMS post tryptic digest (numbered as in Table 6.1).  Each 
dot represents the percentage of labelled peptides measured at the indicated m/z resolution, and 
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There was a difference in the number of peptides identified between the two m/z resolution 
settings. The higher-resolution (70K) analysis was able to identify  28 peptides, while at 
lower-resolution (17K) analysis, 20-22 peptides were identified. Both software packages 
were able to identify more peptides at higher resolution. But as seen from the graph the 
variability both between peptides and between samples analysed by PD was less than that for 
MQ. So, all the further samples were run at 70K m/z resolution and were analysed by PD. 
The 1:1 mixture (by cell count) between heavy and light samples failed to yield a % heavy 
ratio of 50%, as expected theoretically. This may be because of inaccuracy in the 
haemocytometer cell counts, differences in the protein content per cell in light and heavy 
media, or the lower HLA-DR expression in SILAC RPMI. 
 
In order to assess the completion of labelling of the SILAC standards, % Heavy values were 
determined for all the SILAC labelled standards (KG-1, EK and JBUSH), using Proteome 
Discover software, as shown in Figure 6.13. The analysis showed that all the SILAC 
standards were labelled more than 99%.  
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Figure 6.13 SILAC standards were labelled to nearby 100%. Bar graph of % heavy calculated based on 
the output of Proteome Discover after samples were run at 70K resolution in mass spectrometry. 
Each bar represents mean +- SD across all informative peptides observed following tryptic digestion 
by mass spectrometry. There were at least two SILAC standards for each cell line (KG-1 cells had 
four).   
 
6.4.2 Effect of switching media in KG-1 cells. 
 
In order to determine the effect of switching media on the DRB1 alleles, SILAC labelled KG-
1 cells were mixed with unlabelled KG-1 cells grown in either RPMI or IMDM in 1:1 ratio 
by cell counts. Total protein extraction was performed using lysis buffer and were 
immunoprecipitated with monoclonal L-243 antibody and resolved by SDS-PAGE. DR β was 
excised and after tryptic digestion was run at 70K on the Q Exactive™ Hybrid Quadrupole-
Orbitrap. Data analysis was performed using Proteome Discover software . Ideally, both 
culture media produce a similar co-dominant expression of the HLA-DR variants. The results 
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standard, whereas Figure 6.14 (B) represents KG-1 cells cultured in IMDM media mixed 
with SILAC standard.  
 
 
Figure 6.14 SILAC analytics in KG-1 cells. KG-1 cells were cultured in unlabelled RPMI (A) or IMDM (B) 
media with 20% FBS; extracts were mixed 1:1 (by cell count) with extracts from > 99% labelled KG-1 
cells grown in 13C-Arg/Lys RPMI with 20% dialysed FBS. DRβ was isolated by IP and SDS-PAGE, 
trypsinised, and heavy and light peptide mass clusters were quantified by mass spectrometry. Scatter 
plots show the mean % light values +/- SD (n=4) for individual DRβ peptides; the column graphs show 
the means +- SD for groups of peptides from the indicated individual alleles. The colour coding is as 
per Figure 6.7 and Table 6.1 
 
As observed in Figure 6.14 (A), the SILAC ratios for all DR β chain peptides was the same 
when the SILAC labelled KG-1 cells were mixed in 1:1 ratio (by cell count) with unlabelled 
KG-1 cells adapted to RPMI media. All the peptides gave indistinguishable SILAC % light 
values. Surprisingly when KG-1 cells were grown in IMDM media, co-dominant expression 
was also altered.  As observed in Figure 6.14 (B), there was a difference in the SILAC ratios 
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between DR-β1 and DR-β3 peptides when the SILAC labelled KG-1 cells were mixed in 1:1 
ratio with unlabelled KG-1 cells cultured in IMDM media. The % light values differed 
systematically between DR-β1 and DR-β3 derived peptides, showing that the expression of 
the DRB3 gene product was selectively altered in IMDM. Two-way ANOVA revealed that 
there was a statistically significant difference in the HLA-DR expression between the two 
media conditions F (1, 18) = 243.203, p <0.001 (Appendix 6.2).  The Tukey’s post-hoc test 
revealed that allele DRB3 is significantly different from both the DRB1 alleles in the IMDM 
condition (Appendix 6.2). Moreover, SILAC % light values for DRB1/DRB3 shared peptides 
were much closer to those for DRB1 than for DRB3 specific peptides. This suggests that, as 
expected, DRB1 gene products comprise the great majority of the total DR-β chain, though 
with only two B1/B3 shared peptides, quantification of this ratio was not reliable. 
Nevertheless, these results highlight the feasibility of using this SILAC approach (i.e., using 
autologous standards) to quantify subtle changes in DR beta chain composition depending on 
the nutrient status of the cells. 
Another observation from these experiments was that the measured SILAC % light values 
were higher than the 50% expected value, similar to the low % H values in Figure 6.12. One 
contributing factor may be the reduction in total HLA-DR expression when cells were 
cultured in the SILAC labelled media (Figure 6.10), although this alone does not fully explain 
the increase in the % light ratio. There may also be a small contribution from the residual 
unlabelled material in the SILAC standard as a reason of how they were generated. Another 
possible explanation could be the technical issue of creating 1:1 mix due to inaccurate 
haemocytometer counts. As noticed earlier in Figure 6.8 and 6.9 there was a difference in the 
growth rate which may be associated with a difference in the total protein content per cell 
resulting in more % light DR molecules in the mix. In this experiment, the 1:1 mixture was 
based only on cell counts, but it seemed better to use protein concentration when normalising 
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the mixture, rather than cell counts. Hence, all the subsequent mixing was performed based 
on protein concentration. 
 
6.4.3 Allele independent effect of Vitamin D and RA in KG-1 cells. 
 
In order to determine the effect of vitamin D and/or RA on the DRβ chain composition, KG-1 
cells were treated with vitamin D, RA, or both for up to 72 hours. As a vehicle control, 
DMSO matched to the total volume of treatment was used. After 72 hours of treatment, 
protein extraction was carried out from the KG-1 cells for each of the four conditions (i.e. 
DMSO, Vitamin D, RA, and RA + Vitamin D). SILAC labelled KG-1 cells were used as a 
labelled standard. Protein were extracted from the labelled standard, which was mixed in 1:1 
ratio with protein extracted from unlabelled KG-1 cells under the four different conditions. In 
this experiment, normalisation (1:1 mixture) was based on protein content, which was 
determined by BCA assay. The 1:1 mixed protein extracts were then immuno-precipitated 
using L243 antibody and resolved by 12% non-reducing SDS PAGE. DR-β bands were then 
excised and sent to the Cambridge Centre for Proteomics for tryptic digestion and mass 
spectrometry analysis. SILAC ratios were calculated as % light with the help of Proteome 
Discover software . Combined treatment with vitamin D and RA synergistically lowered 
HLA-DR expression, as shown by both flow cytometry and SILAC in Figure 6.15 (A) (also 
in Chapter 5, section 5.2.2).  Since the protein content was normalised, the overall SILAC 
ratios were closer to 50% in vehicle controls, and there was little change on treatment with 
either vitamin D or RA alone.  
 
   
 167 
 
Figure 6.15 Allele independent effect of Vitamin D and RA on KG-1 cells. (A) shows the change in total 
HLA DR levels in KG-1 cells treated with Vitamin D and /or RA for up to 3 days, quantified by flow 
cytometry. Each bar represents the mean fold change in MFI, i.e. treatment divided by DMSO control 
(n=3). (B) KG-1 cultures (n=4) were treated with Vit-D and or RA for 72 hours in light media. Extracts 
were mixed 1:1 (by protein content) with SILAC labelled KG-1cells. Mean % light ratios of the allele-
specific DR β peptide sets were quantified from the SILAC ratios obtained after LC-MS. The result 
indicates that the reduction of the total DR levels is irrespective of the DRB1 allele. The % light ratio 
has been calculated in this instance to emphasise the reduction in the DR levels. The colour coding is 
as per the Figure 6.6 and Table 6.1. 
 
At baseline, as before (Figure 6.15 (B)), DRB3 specific peptides had a slightly higher % light 
value than that of the DRB1 derived peptides (Appendix 6.3). There was no systematic 
difference observed between the DRB1 allele specific peptides. The representation of 
DRB1*11 vs. DRB1*14 gene products was unaffected upon any of the combination 
treatments. In contrast, RA slightly diminished the contribution of DRB3 gene to total HLA-
DR, but this was reversed when the cells were treated with both RA and vitamin D. This 
indicates that the relative expression of the DRB3  gene variants may be differentially 
affected by vitamin D and RA.  Two-way ANOVA revealed that there is a statistically 
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significant effect of treatment, F (3, 36) = 873.473, p <0.001 (Appendix 6.4).  Turkey’s post-
hoc test revealed that there is a reduction in the expression of HLA-DR on combined 
treatment of vitamin D and RA. Moreover there was statistically significant interaction 
between the alleles and culture conditions, F (6, 36) = 41.744, p <0.001 (Appendix 6.4). 
Tukey’s post-hoc test revealed that the DRB3 values were significantly different from both 
the DRB1 alleles. The estimated marginal means plot showed that with RA, there was a 
selective reduction in the expression of DRB3 allele (Appendix 6.4). The effect of vitamin D 
and RA co-treatment on HLA-DR expression was more pronounced when measured by 
SILAC than in the flow cytometry experiment. 
6.4.4 Quantification of HLA-DRB1 allelic contributions in KG-1 cells using mono-allelic SILAC 
standards 
 
In order to quantify the HLA-DRB1 alleles in KG-1 cells, EK and JBUSH cells were used as 
SILAC labelled standards. EK and JBUSH cells are homozygous for the DRB1*14 and 
DRB1*11 alleles respectively, which are expressed in KG-1 cells.  Both EK and JBUSH 
were cultured in in all-[13C] - Arginine/ Lysine SILAC media for labelling. KG-1 cells were 
treated for 72 hours with 1 µM RA and /or 10 nm vitamin D. As a vehicle control, DMSO 
matched to the total volume of treatment was used. After 72 hours of treatment, protein 
extraction was carried out from the KG-1 cells for each of the four conditions (i.e. DMSO, 
Vitamin D, RA and RA + Vitamin D), and extracts were mixed in a 1:1 ratio (based on 
protein content) with the protein extracts from the SILAC labelled cells (JBUSH or EK). The 
1:1 mixed protein extracts were then immuno-precipitated using L243 antibody and resolved 
by 12% non-reducing SDS PAGE. DR β bands were excised and sent to Cambridge Centre 
for Proteomics for tryptic digestion and mass spectrometry analysis. SILAC ratios were 
calculated as % light with the help of Proteome Discover software.  Total HLA-DR 
expression in the two HTCs was not well matched to KG-1 cells, and therefore SILAC % 
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light values for DRB1 shared peptides were either much less than 50 % for the JBUSH/KG-1  
and much more than 50 % EK/KG-1 mixtures, respectively. Figures 6.16 and 6.17 show the 
result representing % light values of EK and JBUSH cells respectively.   
 
 
Figure 6.16 % light values of the alleles in KG-1 vs EK cells.  KG-1 cultures (n=4) were treated with Vit-D 
and or RA for 72 hours in light media. Extracts were mixed 1:1 (by protein content) with SILAC 
labelled EK cells. Mean % light ratios of the allele-specific DR β peptide sets were quantified from the 
SILAC ratios obtained after LC-MS. The column graphs show the means +- SD for groups of peptides 
from the indicated individual alleles. The colour coding is as per Figure 6.6 and Table 6.1. 
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Figure 6.17 % light values of the alleles in KG-1 vs JBUSH cells.  KG-1 cultures (n=4) were treated with 
Vit-D and or RA for 72 hours in light media. Extracts were mixed 1:1 (by protein content) with SILAC 
labelled JBUSH cells. Mean % light ratios of the allele-specific DR β peptide sets were quantified from 
the SILAC ratios obtained after LC-MS. The column graphs show the means +- SD for groups of 
peptides from the indicated individual alleles. The colour coding is as per the Figure 6.6 and Table 
6.1. 
 
The low % light values indicated that the HLA-DR amounts were mismatched between KG-1 
and HTCs standard cells, after matching for protein contents. On this basis, the HLA-DR 
level was highest in JBUSH cells, followed by KG-1 with the lowest levels in EK cells.  
Quantification of allelic composition was attempted, based on the difference in the SILAC % 
light values for DRB1 shared and DRB1 specific peptide, as described in Section 6.2. 
Because of  difficulties in error propagation with this formula, all permutations of values for 
shared and allele specific peptides were generated to estimatethe variance in the values of ‘a’ 
(the % contribution to the total DRβ pool from the allele which is shared between 
heterozygous sample and SILAC standards). This is shown in Figure 6.18 (A) for the 
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DRB1*14 allele and in (B) for the DRB1*11 allele. The data are represented as the mean of 
the quadruplicate analysis. 
 
Figure 6.18 Estimation of the DRB1allelic mix in KG-1 cells.  The table shows the percentage of the 
allele present in the KG-1 cells, calculated based on equation (4) derived in section 6.2. The figure 
represents data for the DRB1*14 allele (A) and DRB1*11 (B) allele. The peptide number is based on 
Table 6.1. The results shown are means of the quadruplicate analysis.  In this figure * indicates 
labelled cells, % values in the shaded region are the % light values obtained from the SILAC 
experiment shown in Figure 6.16 (for A) and  Figure 6.17 (for B) 
 
As seen from the result, the difference in the SILAC ratio between shared and allele specific 
peptides were  small whereas the error on the resulting estimate of the allelic mix was large.  
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For both the alleles, this approach yielded best estimates of allelic contributions of more than 
50%, which is not plausible because the allelic contributions should add up to 100%. It was 
concluded that the approach needed further optimization to yield reliable, internally 
consistent estimates of allelic composition.  
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6.5 Discussion  
 
The aim of this chapter was to develop methods for tracking, in heterozygote APCs, any 
potential difference in the responses of allelic and gene variant of HLA-DR to environmental 
agents, such as vitamin D or RA. The results suggest that HLA-DR β-chain targeted SILAC 
can reliably quantify small effects of media composition or other environmental agents, such 
as vitamin D and RA, on the allelic composition of HLA-DR.  In addition, the findings will 
also help to improve the design of future experiments with primary antigen presenting cells. 
6.5.1 SILAC analytics with KG-1 cells 
 
Experiments with KG-1 cells established proof of feasibility of quantifying changes in allelic 
composition based on the SILAC approach. Pilot studies also showed that there is good 
analytical precision of SILAC values (% heavy or % light) between samples and between sets 
of peptides specific for the same allele. They also helped in choosing the analytical 
parameters; specifically, 70k resolution was better than 17k resolution, and Proteome 
Discover, an analysis software package, yielded more precise estimates of SILAC ratios than 
MaxQuant.Another practical conclusion from the pilot studies was that mixing of SILAC 
standards with unlabelled samples is best done based on protein content rather than cell 
equivalents. 
 
6.5.2 Relative quantification of the effects of vitamin D and/or RA on HLA-DR alleles in KG-1 
cells  
 
SILAC labelled KG-1 cells were mixed with KG-1 cells treated with vitamin D and/ or RA, 
in order to quantify changes from baseline in the relative expression of allelic or gene 
variants. 
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As observed by flow cytometry in Chapter 5, and mass spectrometry combined treatment 
with vitamin D and RA synergistically lowered HLA-DR expression in KG-1. At baseline, 
DRB3 specific peptides had a slightly higher % light value than that of DRB1 derived 
peptides. There was no systematic difference observed between DRB1 allele specific 
peptides. Thus, in this cell line, neither vitamin D nor RA had any substantial effect on the 
relative contributions of DRB1*11 and *14. However, RA seemed to affect the relative 
representation of the minor gene variant, DRB3, but this was reversed when the cells were 
treated with both RA and vitamin D. This observation suggests that the relative expression of 
DRB3  gene variants may be differentially affected by vitamin D and or RA. 
The magnitude of the vitamin D effects on the DRB1 vs. DRB3 contribution in this instance 
was small and would be unlikely to yield biologically meaningful differences in antigen 
presentation or tolerance induction. However, larger effects might be expected, based on 
results in Chapter 5 and previously published literature of PGF cells homozygous for the 
HLA-DR1*15, a major MS risk allele. The PGF cells expresses an alternate β-chain gene, 
DRB5, at a higher level, whereas the DRB1*15 gene product is in the minority, at the mRNA 
level (Andersson et al., Horton et al., 2008). This remains an important focus for future work, 
both in primary cells and in cell lines.  
6.5.3 SILAC based allelic composition quantification in KG-1 cells 
 
In principle, mixing of heterozygous APCs with a mono-allelic standard should enable 
quantification of the contributions of the co-expressed DRB1 alleles to the total DR β1 chain 
pool. The contributions of the two alleles should add up to 100%. However, attempts to 
measure this for KG-1 cells using DRB1 haplotype matched HTCs (JBUSH and EK) have so 
far proved unsuccessful: the estimated allelic contributions obtained from mixing 
experiments with SILAC-labelled HTCs expressing either DRB1*11 (JBUSH) or DRB1*14 
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(EK) were both well above 50% and thus mutually inconsistent, as well as being subject to 
large errors. The actual magnitude of SILAC ratios is not influenced by the mixing ratio but 
also by the amount of HLA-DR present in the standard and the unknown. Therefore, model 
calculations were performed (based on equation 4 in section 6.2) to explore how the 
measured % light difference between the shared and the allele specific peptides is affected by 
the contribution of the allele that is shared with the HTC standard, as well as by the relative 
abundance of total DR in the homozygous standard and the heterozygous unknown sample. 
This is shown in Figure 6.19.   
 
Figure 6.19 Model calculations to estimate optimum mixing ratio. The graph shows how the measured 
% light difference between shared and allele specific peptide depends on the contribution of the allele 
that is shared with the HTC standard at different DR abundance ratios between known and standard. 
This model is ideal when any heterozygous unlabelled unknown cells, such as KG-1, are mixed with 
labelled HTCs mono-allelic for one of the allele from heterozygous. In the above figure, unk and het 
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The model calculations in Figure 6.21 show how the measured output (i.e. the gap  between 
% light values of shared and allele specific peptides) varies as the function of contribution of 
the matched allele at different mixing ratios of HLA-DR protein from SILAC standards in 
unknown. It turns out that the mix between standard and unknown is optimal at around 1:1 
molar ratio, or with the standard in slight excess. This is because the dose response observed, 
with  such mixing ratios is  nearly linear over the entire range of possible allelic 
contributions. When the unknown is in large excess, it turns out that the relationship is non-
linear, so that the dose response is very small for greater than 50% of allelic contribution. 
Conversely, when the SILAC labelled standard is in large excess, there is no % allele 
contribution that creates a large difference. 
In the actual experiments in which KG-1 cells were mixed with SILAC labelled HTCs, in 1:1 
ratio based on total protein, HLA-DR was in large excess in KG-1 cells when mixed with EK 
(Figure 6.16). In contrast, the SILAC labelled standard was in large excess in the mix 
between KG-1 cells and SILAC labelled JBUSH (Figure 6.17).  The predicted responsiveness 
of the experimental measurements to the allelic contribution at HLA-DR abundance ratio 
obtained when KG-1 cells was mixed with SILAC labelled EK or JBUSH cells is shown in 
Figure 6.20. 
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Figure 6.20 Predicted contribution of DRB1 alleles in KG-1 cells based on model calculations.. Due to 
unequal HLA-DR expression there was an unfavourable mixing ratio between the KG-1 cells and 
HTCs which led to  a nonlinear relationship, leading to a poor constraint in determining the allelic 
contribution.  
Since the HLA-DR expression varied between the three cell lines, the DR β-chain SILAC 
ratios observed in both experiments were far from 1:1, the optimal ratio for quantifying the 
allelic contributions based on mathematical modelling.  Instead, when the unlabelled KG-1 
extracts were mixed at 1:1 total protein ratio, with SILAC labelled JBUSH extracts, DR 
molecules derived from JBUSH were in large excess. On the other hand, when the unlabelled 
KG-1 cells were mixed at 1:1 total protein ratio, with SILAC labelled EK cells, the DR 
molecules derived from unlabelled KG-1 cells were in large excess. Under either condition, 
there were small differences in SILAC ratios between DRB1-shared and allele-specific 
peptides, which provided a poor constraint on the allelic composition. Lastly, there was also a 
small amount of residual un-labelled material (< 5%) in the SILAC standards, which could 
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In order to obtain reliable estimates of the DRB1 allelic contributions, it is apparently critical 
to get the mixing ratio correct. The mixing ratio for SILAC standards and the unknown 
samples must be individualised, so that the extracts contain approximately equal amounts of 
total HLA-DR from the labelled HTCs and the unlabelled unknown sample. In this particular 
instance, the protein content of SILAC labelled EK would have to be increased to give an 
approximate ratio of 1:1 for HLA-DR. In contrast, the protein content of KG-1 cells would 
need to be increased in mixtures with the JBUSH cells to get the optimal mixing ratio. Time 
constraints did not permit further optimisation of mixing ratios prior to thesis submission, but 
such experiments are planned after submission. 
The results from this chapter suggest that HLA-DR β-chain targeted SILAC can reliably 
quantify small effects of media composition or other environmental agents, such as vitamin D 
and RA, on the allelic composition of HLA-DR. To our knowledge, this is the first study 
which attempts to determine the effect of vitamin D and RA on the allelic composition in the 
heterozygous cells using SILAC approach. However, in this instance, the allelic contribution 
could not be determined because of differences in the total HLA-DR expression between the 
cell lines. Model calculations performed in this study also establish the foundation for 
performing such studies with precision in order to obtain reliable estimate of the allelic 
contributions of maternal and paternal DRB1 alleles in any particular cell population.  
These studies prompt the re-design of experimental strategies for exploring vitamin D effects 
on DR β chain composition in primary APCs, as follows:  
One option is, following relative quantification (as explained in section 6.1.4.2), to focus on 
changes from baseline of DR β chain composition caused by vitamin D, RA or both. This 
approach requires autologous SILAC standards from each donor. These could be obtained by 
EBV transformation of primary B cells from each donor, but this is subject to regulatory 
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constraints, since this university does not have a Human Tissue Act licence. Alternatively, 
there may be sufficient protein turnover and new synthesis to allow acceptable SILAC 
standards to be produced from short-term primary cell cultures, e.g., from monocytes, 
immature DCs, or LPS/IL4-stimulated B-cell blasts. Either way, a disadvantage is that some 
of the primary samples would be sacrificed for preparation of SILAC standards, and that the 
% contributions of each DRB1 allele to the total β chain pool would not be quantifiable by 
this approach. 
A second option is, following the quantification strategy as explained in section 6.1.4.3, to 
use DRB1-homozygous typing cells as heterologous standards. These can be prepared in 
advance, with a small number of cell lines able to cover one or both alleles in most donors, if 
the study is restricted to a defined ethnicity with a limited number of prevalent alleles (as 
explained in chapter 5). However, in order to extract reliable estimates of DRB1 allelic 
contributions, the results (Figure 6.16, 6.17, and 6.19) show that the mixing ratio for SILAC 
standards and primary APC samples must be individualised, so that the extracts contain 
approximately equal amounts of total DR from the HTC and the primary APC sample. Based 
on the overall experience from these studies, this could be based on flow cytometric analysis 
of HLA-DR levels from primary APCs and standards, as well as on exploratory titrations of 
standard vs unknown, which complicates the logistics of studies with human subjects using 
this approach.  
Thus, this study is an excellent starting point through which much has been learnt about the 
further steps required, and the results from this chapter and Chapter 5 suggest that the goal 
remains achievable.  
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Chapter 7: General conclusions and future perspectives   
 
The overall objective of this PhD thesis was to study  mechanisms by which the expression of 
tissue antigens, specifically,  HLA-DR MHC II proteins, are regulated. This study identified 
Cathepsin D (Cat D) as a lysosomal enzyme playing a vital role in the degradation of HLA-
DR molecules in the myeloid cell line, KG-1. This study also provided evidence that empty 
HLA-DR molecules are especially susceptible to degradation by Cat D. Moreover, this study 
showed that vitamin D interacts with retinoic acid (RA) in regulating the expression of HLA-
DR in B lymphoblastoid cell lines representing some common DRB1 alleles in White British, 
Irish or Caucasian individuals but not others. Lastly, methods were developed to quantify 
changes in HLA-DR allelic composition in response to various interventions, in DRB1 
heterozygous cells, using stable isotopes and mass spectrometry. This provides an approach 
for exploring the consequences of MHC gene/ environment interactions in auto-immune 
diseases, including multiple sclerosis (MS).  
In this final chapter, the limitations of the findings presented herein will be placed in the 
context of the present literature, and potential avenues for further studies will be discussed.   
 
7.1 Characterisation of lysosomal proteases involved in HLA-DR protein breakdown 
 
The results in Chapter 3 showed, for the first time, that the protease, Cat D, plays a non-
redundant role in the degradation of HLA-DR molecules. The identification was based on 
pharmacologically inhibiting Cat D KG-1 cells or using targeted genetic knockdown and 
observing the accumulation of HLA-DR molecules. Based on the limited data available, there 
were no examples of APCs with a high HLA-DR turnover but no pepstatin A effect or Cat D 
expression. This suggests that the mechanism is not limited to the KG-1 cell culture system. 
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Another important conclusion from Chapter 3 was that KG-1 cells by some means adapt to 
the lack of Cat D. One possibility is that the cells have some way of sensing HLA-DR levels 
and  down-regulate the synthesis of new HLA-DR molecules through the master regulator of 
MHC II transcription, CIITA (LeibundGut-Landmann et al., 2004). Another possibility is that 
Cat D can be functionally replaced. It is plausible that cells recognise lysosomal overload and 
there is some compensating change in the composition of lysosomal enzymes. Another 
enzyme that otherwise makes a minor contribution to HLA-DR degradation could take over 
to restore a steady state. Both explanations are compatible with the data. However, the 
adaptation works, this is worth further study, because not much is known about the 
mechanisms by which lysosomal composition responds to demand and there is very little 
understanding on feedback mechanisms regulating MHC II expression. 
Data in Chapter 4 support a model whereby empty HLA-DR molecules are selectively 
degraded by Cat D. The HLA-DR molecules that accumulated when Cat D was inhibited 
were SDS unstable and were neither associated with invariant chain (li) nor conjugated to 
ubiquitin. Their biochemical properties are consistent with empty molecules, and this is 
structurally plausible, based on the results from the initial cleavage site identified in vitro 
(Appendix 7.1). Cleavage occurs at αPhe54 in the peptide binding groove which is “locked” 
in by hydrogen bonds when peptides binds to the HLA-DR complex (Jardetzky et al., 1990), 
while during maturation, the CLIP region of Iistabilizes this region (Cresswell, 1996). 
Moreover, the trimerization domain of intact Iisterically masks the same region (Busch et al., 
1996, Busch and Mellins, 1996). HLA-DM also binds selectively to empty HLA-DR 
molecules, but in the process, it changes the conformation of that binding region and makes it 
sterically inaccessible (Pos et al., 2012). The initial cleavage site at αPhe54 is 
conformationally flexible in mutant DR molecules that undergo rapid peptide exchange 
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without DM (Painter et al., 2011). A working model for Cat D cleavage of empty DR was 
proposed in Chapter 4 (Figure 4.7). 
Together, these findings suggest that Cat D mediates quality control by selectively degrading 
HLA-DR molecules that lack stably bound peptides and that are not associated with Iichain 
or HLA-DM. This is an important insight into normal immune function, but it also has 
implications for autoimmunity. Importantly, this mechanism for lysosomal quality control 
acts to limit the availability of empty molecules that could aberrantly bind peptides outside of 
the conventional peptide-loading pathway. Previous work has failed to provide evidence that 
fast turnover is a factor in MHC II-linked risk of autoimmunity (Busch et al., 2005).  In fact, 
it seems that the selective destruction of empty molecules could limit the risk of triggering 
autoimmunity by ectopic antigen presentation. 
 
7.2 Effects of vitamin D and RA on the co-dominant expression of HLA-DR allelic and 
gene variants  
 
Chapter 5 showed that HLA-DR levels in cell lines respond in several distinct ways to the 
combined or separate treatment with vitamin D and RA. To our knowledge this is the first 
examination of this interaction. In HTCs, the effects of vitamin D and RA on the expression 
of total HLA-DR (i.e. regardless of copy number variation) varied between the cell lines and 
over time and competed with each other. In contrast, in the myeloid cell line, KG-1, 
combined treatment with vitamin D and RA synergistically lowered HLA-DR expression.  
The present work reproduced previously observed differences between HTCs in the effects of 
vitamin D on expression of HLA-DR protein, which another group has attributed to VDRE-
mediated upregulation of DRB1*15:01  but not of other DRB1 alleles (Ramagopalan et al., 
2009). This study extended these findings to other HTCs homozygous for common DRB1 
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alleles found in White British/ Irish population. Vitamin D only increased HLA-DR 
expression in two HTCs, PGF and WDV, homozygous for DRB1*15:01 and DRB1*13:01, 
respectively. In other HTCs, no such induction effect by vitamin D was detected. This 
suggests that there is allele specificity in regard to how vitamin D affects antigen 
presentation.  When some of the HTCs were tested for vitamin D responsiveness (by CD38 
induction), all were vitamin D responsive ((Busch 2018, personal communication, 2 
February). This reflects allelic differences in the VDR mediated transactivation of some DR 
alleles and not others, rather than some differences in cellular background that enables cells 
to respond to vitamin D.  
Conversely, observations also suggested that DRB1*07 allele, possibly by same criterion, is 
inducible by RA in MANN cells. It opens an interesting aspect in future to find whether there 
is retinoic acid response element (RARE) present in that allele. Moreover, complexity of 
VDR-RXR or RAR-RXR mediated regulation is highlighted by the data in this study. The 
combined treatment of HTCs with vitamin D and RA reversed any effects of the individual 
treatments, suggesting that there is mutual competition between the two pathways, such that 
activation of one pathway stops the other pathway from up-regulating HLA-DR expression in 
these cells. The common ability for RXR to bind to both VDR and RAR is one possible 
explanation of cross talk between vitamin D and RA signalling pathway (Tavera-Mendoza et 
al., 2006).  Competition between the nuclear receptors may not be the only possible 
mechanism. This study examined the phenotypic change only and not the genetic mechanism, 
which would be an interesting future aspect. 
Unlike EBV transformed B cell lines (HTCs), in the myeloid KG-1 cells, neither vitamin D 
nor RA alone had any effect on the expression of HLA-DR, but combined treatment reduced 
the expression of HLA-DR. Vitamin D by itself has shown to reduce the MHC II levels in 
primary APCs by reprograming differentiation (Bscheider and Butcher, 2016). In HTCs (EK 
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and JBUSH), having the same alleles as KG-1, there was no effect of vitamin D and no 
reproducible effect of RA on the expression of HLA-DR, which suggests that the effect is 
dependent on the cell type and not only on the type of allele.  
Any one individual human can produce between two and four different variants of DR 
molecules, due to the genetic variation. These variants are difficult to distinguish in the 
experiments normally used to quantify the amounts of DR molecules, but this is important 
because DR variants may respond differently to vitamin D. Therefore, a new analytical 
approach was developed that allowed us to detect such differences.  
Using this approach, the effect of vitamin D and RA on the co-dominant expression of HLA-
DR allelic and gene variants were quantified in KG-1 cells, which express DRB1*11 and 
DRB1*14 alleles and the and DRB3*02 gene variant (Ning et al., 2011) (also Chapters 2,5 
and 6 of this thesis). In this cell line, neither vitamin D nor RA had any substantial effect on 
the relative contributions of DRB1*11 and *14. However, RA seemed to affect the relative 
representation of the minor gene variant, DRB3, and this was reversed when the cells were 
treated with both RA and vitamin D.  This observation suggests that vitamin D and or RA 
may differentially affect the relative expression of DRB3 gene variants. The combination of 
vitamin D and RA did not detectably change the allelic mix for DRB1 but there is a 
possibility that the behaviour of gene variants is not perfectly synchronised with the 
behaviour of DRB1 gene products. This could extend to the DRB1*15 haplotype, where 
DRB1 is a less expressed molecule (Horton et al., 2008). It could be that total HLA-DR 
measurement underestimates the extent to which DRB1*15 changes its expression. This 
remains an important focus for future work in the PGF cell line.  
In addition, JBUSH and EK, two HTCs haplotype matched for the DRB1*11 and DRB1*14 
alleles, respectively, were used as internal SILAC standards to estimate DRB1 allelic 
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contributions to the total DR pool. This experiment was not able to quantify the DRB1 allelic 
contribution, because there were only small differences in SILAC ratios between DRB1-
shared and allele-specific peptides, which provided a poor constraint on the allelic 
composition. These studies were successful in developing a novel stable isotope approach to 
quantify the effect of micronutrients on the HLA-DR molecules.  
Vitamin D in general seems to diminish the total HLA-DR expression in dendritic cells 
(Bscheider and Butcher, 2016), and in KG-1 cells (Chapter 5), whereas in HTCs with a 
VDRE in the promoter of HLA-DRB1, vitamin D is able to increase the expression of HLA-
DR, as shown in Chapter 5 and also by Ramagopalan et al (2009). Thus, it remains an 
important objective to quantify the effects of vitamin D and RA on DR allelic variants in 
primary antigen presenting cells.  
The work here developed a novel approach to investigate how environmental factors such as 
vitamin D and RA effect the allelic composition of the HLA-DR molecules in heterozygous 
cells. This approach can be extended to studies of other autoimmune diseases, in which MHC 
polymorphism plays an important role along with environmental factors, including those 
associated with MHC I alleles. This study provides evidence that allele dependent effects of 
vitamin D or RA on HLA-DR expression could influence MHC associations with auto 
immunity. Lastly, vitamin D and RA could also influence other aspects of MHC II antigen 
presentation by influencing other aspects of MHC protein maturation, peptide loading, 
trafficking and degradation. Future studies, using the tools developed and applied in this 
thesis, can explore these possibilities. It will be also interesting to assess whether there are 
allelic differences in the turnover of the HLA-DR molecules.   
This study will help MS researchers to understand the mechanisms that link MHC II 
molecules to the disease process, and to understand how environmental factors, such as 
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vitamin D, influence disease risk. The methods that will be applied here to MS-related tissue 
antigens will have wider applications in understanding how other genetic and environmental 
factors determine outcomes in MS and other autoimmune diseases. Thus, the findings of this 
project may ultimately contribute to better prevention and/or treatment of MS. 
 
  




Appendix 2.1 L243 antibody activity assay   
L243 monoclonal antibody was produced from the hybridoma cells by affinity 
chromatography as described in section 2.2.1.5. Before the purification, the presence of 
active L243 mAb was detected by competitive inhibition of HLA-DR using flow cytometry. 
Fixed and permeabilized KG-1 cells were incubated with the supernatant from the hybridoma 
producing L243mAb prior to incubation with L243-FITC, creating a competition between 
both antibodies for the binding site (i.e. DR molecules) on KG-1 cells. The general staining 
protocol described in section 2.2.3.1, except that volume of primary antibody was reduced to 
2.5 µl per test. Thus as shown in Figure 2.1, the low median fluorescence intensity (MFI) of 
samples containing L243 supernatant indicated that L243 present in the supernatant binds to 
the DR and thus inhibits the binding of L243-FITC. The decrease in the MFI values provides 
a clear indication for the presence of the L243 Ab in the supernatant 
 
Figure Method for detecting active L243 mAb in hybridoma supernatants by competition for L243-FITC binding to HLA-
DR+ cells: KG-1 cells were incubated with the supernatant containing L243, released from the hybridoma cells, prior to 
incubation with L243-FITC and analysis by flow cytometry. (A) Shows the overlay of the representative FACS plots. (B) 
Staining was quantified by flow cytometry and each bar represents the median fluorescence intensities.  (MFI; mean +- S.D. 
of triplicate analysis). 
 
Thus, this result showed the presence of active L243 mAb in the supernatant of the 
hybridoma cells, which was then purified by affinity chromatography. Purified antibody was 
stored at -20 C in aliquots at concentration of 1mg/ml for future use. 
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 Value Label N 




3 PepA 9 
Hour 24 24 hours 9 
48 48 hours 9 



















Tests of Between-Subjects Effects 
Dependent Variable:   MFI   
Source 
Type III Sum of 










































   
a. R Squared = .954 (Adjusted R Squared = .933) 
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vehicle control 9 313593.4822  
untreated 9 321440.3456  
PepA 9  465868.7700 
Sig.  .712 1.000 
Means for groups in homogeneous subsets are displayed. 
 Based on observed means. 
 The error term is Mean Square(Error) = 440191075.899. 
a. Uses Harmonic Mean Sample Size = 9.000. 





Dependent Variable:   MFI   
Tukey HSD   
(I) Type (J) Type 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
untreated vehicle control 7846.8633 9890.41147 .712 -17395.0810 33088.8077 
PepA -144428.4244* 9890.41147 .000 -169670.3688 -119186.4801 
vehicle control untreated -7846.8633 9890.41147 .712 -33088.8077 17395.0810 
PepA -152275.2878* 9890.41147 .000 -177517.2321 -127033.3435 
PepA untreated 144428.4244* 9890.41147 .000 119186.4801 169670.3688 
vehicle control 152275.2878* 9890.41147 .000 127033.3435 177517.2321 
Based on observed means. 
 The error term is Mean Square(Error) = 440191075.899. 
*. The mean difference is significant at the 0.05 level. 
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Appendix 3.2 One sample t-test of % increase in HLA-DR levels 48 hours after Pep A 
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 Value Label N 
Type 1 untreated 9 
2 vehicle control 9 
3 Pep-Pen 9 
Hour 24 24 hours 9 
48 48 hours 9 
72 72 hours 9 
Tests of Between-Subjects Effects 
Dependent Variable:   MFI   
Source 
Type III Sum of 





































   
a. R Squared = .964 (Adjusted R Squared = .947) 
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Post Hoc Tests 
 
 
Dependent Variable:   MFI   
Tukey HSD   
(I) Type (J) Type 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
untreated vehicle control -3849.0956 4652.80699 .691 -15723.8184 8025.6273 
Pep-Pen -67706.6467* 4652.80699 .000 -79581.3695 -55831.9238 
vehicle control untreated 3849.0956 4652.80699 .691 -8025.6273 15723.8184 
Pep-Pen -63857.5511* 4652.80699 .000 -75732.2739 -51982.8283 
Pep-Pen untreated 67706.6467* 4652.80699 .000 55831.9238 79581.3695 
vehicle control 63857.5511* 4652.80699 .000 51982.8283 75732.2739 
Based on observed means. 
 The error term is Mean Square(Error) = 97418757.872. 










untreated 9 123106.6044  
vehicle control 9 126955.7000  
Pep-Pen 9  190813.2511 
Sig.  .691 1.000 
Means for groups in homogeneous subsets are displayed. 
 Based on observed means. 
 The error term is Mean Square(Error) = 97418757.872. 
a. Uses Harmonic Mean Sample Size = 9.000. 
b. Alpha = 
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Tests of Between-Subjects Effects 
Dependent Variable:   MFI   
Source 
Type II Sum of 
Squares df Mean Square F Sig. 
Corrected Model 6468669705.96
4a 















2 622831111.859 7.429 .004 












   




 Value Label N 
Type 1 untreated 9 
2 vehicle control 9 
3 PepA 9 
Hour 24 24 hours 9 
48 48 hours 9 
72 72 hours 9 
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 Value Label N 
Type 1 vehicle control 15 
2 Pep A 15 
Hour 3 3 hour 6 
6 6 hour 6 
24 24 hours 6 
48 48 hours 6 





Tests of Between-Subjects Effects 
Dependent Variable:   MFI   
Source 
Type III Sum of 
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Protein extracts from equal cell equivalents of KG-1 and Priess cells were resolved by 12% non-
reducing SDS PAGE and immunoblotted for Cat E. rh Cat E migrated partly as a homo-dimer, which 
is observed at 80 kDa and as a 44 kDa (monomer). The quantities of rh Cat E used ranged from 2 ng 
to 250 ng while for rh Cat D they were 50 ng and 250 ng. As observed in the figure, rh Cat D was 
detected with anti-Cat E antibody, demonstrated cross-reactivity. In addition, specific bands were 
detected in KG-1 and Priess cell extracts, but they migrated as a monomer which is typical of Cat D 
rather than as a homodimer seen for Cat E. Hence the result provided by this monoclonal anti- Cat E 
reflected Cat D cross reactivity. 
  
   
 196 
Appendix 3.7 Effect of Pepstatin A on cat D knocked down cells at 24 hours. 
 
Tests of Between-Subjects Effects 
Dependent Variable:   MFI   
CatD KD Source 
Type III Sum of 
Squares df Mean Square F Sig. 























   






PepA 67946887.809 1 67946887.809 81.159 .001 




   
Corrected Total 96174639.232 5    
a. R Squared = .953 (Adjusted R Squared = .941) 
b. R Squared = .706 (Adjusted R Squared = .633) 
Between-Subjects Factors 
CatD KD Value Label N 
Presence PepA 1 Presence 3 
2 Absent 3 
Absent PepA 1 Presence 3 
2 Absent 3 
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Tests of Between-Subjects Effects 
Dependent Variable:   MFI   
CatD KD Source 
Type III Sum of 
Squares df Mean Square F Sig. 























   


























   
a. R Squared = .659 (Adjusted R Squared = .573) 





CatD KD Value Label N 
Presence PepA 1 Presence 3 
2 Absent 3 
Absent PepA 1 Presence 3 
2 Absent 3 
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CatD KD Value Label N 
Presence PepA 1 Presence 3 
2 Absent 3 
Absent PepA 1 Presence 3 
2 Absent 3 
Tests of Between-Subjects Effects 
Dependent Variable:   MFI   
CatD KD Source 
Type III Sum of 
Squares df Mean Square F Sig. 


























   



























   
a. R Squared = .344 (Adjusted R Squared = .180) 
b. R Squared = .953 (Adjusted R Squared = .941) 
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Appendix 4.1: Pep A does not accumulate the Iichain in KG-1 cells 
 
Between-Subjects Factors 
 Value Label N 
Type 1 untreated 6 
2 vehicle control 6 
3 Pep A 6 
 
 
Tests of Between-Subjects Effects 
Dependent Variable:   MFI   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 163740942.005
a 







Type 163740942.005 2 81870471.002 1.388 .280 
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 Value Label N 
Type 1 untreated 6 
2 vehicle control 6 




Tests of Between-Subjects Effects 
Dependent Variable:   MFI   
Source 
Type III Sum of 






























   
a. R Squared = .708 (Adjusted R Squared = .669) 
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 Value Label N 
Type 1 Vehicle control 15 
2 Pep A 15 
Hour 3 3 hour 6 
6 6 hour 6 
24 24 hours 6 
48 48 hours 6 




Tests of Between-Subjects Effects 
Dependent Variable:   MFI   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 






Type 290807.518 1 290807.518 .124 .729 
Hour 426282129.384 4 106570532.346 45.326 .000 
Type * Hour 20466704.559 4 5116676.140 2.176 .109 




   
Corrected Total 494063330.840 29    






   
 202 




Effect of vitamin D and RA on total HLA DR expression in HTCs: EBV transformed homozygous 
typing cell lines containing six of the most common allele found in the UK cohort (White/Irish) and 
two alleles present in KG-1 cells were treated with 10 nM VitD and /or 1 µM RA. DMSO treated cells 
were used as a vehicle control. L243-FITC antibody was used to stain the DR molecules. Cells were 
analysed after fixation and permeabilization at 48 and 72 hours post treatment.  Staining was 
quantified by flow cytometry and is reported as mean fluorescence intensities (MFI; mean+- S.D. of 
triplicate cultures).  
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Effect of vitamin D and RA on total HLA DR expression in HTCs: EBV transformed homozygous 
typing cell line containing six of the most common allele found in the UK cohort (White/Irish) and 
two alleles present in KG-1 cells were treated with 10 nM VitD and/ or 1 µM RA. DMSO treated cells 
were used as a vehicle control. L243-FITC antibody was used to stain the DR molecules. Cells were 
analysed after fixation and permeabilization at 48 and 72 hours post treatment.  Staining was 
quantified by flow cytometry and is reported as mean fluorescence intensities (MFI; mean+- S.D. of 
triplicate cultures).  
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Appendix 5.3: Effect of vitamin D on Live KG-1 cells. 
 
Between-Subjects Factors 
 Value Label N 
Type 1 untreated 9 
2 vehicle control 9 
3 Vitamin D 9 
Hour 24 24 hours 9 
48 48 hours 9 
72 72 hours 9 
 
 
Tests of Between-Subjects Effects 
Dependent Variable:   MFI   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 






Type 9280106.797 2 4640053.398 3.859 .040 
Hour 427496371.178 2 213748185.589 177.781 .000 
Type * Hour 34214722.268 4 8553680.567 7.114 .001 
Error 21641617.728 18 1202312.096   
Total 22006019269.521 27    
Corrected Total 492632817.970 26    
a. R Squared = .956 (Adjusted R Squared = .937) 
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Appendix 5.4 Effect of Vitamin D on fixed and permeabilized KG-1 cells 
 
Between-Subjects Factors 
 Value Label N 
Type 1 untreated 9 
2 vehicle control 9 
3 Vitamin D 9 
Hour 24 24 hours 9 
48 48 hours 9 
72 72 hours 9 
 
 
Tests of Between-Subjects Effects 
Dependent Variable:   MFI   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 






Type 51308035.327 2 25654017.664 17.956 .010 
Hour 264634371.494 2 132317185.747 92.613 .000 
Type * Hour 19652930.855 4 4913232.714 3.439 .030 
Error 25716797.169 18 1428710.954   
Total 33825031293.081 27    
Corrected Total 361312134.846 26    
a. R Squared = .929 (Adjusted R Squared = .897) 
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 Value Label N 
Vitamin-D 1 Presence 6 
2 Absent 6 
RA 1 Presence 6 





Tests of Between-Subjects Effects 
Dependent Variable:   MFI   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 






Vitamin-D 16426800.000 1 16426800.000 6.220 .166 
RA 27809985.333 1 27809985.333 10.531 .084 
Vitamin-D * RA 100057650.083 1 100057650.083 37.888 .000 




   
Corrected Total 165421437.417 11    
a. R Squared = .872 (Adjusted R Squared = .824) 
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 Value Label N 
Vitamin D 1 Presence 6 
2 Absent 6 
RA 1 Presence 6 




Tests of Between-Subjects Effects 
Dependent Variable:   MFI   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 1287913985.55
0a 






Vitamin-D 183383777.548 1 183383777.548 7.565 .025 
RA 210655686.164 1 210655686.164 8.690 .018 
Vitamin-D * RA 893874521.839 1 893874521.839 36.873 .000 








   
a. R Squared = .869 (Adjusted R Squared = .820) 
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 Value Label N 
Vitamin-D 1 Presence 6 
2 Absent 6 
RA 1 Presence 6 
2 Absent 6 
 
 
Tests of Between-Subjects Effects 
Dependent Variable:   MFI   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 






Vitamin-D 253285596.750 1 253285596.750 17.709 .000 
RA 146629234.083 1 146629234.083 21.830 .002 
Vitamin-D * RA 219281850.750 1 219281850.750 32.647 .000 




   
Corrected Total 672931390.250 11    
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MFI   
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Appendix 6.2 Effect of media switching on the alleles  
 
Between-Subjects Factors 
 Value Label N 
Allele 3 DRB3 8 
11 DRB1*11 8 
14 DRB1*14 8 
Type 1 RPMI vs SILAC 
RPMI 
12 






Tests of Between-Subjects Effects 
Dependent Variable:   SILACvalue   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 243.330a 5 48.666 101.430 .000 
Intercept 148991.890 1 148991.890 310529.158 .000 
Allele 95.236 2 47.618 99.245 .000 
Type 116.689 1 116.689 243.203 .000 
Allele * Type 31.406 2 15.703 32.728 .000 
Error 8.636 18 .480   
Total 149243.857 24    
Corrected Total 251.967 23    
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 Type * Allele 
Dependent Variable:   SILACvalue   
Type Allele Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
RPMI vs SILAC RPMI DRB3 77.743 .346 77.015 78.470 
DRB1*11 76.378 .346 75.650 77.105 
DRB1*14 75.638 .346 74.910 76.365 
IMDM vs SILAC RPMI DRB3 85.385 .346 84.657 86.113 
DRB1*11 79.293 .346 78.565 80.020 
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Dependent Variable:   SILACratio   
Tukey HSD   
(I) Allele (J) Allele 
Mean Difference (I-
J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
DRB3 DRB1*11 3.7287* .34634 .000 2.8448 4.6127 
DRB1*14 4.5900* .34634 .000 3.7061 5.4739 
DRB1*11 DRB3 -3.7287* .34634 .000 -4.6127 -2.8448 
DRB1*14 .8612 .34634 .057 -.0227 1.7452 
DRB1*14 DRB3 -4.5900* .34634 .000 -5.4739 -3.7061 
DRB1*11 -.8612 .34634 .057 -1.7452 .0227 
Based on observed means. 
 The error term is Mean Square(Error) = .480. 
*. The mean difference is significant at the 0.05 level. 
 
SILACratio 




DRB1*14 8 76.9738  
DRB1*11 8 77.8350  
DRB3 8  81.5638 
Sig.  .057 1.000 
Means for groups in homogeneous subsets are 
displayed. 
 Based on observed means. 
 The error term is Mean Square (Error) = .480. 
a. Uses Harmonic Mean Sample Size = 8.000. 
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As described in Figure 6.16, KG-1 cultures (n=4) were treated with DMSO for 72 hours in 
light media. Extracts were mixed 1:1 (by protein content) with SILAC labelled KG-1cells. 
Mean % light ratios of the allele-specific DR β peptide sets were quantified from the SILAC 
ratios obtained after LC-MS. The colour coding is as per the Figure 6.7 and Table 6.1. The 
result describes that at baseline, DRB3 specific peptides had a slightly higher % light value 
than that of the DRB1 derived peptides 
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Appendix 6.4 Relative quantification of the effects of vitamin D and/or RA on HLA-DR 




 Value Label N 
Allele 3 DRB3 16 
11 DRB1*11 16 
14 DRB1*14 16 
Type 1 DMSO 12 
2 Vit D 12 
3 RA 12 




Tests of Between-Subjects Effects 
Dependent Variable:   SILAC ratio   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 6377.729a 11 579.794 263.376 .000 
Intercept 106126.021 1 106126.021 48208.666 .000 
Allele 57.792 2 28.896 13.126 .000 
Type 5768.563 3 1922.854 873.473 .000 
Allele * Type 551.375 6 91.896 41.744 .000 
Error 79.250 36 2.201   
Total 112583.000 48    
Corrected Total 6456.979 47    
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Dependent Variable:   SILAC ratio   
Tukey HSD   
(I) Allele (J) Allele 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
DRB3 DRB1*11 2.6250* .52457 .000 1.3428 3.9072 
DRB1*14 1.8125* .52457 .004 .5303 3.0947 
DRB1*11 DRB3 -2.6250* .52457 .000 -3.9072 -1.3428 
DRB1*14 -.8125 .52457 .281 -2.0947 .4697 
DRB1*14 DRB3 -1.8125* .52457 .004 -3.0947 -.5303 
DRB1*11 .8125 .52457 .281 -.4697 2.0947 
Based on observed means. 
 The error term is Mean Square (Error) = 2.201. 











DRB1*11 16 45.8750  
DRB1*14 16 46.6875  
DRB3 16  48.5000 
Sig.  .281 1.000 
Means for groups in homogeneous subsets are 
displayed. 
 Based on observed means. 
 The error term is Mean Square(Error) = 2.201. 
a. Uses Harmonic Mean Sample Size = 16.000. 
b. Alpha = 0.05. 
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